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Summary 
 
In the last ten years there has been considerable focus on the impact of pollution on the 
environment driven by research and government policies. With particular interest in soils and 
environmental waters there is the need to monitor for a wide range of potential organic 
pollutants, including pesticides, personal care products and pharmaceuticals. The research 
focus has shifted to the study of wastewater, which has been largely un-investigated as an 
environmental matrix, with an aim to detect lower amounts than those achieved with current 
methods. Current approaches for analysing complex environmental matrices such as soil and 
wastewater effluent are typically multi-step analyses using a range of procedures and 
apparatus, resulting in methods that are time and resource consuming, unsuitable for high-
throughput analysis. This study has investigated new approaches to monitoring 
concentrations of commonly used pharmaceuticals and biocides in environmental samples, as 
detailed by UK Water Industry Research and the Chemical Investigation Programme (CIP). 
A modified QuEChERS sample preparation method has been developed and tested for the 
extraction of a selection of pharmaceuticals of interest to CIP and extended to biocides, as 
newly proposed pollutants following an initial investigation in sludge. These were analysed, 
with results showing sixteen target analytes of variable lipophilicity/acidity were successfully 
extracted using the developed protocol. Excellent repeatability within a “control” sample of 
soil was achieved with a relative standard deviation of <10% for the majority of 
pharmaceuticals and <15% for the biocides, with low matrix effects, and recovery values of 
between 40-75%. This method was applied to two samples of locally sourced treated 
sludgecake, two samples of homogenised biota (mussel tissue) and a sample of locally 
sourced treated effluent as part of a qualitative and quantitation study. A selection of 
pharmaceuticals and the suite of biocides were quantifiable within each sample matrix. This 
novel sample preparation method is labour-saving and cost effective, offering an improved 
approach for multiple sample matrices for high throughput analysis versus current protocols. 
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Chapter 1: Introduction and Background 
 
In the last twenty years, there has been considerable focus on the impact of pollution on the 
environment as a result of research and government policies. With particular interest in soils 
and environmental waters is the need to monitor for a wide range of potential organic 
pollutants, including pesticides, personal care products (PCP) and pharmaceuticals. For the 
latter, the research focus has shifted to the study of wastewater, which has been largely un-
investigated as an environmental matrix [1], and the need to detect lower trace concentrations 
than those achieved with current methods used in the environmental industry [2,3]. This 
study aims to investigate a new method of analysis, suitable for quantifying trace 
concentrations of compounds of interest to the Chemical Investigation Programme, in 
environmental wastewater and biota samples, as detailed by current EU regulations.  
 
1.1: Environmental Pollution 
Environmental pollution is the contamination of the environment by the introduction of any 
substance (solid, liquid or gas) that can cause damage and harm to the surroundings, humans 
or other living species. It can occur when these substances are introduced at a faster rate than 
can be dispersed, diluted, decomposed or recycled. The major kinds of pollution are air 
pollution, water pollution, and land pollution. When considering environmental pollution, the 
most prevalent focus is on the use of fossil fuels and the subsequent carbon emissions 
contributing to the production of smog (the result of fossil fuel combustion combined with 
sunlight and heat), resulting ground-level ozone which can cause irritation to the respiratory 
system [4]. However, water pollution is also a major environmental concern and can occur in 
a number of ways. For example, chemicals in fertilisers used on agricultural land can 
gradually be washed into surrounding surface and groundwater systems by rainfall. Domestic 
households, industrial and agricultural practices produce wastewater (sewage), which is 
treated in a water treatment plant. The resulting treated waste is disposed of into the sea, and 
can cause pollution of many rivers and other watercourses.  
 
1.1.1: Wastewater Treatment Process 
According to the Urban Wastewater Directive (91/271/EEC), urban wastewater is defined as 
“domestic wastewater or the mixture of domestic wastewater with industrial wastewater and/or 
run-off rain water” [5]. For waste management this is treated by mechanical or biological 
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means before being released as effluent from the waste water treatment plant (WWTP) with 
destinations that may include watercourses or agricultural land. This treatment is designed to 
reduce the risk of adverse impact to the environment through oxygen depletion of receiving 
waters, or ecosystem eutrophication by the increase in nitrogen and phosphates [6] is divided 
into three stages; primary, secondary and tertiary treatment. Primary treatment is concerned 
with the removal of suspended solids from the raw sewage using screening and sedimentation 
by gravity techniques, while secondary treatment is typically microbial digestion that 
encourages aerobic degradation of organic matter to carbon dioxide and water by pumping air 
throughout the wastewater. The treated water is separated from the residual sludge and is 
deemed suitable for discharge into the environment [7], while the sludge layer requires further 
clean-up. This may include liming or dewatering, producing a treated sludge deemed suitable 
for use as fertiliser for agricultural land, or used as feedstock for energy production [7,8]. A 
final, less common, tertiary treatment stage involves a disinfection step to destroy any residual 
micro-organisms through the application of ultraviolet light or chlorination with the resulting 
effluent discharged back into the water course or subjected to further treatment to produce 
drinking water [9]. 
 
 
Figure 1.1: A schematic of the wastewater treatment process detailing the primary, secondary and tertiary stages 
of wastewater treatment, including removal of bio-solids, microbial degradation and disinfection, respectively.  
 
Secondary treated sludge is nutrient-rich, making it a very appropriate fertiliser and this has 
been the favoured option of disposal since the Urban Wastewater Directive (91/271/EEC) 
proposed the phasing out of removal of sludge to surface waters in 1991 [5]. Since then, 80% 
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of sewage sludge is now recycled onto agricultural land in accordance with the procedures 
outlined in the Sludge (Use in Agriculture) Regulations 1989 and the Safe Sludge Matrix 
guidelines [6,10,11] published in 2001. 
 
1.2: Current Regulatory Landscape for Environmental Analysis 
The publication of the Water Framework Directive, 2000/60/EC (WFD) in 2000 [12] was a 
new era for environmental monitoring. Member states were now obligated to look at the 
environment with a more holistic approach, considering the impact of environmental 
pollution on the ecosystem as a whole. This included water courses but also land and 
organisms living in these catchments such as biota. Information gathered from monitoring 
programmes following the introduction of this policy led to the development of 
environmental standards for hazardous substances, the Environmental Quality Standards 
Directive, 2008/105/EC (EQSD) in 2008. This directive detailed the maximum allowable 
concentration [13] in water samples before action must be taken for each compound deemed 
to be a hazardous substance (i.e. heavy metals and pesticides). However, this regulation was 
specific to water and did not consider wastewater effluent and its by-products, (i.e. sludge) or 
biota, or their potential impact on environmental pollution. Driven by this legislation the 
Chemical Investigation Programme (CIP) was established in 2009 [14], as a UK based 
initiative aiming to understand the prevalence of substances that may be potential pollutants 
in sewage samples, and to establish quality standards similar to those outlined in the EQSD 
(2008/105/EC) [13]. This initial CIP study was one of a number that directly fed into the 
amended environmental Directive, 2013/39/EU, which also encompassed findings from the 
WFD and EQSD. This legislation adopted a more complete approach to environmental 
monitoring considering alternative sample matrices and highlighted substances of emerging 
concern to the environment that are not yet subject to legislation in the form of a “watch list” 
(predominantly pharmaceuticals) [15]. This “watch list” functions differently to the priority 
substance list; here the obligation is to monitor the three nominated pharmaceuticals (with a 
maximum capacity of ten), considered to be hazardous, and gather data to determine the risk 
of these compounds within the environment. The candidates on this “watch list” may then be 
replaced or escalated to priority substance status depending on the outcome of the monitoring 
data. In 2015, a broader UK programme CIP II, was launched to investigate these 
pharmaceuticals and others identified as a potential environmental concern (see Table 1.1), 
focussing on their concentrations in environmental samples and again, to establish quality 
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standards similar to those outlined within the EQSD, with proposed limits of detection for 
pharmaceuticals in sewage sludge of 0.1 mg/kg, based upon the findings of the initial CIP 
study [16].  
 
Table 1.1: The pharmaceuticals and metabolites currently classed as emerging substances within the Chemical 
Investigation Programme, II. 
Pharmaceuticals Statins and Antifungals Metabolites 
Diclofenac Atorvastatin 10,11- Epoxycarbamazepine 
Ibuprofen Ortho-hydroxyatorvastatin Norerythromycin 
Propranolol Para-hydroxyatorvastatin Norsertraline 
Atenolol Azithromycin  
Erythromycin Clarithromycin  
Metformin Ciprofloxacin  
Ranitidine Benzotriazole  
Carbamazepine Tolyltriazole  
Sertraline   
Fluoxetine   
Tamoxifen   
 
1.3: Persistent Organic Pollutants 
Persistent organic pollutants (POPs) are chemicals of global concern due to their potential for 
long-range transport, persistence in the environment (including air, water, soil and sediment), 
ability to bioaccumulate in ecosystems, as well as their significant negative effects on human 
health and other living species [17]. Humans are exposed to these chemicals in a variety of 
ways: mainly via the food chain, but also through the air we breathe. Many commonly used 
products may contain POPs, which have been added to improve product characteristics, such 
as flame retardants or surfactants. As a result, POPs can be found almost everywhere on our 
planet in measurable concentrations [17,18]. Many POPs were widely used during the post 
war industrial production boom when thousands of synthetic chemicals were introduced into 
commercial use, many of which proved beneficial in pest and disease control and crop 
production. Some of the more well-known POPs are pesticides, such as aldrin, dieldrin and 
dichlorodiphenyltrichloroethane (DDT) and industrial chemicals such as polychlorinated 
biphenyls (PCBs). However, due to the demands for environmental monitoring programmes, 
more candidate pollutants are being discovered in recycled waste with a significant potential 
impact for both environmental and public health, such as pharmaceuticals and other classes of 
biocides. There have already been global reports of the adverse effects of pharmaceuticals on 
the animal kingdom. For example, the non-steroidal anti-inflammatory, diclofenac, has 
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caused multiple species of vulture in Asia to become critically endangered [19] with the 
Indian long-billed vulture and red-headed vulture populations decreased by 97-99% [20]. The 
female contraceptive pill is another pharmaceutical with longstanding environmental impact; 
the feminisation of male fish due to expose to this particular hormone has caused a rapid 
decrease in population over a 2 year monitoring period [21]. Similarly biocides, such as 
triclosan and glutaraldehyde have been linked to a number of ailments, from skin irritation to 
breathing disorders, respectively [22,23], and the use of tributyltin (TBT), an antifouling 
agent, has been shown to have a long-lasting impact on marine eco-systems [24]. 
 
1.3.1: Pharmaceuticals as Persistent Organic Pollutants in the Environment 
There are different classes of pharmaceuticals available for both human and veterinary use.  
The use of pharmaceuticals has risen year on year due to an ever aging population, the rise of 
chronic diseases and a general change in lifestyle. In Wales alone, the number of prescription 
items dispensed in 2016 totalled 80.3 million, a 1.0% increase from 2015 [25]. Over-the-
counter medicines, by comparison, are more difficult to regulate and determine exposure 
rates. While annual sales are recorded, there is no way to monitor how much is actually used 
and therefore estimating the potential quantity released into the environment, either as 
excretion products or by poor disposal of out-dated medication can make targeted analysis 
challenging.  Those commonly administered include “over-the-counter” medicines such as 
non-steroidal anti-inflammatory drugs (e.g. ibuprofen), antihistamines (e.g. 
diphenhydramine), or prescription medications such as anticonvulsants (e.g. carbamazepine) 
and antibiotics (e.g. erythromycin). While drugs may group exert different effects on the 
body, they share several physiochemical characteristics, such as organic functionalities to 
encourage lipophilicity and polar groups, such as an alcohol, carboxyl or amino group to 
allow interaction with the target receptor. The drug lipophilicity is an important consideration 
for the environmental fate of a drug. This can be estimated by the octanol/water partition 
coefficient (logKow or logP), as a measure of affinity to either organic or aqueous conditions, 
or more importantly for complex environments with sediment, by the solid-specific 
equilibrium sorption constant (Kd), describing the distribution of a compound between 
sediment/sludge and water [26]. Values of Kd can range from 10
5
 to less than 1, and it is 
reported that high values of Kd and logP (usually a value greater than 3) are consistent with 
those compounds that can potentially adsorb to sludge, or bioaccumulate within soil and 
biota, respectively [27].  
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1.3.2: Biocides as Persistent Organic Pollutants in the Environment 
There are two main classes of compound that are used to control and destroy bacterial 
growth, antibiotics and biocides. Antibiotics are typically derived from natural organic 
compounds and are effective in low concentrations with a specific single cellular target, 
whereas biocides are typically used against microbes on surfaces or in suspensions, applied at 
concentrations much greater than the minimum inhibitory concentration, unachievable with 
in vivo application [28]. The European biocide market amounted to approximately €10-11 
billion, with an annual growth of 4-5% over the last 15 years, with a predicted increase over 
the coming years [29]. The uninhibited use of these compounds has led to an increasing 
concern of environmental exposure as the major disposal route of biocides is via drains and 
sewage system. It has been estimated that 50% of these biocides are degraded during the 
wastewater treatment process with 25% adsorbed to suspended solids and the remaining 25% 
dissolved into the water fraction [30,31]. As the treated wastewater effluents (i.e. solids and 
liquids) are recycled back into the environment, there is a potential for biocides to 
bioaccumulate and cause adverse effects on the ecosystem, with studies showing quaternary 
ammonium compounds in particular, are toxic to aquatic organisms at concentrations of 
approximately 1 mg/L [32]. 
Quaternary ammonium compounds (QACs) are broad spectrum, amphoteric surfactants used 
heavily in industrial and clinical applications, with increasing use in domestic cleaning 
products, such as laundry detergents, dishwashing liquids and disinfectants [33], over the last 
10 years [34]. These cationic surfactants typically comprise of a positively charged nitrogen 
atom bonded to four carbon atoms, with at least one alkyl chain and form hygroscopic 
chloride or bromide salts. As a result of their structure, surfactants show solubility in polar 
and non-polar liquids and tend to adsorb at the phase interface, reducing the surface tension 
by disrupting interactions between solvent molecules. Finally, when the total surfactants 
concentration exceeds the critical micelle concentration, surfactants will aggregate into 
soluble structures, such as micelles, after which surface tension plateaus [33].  
 
1.3.2.1: Antimicrobial Resistance 
Quaternary ammonium compounds have been used extensively since the 1930s [34], and 
while there has been no evidence to show a reduction in effectiveness, studies have shown 
decreases in susceptibility of repeatedly exposed bacteria, as a result of hyper-expression of 
certain multi-drug efflux pumps [34,35], such as those associated with qacA-G genes in 
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Staphylococcus aureus [36]. These efflux pump proteins are used to expel compounds that 
are damaging to the microbial cell and are found in both Gram-positive and Gram-negative 
bacteria. Activation of efflux pumps by biocides can also be effective on antibiotics, thereby 
increasing cross-resistance [37]. Another mechanism for simultaneous biocide and antibiotic 
resistance is co-resistance, and this occurs when multiple resistance genes are present [50]. 
Antibiotic resistance of bacteria can be increased by single-step mutations in the target 
enzymes or by neutralising enzymes, particularly beta-lactamases [38]. Given these 
mechanisms for both cross and co-resistance, there is a concern that an increase in multi-drug 
efflux pumps actively increase the frequency of mutational high-level resistance by allowing 
a greater proportion of organisms to survive antimicrobial exposure [38]. 
 
1.4 Trace Analysis of Environmental Samples 
Since the implementation of WFD and CIP, there is a much broader range of environmental 
pollutants that require monitoring. The analysis of different chemistries at trace 
concentrations is one of the main challenges faced by the environmental industry. For trace 
quantitation, there first needs to be an effective and robust sample preparation method for the 
necessary sample clean-up, alongside sensitive and selective instrumentation. Liquid 
chromatography-mass spectrometry (LC-MS) is the gold-standard for environmental 
monitoring and trace quantitative analysis of non-volatile species, capable of reaching trace 
level sensitivity when used in combination with suitable sample preparation methods [39].  
 
1.4.1: Sample Preparation Techniques 
Sample preparation is an important stage of analytical analysis, especially when working with 
complex samples, such as biological or environmental matrices. By removing any 
interferences, such as salts or acids present in the matrix allows better sensitivity and 
recovery of the target analyte. The most commonly used sample preparation technique for 
environmental analysis is solid-phase extraction (SPE), however recent studies have shown 
that the Quick, Easy, Cheap, Effective, Rugged and Safe (QuEChERS) method has been 
investigated as an alternative to SPE [40,41,42]. 
 
1.4.1.1: Solid-Phase Extraction 
Solid-phase extraction (SPE) is a sample clean-up technique generally used to selectively 
separate and concentrate a known target analyte within the sample. This preparation method 
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has two modes of operation; it can work either by removing matrix interferences from a 
liquid sample using a solid sorbent (typically in cartridge form), or by retaining the target 
analyte which can be later eluted from the sorbent using appropriate solvents, also working as 
an effective concentration step (if the elution volume is less than loading volume). There are 
several sorbent chemistries available, with typical sorbents being silica based containing 
alternative functional groups bonded to the silanol surface [43]. Common SPE protocols used 
for environmental matrices have four main stages (see Figure 1.2): 
 
 
Figure 1.2: A diagram showing how a typical solid-phase extraction (SPE) is carried out. By retaining the 
sample components on the sorbent, matrix interferences can be selectively eluted before the analytes of interest 
are eluted for analysis. 
 
1) Column pre-conditioning: Some sorbents require activation to solvate the column ready 
to interact with the target analyte. This is achieved by rinsing with a solvent of high 
elution strength, such as methanol or acetonitrile, followed by a rinse stage with the 
sample solvent, promoting the optimum environment for retention. 
2) Sample Loading: The sample is loaded onto the cartridge where the target analytes are 
retained.  
3) Wash: The cartridge is washed to remove interferences off the sorbent. This “wash” 
eluent can either be discarded, or saved for a secondary SPE procedure to ensure all of the 
analyte of interest is retained. 
4) Elution: A suitable solvent of sufficient elution strength is used to displace the analyte of 
interest from the sorbent ready for analysis [44]. 
While SPE offers several advantages as a sample preparation method, including high 
selectivity and recovery of target analytes with good reproducibility, it can be complex when 
considering multiple analyte chemistries due to the need for extensive pH modification and 
2. SAMPLE 
LOADING 
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despite there being a wide variety of sorbent types/ cartridge size available, the options can be 
costly. For example, one of the recognised methods for the analysis of complex 
environmental matrices such as soil and wastewater effluent (Environmental Protection 
Agency (EPA) Method 1694 [3]) requires the use of 20 mL Oasis HLB cartridges with 1g of 
sorbent. These cartridges retail for approximately £200 for 20, resulting in a cost per sample 
of approximately £10, which is undesirable for high throughput analysis. 
 
1.4.1.2: Quick, Easy, Cheap, Effective, Rugged and Safe (QuEChERS) 
The QuEChERS sample preparation method was developed in 2003 by Anastassiades and 
Lehotay for the extraction of pesticides from fruit and vegetables [45]. This is a two-step 
process involving a liquid partition into acetonitrile with the addition of drying agents 
(typically magnesium sulphate (MgSO4)) for dehydration and salts and buffers to limit polar 
interferences and facilitate phase transfer, followed by a dispersive solid-phase extraction 
(dSPE) for further interference removal, using sorbents such as primary-secondary amine 
(PSA), C18 and graphitised carbon black (GCB), as shown in Figure 1.3. At present, there are 
three standardised approaches, the original unbuffered method [34], the Association of 
Analytical Communities (AOAC) method [46] and the European Standard (EN 15662) 
method [47]. These methods were developed to incorporate a larger number of pesticides 
from a wider variety of fruit and vegetables, and each differ by the addition of buffers in the 
extraction kit; sodium acetate for the AOAC method, regulating the pH of the extraction 
solution to 3.6-5.6, and a combination of sodium citrate buffers for the EN 15662 method to 
regulate the pH of the sample to 3.0-6.2 [48]. Understanding the behaviour of the analyte in 
acidic and basic conditions using the acid dissociation constant (pKa) can ensure the 
compound is in a neutral state to achieve maximum recovery into the acetonitrile extraction 
solvent. Therefore, for samples that are pH sensitive, recoveries may be improved by using 
one of the adapted methods. Due to its low cost and resource requirement [45,49], the 
QuEChERS method has undergone some initial investigation for sediment and soil samples 
to extract select pharmaceuticals, metabolites and pesticides [50,51,52], providing scope for 
further development for use with a larger suite of compounds from alternative matrices.  
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Figure 1.3: A diagram showing how the two-step QuEChERS sample preparation method is performed. Firstly, 
is the liquid partitioning into the acetonitrile (ACN) solvent, followed by a dispersive-SPE (dSPE) step, before 
the sample is ready for analysis.  
 
1.4.2: Liquid Chromatography (LC) 
While sample preparation can assist with the removal of matrix interferences, the final extract 
may still contain a complex mixture of different compounds. The most widely used 
separation technique used for quantitative analysis is reversed-phase liquid chromatography, 
which uses a non-polar (hydrophobic) stationary phase, like a C18 sorbent and a polar 
(aqueous) mobile phase such as water. Given this, it is considerably more versatile for a 
broad range of compounds with relatively inexpensive solvents that are safer than those used 
for normal phase.  
 
1.4.2.1: Principles 
Reversed-phase LC achieves separation of compounds within a mixture by the adsorption 
between a non-polar, hydrophobic stationary phase, packed into an analytical column, and a 
polar mobile phase [53]. The stationary phase consists of a packing material which differs in 
composition depending on the type of interaction required, for example, for 
environmental/pharmaceutical analysis a non-polar hydrophobic C18 column is typically 
used. Mobile phases are typically comprised of an aqueous mixture of water and a miscible 
polar solvent, such as acetonitrile or methanol, which solubilises the analyte retained on the 
stationary phase resulting in elution from the column. For compounds with poor retention on 
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column, the addition of buffers or weak acids/bases can effectively improve compound 
retention by adjustment of the pH of the mobile phase. This adjustment can determine 
whether the compound of interest exist in the ionised or neutral form, where the ionised 
species elutes earlier from the column [53]. The mobile phase flow can be operated either 
isocratically, where there is a fixed mobile phase composition (i.e. 50% mobile phase A:50% 
mobile phase B) throughout the entire run, or using a gradient elution, where the proportion 
of the organic mobile phase solvent is increased throughout the run. Gradient elution is 
typically used when high levels of resolution are required for separation of a complex mixture 
to ensure elution of all compounds of interest, as analytes will be eluted sequentially in order 
of hydrophobicity. 
 
1.4.2.2: Chromatographic Parameters 
There are several factors that describe the performance of the chromatographic separation; 
column efficiency (N), retention factor (k), selectivity (α) and resolution (R) [39]. 
 
 
Figure 1.4: An example chromatogram displaying signal response versus time, demonstrating good separation 
of two retained compounds and an example of a poorly resolved peak, annotated with the following: retention 
time of the unretained compounds (tM), analytes (tR), and the peak width at the base (W) or at half the maximum 
(W0.5) are used to evaluate chromatographic performance. 
 
1)  Column Efficiency (N): This is also referred to as the number of theoretical plates, and 
can be related to the dispersion of the analyte band through the column. This can be 
dictated by the flow rate of the mobile phase and the column packing particle size (i.e. the 
diameter of the supporting silica beads). The smaller the particle size, the shorter the 
diffusion path length and time for the analyte, therefore decreasing the time spent inside 
the particle where peak diffusion can occur.  
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N = 16 (
𝑡𝑅
𝑊
)
2
=  5.54 (
𝑡𝑅
𝑊0.5
)
2
   (Eq. 1.1) 
 
The relationship between column flow rate and efficiency is described by the Van 
Deemter relationship and this helps define the contribution of diffusion, defined by three 
main terms; eddy diffusion, longitudinal diffusion and mass transfer, shown in Figure 1.5.  
 
 
 
Figure 1.5: A diagram of the Van Deemter relationship describing the effect of plate height (HETP) with linear 
velocity and the impact of analyte diffusion within the column. 
 
Eddy diffusion (A) refers to the different paths an analyte in a “band” can take when 
travelling through the column. The paths available are due to the variation in the particle 
size of the column packing. These inconsistencies can lead to the analytes travelling 
through multiple pathways resulting in band broadening producing a broader peak shape 
therefore reducing the resolution of the separation. However, this can be reduced by using 
a column with smaller particle size [54]. 
Longitudinal diffusion (B) is related to the diffusion of the analyte contained in the 
injection solvent along the axis of flow and typically occurs when the internal volumes 
with the LC systems are larger than necessary [54]. For example, tubing that is too long, or 
has a wide internal diameter, or incorrectly connected zero dead volume fittings. 
Mass transfer (C) refers to the speed of the mobile phase and the particle size and relates 
to the interaction of analyte molecules with the internal surface of the stationary phase and 
their distance of diffusion into and out of the pores of the packing material. As with eddy 
diffusion, the band broadening effect of mass transfer can be reduced by selecting a 
column with a smaller particle size. 
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2) Retention Factor (k): The retention factor refers to the degree of retention of an analyte 
on column, and is defined by the time in which the analyte resides in the stationary phases 
relative to the time it resides in the mobile phase. Compounds with low retention often 
have varying retention time, making analysis irreproducible, while compounds that have 
high retention can exhibit peak broadening due to strong retention with the stationary 
phase. This can be controlled by the polarity of the mobile phase. 
 
k = 
tR-tM
tM
        (Eq. 1.2) 
 
3)  Selectivity (α): Selectivity is the measure of separation of two analytes, and can be 
controlled by the type of column and mobile phase composition used.  
 
α = 
k1
k2
 , k2 > k1    (Eq. 1.3) 
 
4) Resolution (Rs): Resolution refers to the degree to which two compounds are separated. 
This is determined by the selectivity and column efficiency. Poor resolution can lead to a 
co-elution of analytes, shown in Figure 1.4. 
 
Rs = 
√N
4
(
k
k+1
) (
α-1
α
)      (Eq. 1.4) 
 
Rs = 
2 (tR,2-tR,1)
W1+W2
=  
1.18 (tR,2-tR,1)
W0.5,1+W0.5,2
     (Eq. 1.5) 
 
 
1.4.2.3: Column Characteristics for Reversed-Phase Chromatography 
Typically columns consist of a non-polar, hydrophobic stationary phase and while C18 
bonded silica is the most commonly used column type, a number of modifications are 
available to improve retention and selectivity of more challenging analytes. This can be 
achieved by alteration of the silica surface by bridging the silica and C18 chain with ethylene 
(bridged ethylene hybrid (BEH)), which provides a wider operational pH range (pH 1-12) due 
to increased chemical stability of hybrid particle, or by the application of a small charge to 
the surface of the bead, (charged surface hybrid (CSH)) leading to improved performance of 
basic compounds with acidic, low ionic strength mobile phases (i.e. acetonitrile). 
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Endcapping is commonly used to improve chromatography, and refers to the derivatisation of 
accessible silanol groups in a bonded stationary phase with trimethylsilane (TMS) to prevent 
peak tailing, common to polar compounds. New technology has been developed to use a 
trifunctional C18 alkyl phase bonding (T3) compatible with high-aqueous mobile phase 
conditions and to promote polar compound retention due to low-ligand density, enabling 
analytes to more readily access the pore structure. 
 
1.4.3: Mass Spectrometry (MS) 
Mass spectrometers are the most sensitive and selective detector used in conjunction with LC 
analysis. While LC separates compounds within a mixture by their physico-chemical 
properties, MS differentiates compounds by mass, specifically their mass-to-charge ratio 
(m/z) and provides the capability to identify the species corresponding to each 
chromatographic peak through its unique mass spectrum.  
 
1.4.3.1: Principles 
Mass spectrometry is used to analyse the mass of a gaseous ion under vacuum and separate 
those ions based upon the molecular m/z, which is plotted against relative abundance as a 
mass spectrum. A mass spectrometer comprises of four main components, and inlet, and 
ionisation source, a mass analyser and a detector [55]. The inlet is where the sample is 
introduced into the mass spectrometer; for example, when coupled with an LC system, the 
eluent is directly connected from the end of the analytical column into the ionisation source. 
The ionisation source generates gaseous ions from sample molecules delivered by the inlet. 
When coupled to an LC system, the most common interfaces are atmospheric pressure 
chemical ionisation (APCI) or electrospray ionisation (ESI). These sources negate the 
difficulties in interfacing a liquid phase (i.e. LC) into a gas phase technique (i.e. MS) as the 
atmospheric pressure source can tolerate flow rates up to 1 mL/min, typical of LC analysis 
[55]. The mass analyser is the vacuum chamber in which separation of ions according to their 
m/z occurs. Similarly with ionisation sources, there are multiple mass analysers to choose 
from depending on the needs of analysis being performed; quadrupole mass spectrometers are 
good for quantitation due to their fast scanning capabilities and robust operation, while ion 
traps are useful for rich qualitative data sets containing multiple stages of fragmentation of an 
analyte. Finally there is a detector, typically an electron multiplier, which detects the ions and 
amplifies them into a signal that can be used to produce a mass spectrum. The resulting mass 
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spectrum can then be used to determine the presence of isotopes, chemical structure and with 
high resolution instruments, the accurate mass of the ion. 
 
Figure 1.6: Schematic of a basic mass spectrometer showing three main sections; an ionisation source, mass 
analyser and detector. 
 
1.4.3.2: Ionisation Sources 
1.4.3.2.1: Electrospray Ionisation 
Electrospray is a soft ionisation technique which results in little fragmentation and can be 
used for both positive and negative ions. It is typically used for the analysis of polar 
molecules, which, through the use of pH modifiers, forms characteristic ions such as [M+H]
+
, 
[M+Na]
+
, [M+Cl]
-
 and [M-H]
-
. This is achieved by the application of an electric field to a 
liquid sample passing through a capillary tube, creating a fine spray of highly charged 
droplets. As the droplets decrease in size due to solvent evaporation through the use of heat 
and a desolvation gas (N2), the charge density on the droplet surface increases causing a 
deformation of the droplet into a Taylor Cone, eventually releasing many smaller droplets by 
repetitive Coulombic explosion [56]. This process occurs repeatedly until droplet sizes of 20 
nm [57] are reached, at this stage two theories are proposed; and the ion evaporation model 
(IEM) and the charge residue model (CRM) [56, 58]. The IEM, proposed by Iribarne and 
Thomson, suggests that once a droplet with a radius of between 10-20 nm reaches its 
Rayleigh limit (the maximum amount of charge a liquid droplet can carry before ejecting fine 
jets of liquid), the electric field on the surface of the charged droplet is high enough that the 
solvated ions are released from the droplet directly into the gas phase. The CRM, proposed 
by Dole and Röllgen, states that as the solvent evaporates from the droplet, the decrease in 
size causes the charge density to exceed the surface tension of the droplet causing Coulombic 
fission, producing several smaller droplets. Successive fissions result in the formation of 
nanodroplets that contain a single analyte ion. Electrospray ionisation can be particularly 
prone to matrix suppression with ionisation occurring through adduct formation. Thus, for 
adduct formation through proton ionisation will favour molecules with the greatest proton 
affinity, thereby suppressing molecules with a lower affinity. It is therefore, key that the 
degree of matrix effects is considered and addressed when using this ionisation technique 
Inlet 
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Mass Analyser Detector 
Rachel Townsend 
__________________________________________________________________________________________ 
 
__________________________________________________________________________________________ 
 
Page 28 of 177 
with complex samples and for applications requiring a reliable signal that is representative of 
a measured amount (i.e. quantitation). 
 
Figure 1.7: Schematic of an electrospray ionisation source showing the nebulised spray from the capillary tip 
and the fission of liquid droplets forming gaseous ions into the mass analyser. 
 
1.4.3.3: Mass Analysers 
1.4.3.3.1: Quadrupole Mass Analyser 
A quadrupole is a scanning mass analyser consisting of four parallel circular or hyperbolic 
rods, to which a high-frequency oscillating electric field is applied. Ions are introduced into 
the analyser from the ionisation source and travel in the z-direction (see Figure 1.8). Ions are 
then separated according to their m/z as a result of alternating a direct-current (DC) and radio-
frequency (RF) voltages. When the DC potential is applied to the positive pair of electrodes, 
ions accelerate towards the centre of the quadrupole. The oscillating voltage of positive and 
negative charge causes ions to successively be attracted and then repelled from each rod, 
therefore drawing the ions through the quadrupole. The simultaneous action of these voltages 
enables a stable trajectory for ions of a certain m/z, causing them to reach the detector for a 
given ratio of voltages: other ions have unstable trajectories and will collide with the rods. 
This allows the operator to scan for a range of m/z values by continuously varying the applied 
voltage [59]. An alternative, more selective mode includes single ion monitoring (SIM). This 
requires the quadrupole to be fixed on a specific RF/DC voltage, enabling the stable 
trajectory of the relevant m/z. This more specific approach increases the frequency of 
measurement at the relevant m/z, subsequently increasing the signal-to-noise ratio and the 
sensitivity. Therefore, LC–MS using a quadrupole provides a sensitive and selective means of 
ion detection.  
 
Droplet Fission 
Taylor  
Cone 
Charged 
Droplets 
Capillary Tip 
+  1.5-2kV  - 
Desolvation 
Gas (N2) 
Mass 
Analyser Voltage: 3 – 5kV 
Rachel Townsend 
__________________________________________________________________________________________ 
 
__________________________________________________________________________________________ 
 
Page 29 of 177 
 
Figure 1.8: Schematic of a single quadrupole mass analyser showing the path of an ion with a stable trajectory 
through the quadrupole. 
 
1.4.3.3.2: Ion Trap Mass Analyser 
The quadrupole ion trap mass analyser consists of three electrodes to confine ions; two end-
cap electrodes and a central ring electrode. When subjected to an electric field created by a 
RF voltage, the ions are held inside the trap and take on an oscillating path related to their 
m/z, forming a figure-of-eight shaped trajectory, known as a Lissajous figure [60,61]. A 
dampening gas, typically helium, is used to stabilise the ion trajectories towards the centre of 
the trap, preventing any loss of ions through collision or coalescence by removing excess 
energy through collision. Ion stability is based upon the Mathieu equations which, when 
simplified shows that the stability of any ion of a given m/z depends upon the parameters ‘a’ 
and ‘q’, relating to DC and RF voltages, respectively, as shown in the following equations: 
 
q = k 
V
m/z
 
 𝑎 = 0 
 
Figure 1.9: A visual representation of the Mathieu equations (also shown) relating to ion stability within an ion 
trap. 0.908 is the critical point at which the ions would become unstable in both the x and y directions. 
 
As ‘a’ is constantly set to zero, the ‘q’ value is proportional to an ion’s m/z, with smaller ions 
will having a larger ‘q’ value, and therefore be ejected from the trap first. An AC voltage, 
known as the resonance ejection voltage, is applied to prevent the ions from becoming 
unstable in both the x and y directions, then the instrument ramps the RF amplitude from a 
low voltage to a high voltage, causing the ‘q’ values of the ions to increase and the ions start 
moving towards the edge of the stability diagram and scan out of the trap [62].  
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Figure 1.10: Cross-sectional schematic of a quadrupole cubic ion trap mass analyser showing a central ring 
electrode with a top and bottom end cap electrode, containing ions oscillating in a figure-of-eight orbit. 
 
1.4.3.3.3: Orbitrap Mass Analyser 
The Orbitrap is an electrostatic ion trap and consists of two endcap electrodes, and an inner 
“spindle” shaped electrode. A DC voltage is applied to the spindle electrode, resulting in a 
high static voltage between the two endcap electrodes. When ion packets enter the Orbitrap, 
they are trapped by their attraction to the spindle electrode, which, contrasted by their inertia 
begin to orbit around the inner electrode, oscillating between the two outer electrodes. The 
ions separate into discrete bands that are determined by their differing masses, and m/z 
measurements are delivered as a function of oscillation frequency using Fourier Transforms 
(FTs) [63]. The translation of these frequencies into m/z values and their amplitudes into 
intensities relates to the resolution of the mass spectrum obtained, whereby the longer the 
transient signal is recorded, the higher the resolution. This allows for high resolution 
measurements of up to 500,000 full width-half maximum, and accurate mass measurements 
with <1ppm mass accuracy. 
 
 
 
Figure 1.11: Cross-sectional schematic of an Orbitrap mass analyser showing the two outer electrodes and the 
central “spindle” electrode, containing ions orbiting the central electrode along the z-axis. 
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1.4.3.3.4: Quadrupole Time-of-Flight Mass Analyser 
To maximise the sensitivity and resolving power of mass spectrometry, hybrid instruments 
such a quadrupole time-of-flight (Q-ToF) mass spectrometer are commonly used for the 
acquisition of high resolution and high accuracy data. A Q-ToF comprises of a combination 
of a quadrupole (and collision cell) and a time-of-flight mass analyser, where ions are 
separated according to m/z derived from the time taken to reach a detector at a known 
distance in either a linear or reflectron configuration, with the latter being more typical of 
high resolution analysis due to the increased flight path of the ion.  
Typical operation of a Q-ToF involves the introduction of ions into a mass filter, followed by 
a collision cell in which fragmentation can occur by applying an RF voltage to the rods. This 
creates an electromagnetic field confining ions above a particular mass to the centre of the 
rods and collision induced dissociation (CID) occurs using a collision gas, such as argon [64]. 
Ions then exit the collision cell as an ion beam, and pass through into the ToF analyser and 
into the ion pulser, which consists of multiple stacked plates to which a high voltage is 
applied, accelerating the ions through a low pressure flight tube. An electrostatic ion mirror is 
used to reflect the ions back towards the multi-channel plate detector (MCP) at the top of the 
flight tube. As all similarly-charged ions have the same kinetic energy, those with low mass 
show greater velocity and therefore reach the detector first. Since mass (m), charge, and 
kinetic energy (KE) determine the arrival time of an ion at the detector, the ion’s velocity (v) 
can be represented using the following equation: 
 
v = 
d
t
=  (
2KE
m
)
1
2
 
 
Where, d is the given distance travelled by the ions, t is the time taken to for the ion to reach 
the detector, where t depends on the m/z [65]. 
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Figure 1.12: Schematic of a typical Q-ToF mass analyser, showing the path of an ion through the quadrupole 
and collision cell and the flight path when operated in reflectron mode.  
 
1.4.3.4: Data Acquisition 
To carry out qualitative and quantitative analysis using a mass spectrometer, several scan 
modes can be applied depending on the needs of the experiment. For qualitative analysis, 
there are multiple scan types that can be used, for example, a full mass scan, a product ion 
scan or data dependant analysis. A full mass scan is used to record all ions over a selected 
mass range, and is useful to aid identification of unknown compounds as it can give 
information regarding the sample composition [59]. A product ion scan is more selective, 
focussing on recording all product ions from a single precursor ion m/z. Similarly a data 
dependant acquisition (DDA) can be performed, whereby a number of precursor m/z recorded 
in a survey scan can be selected using predetermined rules and subjected to a second stage of 
mass selection in an MS/MS analysis, typically achieved by collision induced dissociation 
(CID) with a neutral species (i.e. helium or argon gas). Quantitative analysis typically 
requires a more selective approach to data acquisition, whereby a single ion monitoring 
(SIM) scan, or a selected/multiple reaction monitoring (SRM/MRM) scan is used. A SIM 
scan is used to measure a single ion’s m/z rather than the whole mass range and can result in 
an enhancement of sensitivity versus a full mass scan, lending itself well to quantitative 
analysis. An SRM or MRM is used to record a specified reaction pathway of an ion of 
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interest, increasing specificity and further enhancement in sensitivity of the measurement 
versus a SIM or full mass scan. 
 
1.5: Current Research 
1.5.1: Pharmaceuticals in Wastewater and Sludge 
The majority of research that has been carried out regarding the detection of pharmaceuticals 
in the environment involves the analysis of water samples, with very little in the UK 
focussing on wastewater. The research regarding wastewater typically involves the use of 
SPE as the sample preparation method with the standard protocol published by the 
Environment Protection Agency (EPA), Method 1694 [3] also recommending this approach. 
However, there have been difficulties with the widespread adaption of this method with UK 
regulatory agencies (e.g. Environmental Agency and Natural Resources Wales) using 
alternative methods that are laborious, some taking days of preparation. Work carried out in-
house has also shown further challenges with ineffective results for sludge samples collected 
within the UK. Of the studies carried out in Europe, a range of methods have been used for 
various pharmaceuticals but not specific for CIP II. In a study carried out by Gracia-Lor et al. 
[66], 19 samples of effluent wastewater were tested from different WWTP around Spain, and 
37 out of 47 pharmaceuticals investigated were detected at least once. The highest 
concentrations reported were 200 µg/L for acetaminophen and 15 µg/L for ibuprofen, which 
are both well above the recommended detection limits outlined in CIP II. Similarly for a 
study carried out by López-Serna et al. [67], the concentrations detected in river water 
collected downstream from WWTP for non-steroidal anti-inflammatory drugs such as 
naproxen, ibuprofen and acetaminophen also exceeded these recommended maximum 
concentrations with 109, 541 and 872 ng/L reported, respectively.  
Another extensive study looked at 81 pharmaceutical residues and some of their metabolites 
in Spanish surface waters, and both secondary and tertiary wastewater [68]. Again, SPE was 
used as a sample preparation technique and analysed using UPLC-MS with an ESI-
quadrupole linear ion trap mass spectrometer. The method was validated to determine the 
method detection and quantitation limits (MDL and MQL), as well as matrix effects and the 
recovery, with the latter showing values greater than 50% for most compounds. However, 
only selected compounds were investigated for matrix effects by comparing the drug 
response in matrix versus a solvent based sample. For these compounds it was reported that 
high levels of ionisation suppression occurred (20-90%). Despite these deficiencies when the 
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method was applied to effluent wastewater after secondary biological treatment 40 of the 81 
pharmaceuticals targeted were still detected at concentrations ranging from ng/L to low µg/L, 
well above the MQL of 1-50 ng/L, highlighting that concentrations of pharmaceuticals within 
wastewater samples could be severely underestimated and further method improvement is 
needed to assess actual pharmaceutical concentrations. 
More recent studies have been carried out to determine the bioaccumulation of 
pharmaceuticals within wastewater treatment effluents [40,69,70]. A study carried out by 
Kachhawaha et al. [40] investigates the use of a QuEChERS-based extraction process on 
sewage water from a WWTP in India. A total of six pharmaceuticals were detected, 
metformin, acetaminophen, atenolol, carbamazepine, methylparaben and triclosan, with 
concentrations between 0.1-13.4 ng/mL, with the most abundant being acetaminophen and 
metformin at 6.9 and 13.4 ng/mL, respectively. These concentrations, while less than those 
observed in studies of sewage sludge, show that pharmaceuticals have the ability to 
accumulate within aqueous wastewater fractions. 
A study carried out by Luque-Muñoz et al. [69] investigated the concentrations of a selection 
of pharmaceuticals within compost derived from sewage sludge in Spain; a method of 
recycling that is said to reduce the concentrations of PPCPs over time [69]. Using an salt-
assisted liquid-liquid extraction method, similar to the salting out step of a QuEChERS 
extraction, concentrations of ketoprofen, methylparaben, diclofenac and flufenamic acid were 
reported to be the most abundant at 510, 240, 175 and 128 ng/g, respectively. A study carried 
out in the Slovak Republic reports similar concentrations of commonly prescribed and illicit 
drugs from five wastewater treatment plants [70], with the highest concentrations found to be 
1300, 800 and 580 ng/g for fexofenadine, verapamil and citalopram, respectively. Other 
compounds detected include diclofenac, carbamazepine, acetaminophen, codeine, cannabinol 
and MDMA (concentrations between 3.3-330 ng/g). These studies further support the need to 
determine the pharmaceutical content of wastewater samples within the UK, characterising 
any matrix effects and the absolute recovery of analytes, to ensure accurate quantitation in 
complex matrices. 
 
1.5.2: Biocides in Wastewater and Sludge 
Similarly to the pharmaceuticals, there is little research regarding the detection of QACs in 
wastewater, with no studies based in the UK. Of the studies carried out; one in Austria and 
one in China, a range of methods have been used, typically sample preparation methods 
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involving the use of liquid-based extractions, such as Soxhlet extraction and SPE In a study 
carried out by Martínez-Carballo et al. [71], 21 samples of river sediment and 6 samples of 
sludge were tested from different WWTP around Austria using a Soxhlet extraction method, 
involving 150 mL of acidified methanol over an 18 hour time period. Of the 12 QACs 
analysed (alkyl benzyl, dialkyl and trialkyl QACs), benzalkonium salts (BACs) and 
dialkyldimethylammonium salts (DDACs) were detected in the highest concentrations, with 
maximum concentrations of 3.6 and 2.1 mg/kg for BAC-C12 and DDAC-C18 in sediment, 
respectively. Within the sludge samples, DDAC-C18 was quantified with a mean 
concentration of 10 mg/kg, however the BAC compounds and the trialkylammonium salts 
(ATACs) were also detected, but at lower concentrations of between 0.16-8.4 mg/kg. This 
confirms the need to study QACs in wastewater samples, and also highlights the need for an 
alternative sample preparation method, more suited to high-throughput monitoring analysis. 
Another study carried out in China, looked at 17 QACs within 52 samples of digested sludge 
collected from WWTP around the country [72]. Samples were extracted using a two-step 
liquid extraction, first with 10 mL of methanolic hydrochloric acid then with 10 mL of 
chloroform before being passed through an anion exchange resin. Total concentrations were 
similar to those seen in the Austrian study, with concentrations of ATACs, BACs and 
DDACs found to be in the range of 0.38-293, 0.09-344 and 0.64-344 mg/kg, respectively.  
A more recent study investigated the concentrations of biocides, including BACs, within 
Swedish sewage sludge and wastewater [73]. Samples of digested sludge and treated effluent 
were extracted using SPE before LC-MS/MS analysis. Concentrations of biocides within the 
digested sludge samples were found to be the highest with BAC-C10 to C16 observed in the 
range of 0.1-35 mg/kg, with the most abundant biocide found to be 
hexadecyltrimethylammonium bromide (HDTMA) at 79 mg/kg. Surprisingly, each of the 
biocides studied were detected within the treated effluent samples, despite their preference to 
adsorb to biosolids. Concentrations were predictably much lower, with BAC-C12 and 
HDTMA found to be the most abundant at 66 and 72 ng/L, respectively, and concentrations 
of between 2 and 30 ng/L were recorded for BAC-C10, C14 and C16.  
The high concentrations determined within these studies further highlights the need to 
determine QAC concentration within UK wastewater to inform WFD. 
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1.5.3: Pollutants in Biota 
A concern arising from studies investigating the detection of pharmaceuticals in water is the 
potential of drugs to bioaccumulate in biota, specifically filter feeders such as shellfish, and 
the possibility of drug transfer into the food chain. Research in this area is sparse with only a 
few publications investigating these concerns within the UK, with no published research 
concerning the detection of QACs within biota. Of the most notable studies, McEneff et al. 
[74] in 2013, investigated the bioaccumulation of pharmaceuticals in cooked and uncooked 
bivalves (blue mussels) collected from a pristine site in west Ireland. The five compounds 
chosen for the study, diclofenac, mefenamic acid, trimethoprim, carbamazepine and 
gemfibrozil, were administered to the bivalves by direct injection of a 10 ng pharmaceutical 
mixture or by daily exposure via spiked artificial seawater. Samples of freeze-dried cooked 
and uncooked bivalve tissue were homogenised and prepared using a pressurised liquid 
extraction followed by solid-phase extraction. The results showed that, with the exception of 
trimethoprim (a basic antibiotic), the concentrations of the pharmaceuticals increased after 
the bivalves were steam cooked, with the biggest increase from 1.6 µg/g to 89.6 µg/g 
observed for mefenamic acid. This result indicates the capture of drug within the tissue and 
correlates with studies of pesticides and heavy metals in other foods. For example, 
concentrations of the pesticide hexachlorobenzene in meat and fish increased significantly 
when cooked [75] along with the concentrations of heavy metals when in seafood [76]. This 
is reportedly due to the loss of water encountered during cooking acting as a concentration 
step. This effect is an important factor that must be considered when investigating both the 
amount of “free” pharmaceutical within biota samples and any (eco)-toxicity studies that may 
inform subsequent environmental and human risk assessments during drug development and 
environmental impact work. This study highlights the potential of pharmaceuticals to 
accumulate within biota under controlled conditions however, there is little evidence to 
determine the level of pharmaceutical contamination within biota exposed to wastewater 
effluent.   
 
1.6: Research Need  
The environmental persistence of organic pollutants, such as pharmaceuticals and biocides, is 
a growing area of research. Until the introduction of the Water Framework Directive 
(2000/60/EC) and Environmental Quality Standards (Directive 2008/105/EC), the impact of 
drug emission into the environment through wastewater treatment plants has been largely 
Rachel Townsend 
__________________________________________________________________________________________ 
 
__________________________________________________________________________________________ 
 
Page 37 of 177 
unconfirmed and unrestricted. Preliminary research has shown that compounds with high 
octanol-water partition coefficient (Kow/logP), like many common pharmaceuticals and 
biocides, are not biodegraded during wastewater treatment and are able to bioaccumulate, 
adsorbing to soils and sludge. As treated sludge is routinely deposited on land, it is important 
to understand the extent of any chemical accumulation. Current recognised methods for 
preparing complex environmental matrices such as soil and wastewater effluent for analysis 
are typically multi-step procedures using a range of techniques and apparatus, resulting in 
methods that are time and resource consuming, unsuitable for high-throughput analysis. 
Focussing on compounds of interest to the Chemical Investigation Programme; a British 
research initiative concentrating on the monitoring of pollutants in sludge, and those detected 
in preliminary in-house data (see Appendix 1.1), we propose to develop a suitable sample 
preparation method for the simultaneous extraction of a selection of pharmaceuticals and 
biocides, commonly used in a domestic capacity (see Table 1.2) from complex environmental 
matrices including water, soil, sludge and biota, based upon the QuEChERS (Quick, Easy, 
Cheap, Effective, Rugged and Safe) methodology. Compounds were chosen according to 
their lipophilicity (i.e. logP), based on the predication that compounds with a logP of around 
3 are likely to adsorb to soils and sludge, commonly used over-the-counter medicines [77], 
and highly prescribed pharmaceuticals, where prescriptions dispensed have increased over 
successive years [25,78]. Compared to recognised environmental preparative methods for 
wastewater and solid samples, the QuEChERS approach potentially offers a reduction in 
preparation time, from hours to ~20 minutes per sample and reduced extraction cost, 
estimated at 63% for the extraction cartridges alone, therefore, it is prudent to investigate the 
potential of the QuEChERS method further. We aim to develop a method that offers good 
recovery of compounds, with minimal matrix interferences, using a reversed-phase liquid 
chromatography-mass spectrometry (LC-MS) method for multi-residue detection to reliably 
quantitate these compounds using an internal standard approach.  
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Table 1.2: Summary data for the suite of compounds chosen for this study, based upon the compounds of 
interest to CIP and WFD, and previous in-house data. 
Compounds Structure 
Acetaminophen 
Formula: C8H9NO2 
pKa: 10.2 
logP: 0.34 
Chemistry: Basic 
 
Citalopram Hydrobromide 
Formula: C20H21FN2O 
pKa: 9.4 
logP: 2.51 
Chemistry: Basic 
 
Carbamazepine 
Formula: C15H12N2O 
pKa: 14.3 
logP: 2.67 
Chemistry: Basic  
Erythromycin  
Formula: C37H67NO13 
pKa: 8.6 
logP: 2.83 
Chemistry: Basic 
 
Propranolol Hydrochloride 
Formula: C16H21NO2 
pKa: 9.5 
logP: 3.1 
Chemistry: Basic  
Diphenhydramine Hydrochloride 
Formula: C17H21NO 
pKa: 8.7 
logP: 3.66 
Chemistry: Basic  
Ibuprofen  
Formula: C13H18O2 
pKa: 4.3 
logP: 3.72 
Chemistry: Acidic  
Diclofenac Sodium 
Formula: C14H11Cl2NO2 
pKa: 4.4 
logP: 4.06 
Chemistry: Acidic  
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Fluoxetine Hydrochloride 
Formula: C17H18F3NO 
pKa: 9.6 
logP: 4.09 
Chemistry: Basic  
Loratadine 
Formula: C22H23ClN2O2 
pKa: 4.7 
logP: 5.94 
Chemistry: Basic 
 
Benzyldimethyldodecylammonium Chloride 
(BAC-C12) 
Formula: C21H38N 
pKa: - 
logP: 1.69 
Chemistry: Basic 
 
Hexadecyltrimethylammonium Chloride 
(HDTMA) 
Formula: C19H42N 
pKa: - 
logP: 2.40 
Chemistry: Basic 
 
Didecyldimethylammonium Bromide 
(DDMA) 
Formula: C22H48N 
pKa: - 
logP: 2.51 
Chemistry: Basic 
 
Benzyldimethyltetradecylammonium 
Chloride (BAC-C14) 
Formula: C23H42N 
pKa: - 
logP: 2.55 
Chemistry: Basic 
 
Benzyldimethylhexadecylammonium 
Chloride (BAC-C16) 
Formula: C25H46N 
pKa: - 
logP: 3.42 
Chemistry: Basic 
 
Stearalkonium Chloride (BAC-C18) 
Formula: C27H50N 
pKa: - 
logP: 4.28 
Chemistry: Basic 
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1.7: Research Aims 
The overall aim of this thesis was to develop a QuEChERS-based sample preparation method 
suitable for the extraction of acidic and basic compounds, including a selection of 
pharmaceuticals and biocides of interest to the Chemical Investigation Programme. This 
development was undertaken to ensure minimal matrix effects and maximum compound 
recovery were achieved from complex environmental matrices, including wastewater 
effluent, treated sludgecake and locally sourced biota, with qualitative and quantitative 
investigations achieved using an LC-MS approach. The specific objectives were to: 
1. To develop a liquid chromatography-mass spectrometry (LC-MS) qualitative and 
quantitative analytical platform for a suite of pharmaceuticals, with a particular focus 
on highly prescribed and common over-the-counter medicines, and commonly used 
biocides that may contribute to informing CIP II and WFD. 
2. To investigate and benchmark the QuEChERS sample preparation technique for the 
chosen compounds versus current recognised methods used by regulatory agencies 
(e.g. EPA and Natural Resources Wales (NRW)) for wastewater treatment samples 
(i.e. treated effluent and sludgecake) and chosen species of biota (molluscs).  
3. Qualitative mass spectrometry investigation of wastewater treatment samples (i.e. 
treated effluent and sludgecake) and chosen species of biota (molluscs) for 
compounds of interest to CIP II and WFD.  
4. Quantitative mass spectrometry investigation of wastewater treatment samples (i.e. 
treated effluent and sludgecake) and molluscs for the selected compounds of interest.  
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Chapter 2: Materials and Methods 
 
2.1: Laboratory Equipment 
 10 µL, 100 µL, 1 mL, 10 mL Transferpette air displacement pipettes 
 Mettler Toledo EL204 analytical balance (4 decimal places) 
 Fisherbrand FB15012 vortex mixer 2x classic 
 Eppendorf centrifuge 5810R 
 Scanvac Lyophilser 
 Techne Sample Concentrator 
 SPE Vacuum Box 
 Desiccator 
 
2.2: Chemicals and Consumables 
2.2.1: Chemicals 
A suite of 10 pharmaceuticals and 6 quaternary ammonium biocides (QACs) of interest to the 
Chemical Investigation Programme (CIP) were chosen, based on compounds seen in a 
qualitative screen as part of previous in-house study. In order to be able to quantify the target 
pharmaceuticals, surrogate internal standards (IS) were sourced. Unfortunately, due to the 
high cost of isotopically labelled analogues of most of the target compounds, more pragmatic 
alternatives were sourced. The IS chosen are drugs that did not pass the pre-clinical studies 
during drug development or not marketed and therefore should have not been emitted into the 
environment. Talopram hydrochloride and pronethalol hydrochloride are structural analogues 
of citalopram and propranolol; these were investigated to determine whether they could be 
used as an IS and for their scope to be broadened to include for citalopram, diphenhydramine, 
fluoxetine and diclofenac, and propranolol, respectively due to similarities in structure and 
retention times. For carbamazepine, a synthetic impurity, 10,11-dihydrocarbamazepine, was 
chosen and due to similar physio-chemical properties in logP and structure this was also 
tested as an IS for erythromycin and loratadine. For acetaminophen, the smallest compound 
in the suite, a deuterated analogue was sourced as the physio-chemical properties differed 
significantly from the rest of the suite. For the biocides (BAC-C12-C18, DDMA and 
HDTMA), a single IS was chosen for all 6 compounds; the deuterated analogue of BAC-C14, 
benzyldimethyltetradecylammonium chloride-d7 (BAC-C14-d7) due to the similarity in 
molecular structures and retention time.  
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The chemicals and standards used are listed in Table 2.1. 
 
Table 2.1: List of chemicals and pharmaceuticals used and their grade i.e. pharmaceutical secondary standard 
(PSS), CAS number and the supplier details. 
Chemical CAS N
o
 Grade Supplier 
Acetonitrile 75-05-8 HPLC Fisher Scientific 
(Loughborough, 
England) 
Water 7732-18-5 HPLC 
Formic acid 64-18-6 99.44% 
Acetaminophen 103-90-2 PSS 
Sigma Aldrich (Dorset, 
England) 
Carbamazepine 298-46-4 PSS 
Diclofenac 15307-79-6 PSS 
Diphenhydramine Hydrochloride 147-24-0 ≥ 98.0% 
Erythromycin 114-07-8 PSS 
Fluoxetine Hydrochloride 56296-78-7 PSS 
Ibuprofen 15687-27-1 PSS 
Loratadine 79794-75-5 PSS 
Propranolol Hydrochloride 318-98-9 PSS 
Citalopram Hydrobromide 59729-32-7 >99.0% 
Tocris (Abingdon, 
England) 
Benzyldimethyldodecylammonium 
Chloride (BAC-C12) 
139-07-1 >99.0% 
Sigma Aldrich 
 
Benzyldimethyltetradecylammonium 
Chloride (BAC-C14) 
139-08-2 >99.0% 
Benzyldimethylhexadecylammonium 
Chloride (BAC-C16) 
122-08-9 n/a 
Didecyldimethylammonium 
Bromide (DDMA) 
2390-68-3 98% 
Hexadecyltrimethylammonium 
Chloride (HDTMA) 
112-02-7 >98% 
Stearalkonium chloride (BAC-C18) 122-19-0 n/a 
LGC Standards 
(Teddington, England) 
Internal Standards 
Acetaminophen-(methyl)-d3 60902-28-5 n/a 
Sigma Aldrich 
10,11-Dihydrocarbamazepine 3564-73-6 99.0% 
Pronethalol Hydrochloride 51-02-5 >99.0% 
Tocris 
Talopram Hydrochloride 7013-41-4 >99.0% 
Benzyldimethyltetradecylammonium 
chloride-d7 (BAC-C14-d7) 
1219178-
72-9 
n/a 
Toronto Research 
Chemicals (Ontario, 
Canada) 
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2.2.2: Consumables 
 2 mL and 4 mL amber-glass Chromacol Ltd. vials 
 20 mL disposable scintillation vials 
 Glass Wheaton and Duran bottles 
 15 mL and 50 mL Corning Centristar centrifuge tubes 
 20 mL Oasis HLB cartridges 
 
2.2.3: Sample Preparation Consumables 
The following sample preparation consumables were supplied by Biotage EU (Uppsala, 
Sweden) and Biotage GB (Ystrad Mynach, Wales). 
 6 mL ISOLUTE® ENV+ SPE cartridges 
 6 mL ISOLUTE® SCX-2 SPE cartridges 
 3 mL, 6 mL and 10 mL custom SPE cartridges containing MgSO4 and PSA 
 QuEChERS extraction tubes, detailed in Table 2.2 below 
 
Table 2.2: List of QuEChERS kits used in this project and their chemical composition.  
 Composition 
QuEChERS 
Consumable 
MgSO4 PSA C18 GCB 
Na 
Acetate 
NaCl 
Na 
Citrate 
Na Citrate 
sesqui-
hydrate 
Custom Extraction Tube 4 g    1.5 g    
AOAC Extraction Tube 
(Q0010-15V) 
6 g    1.5 g    
EN Extraction Tube 
(Q0020-15V) 
4 g     1 g 1 g 0.5 g 
AOAC Fruit and Vegetable 
(F&V) Kit (Q0030-15V) 
1200 mg 400 mg       
EN Fruit and Vegetable 
(F&V) Kit (Q0035-15V) 
900 mg 150 mg       
AOAC Waxed F&V Kit  
(Q0050-15V) 
1200 mg 400 mg 400 mg      
EN Waxed F&V Kit  
(Q0060-15V) 
900 mg 150 mg 150 mg      
EN Pigmented F&V Kit 
(Q0080-15V) 
900 mg 150 mg  15 mg     
EN Highly Pigmented F&V 
Kit (Q0090-15V) 
900 mg 150 mg  45 mg     
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2.3: Instrumentation 
2.3.1: Liquid Chromatography System 
Thermo Finnigan LC system consisting of a Micro AS autosampler and MSPump Plus was 
used throughout this study and interfaced to mass spectrometry for detection. A confirmatory 
qualitative screen was performed using a Dionex Ulitmate 300, however LC conditions 
remained the same. 
 
2.3.1.1: Liquid Chromatography Columns 
Various LC columns were investigated throughout the method development stage, as 
described below: 
 Waters Xbridge C18 column (1.0 x 100 mm ID, 3.5 µm) Waters Xselect charged surface 
hybrid (CSH) C18 column (2.1 x 150 mm ID, 3.5 µm) 
 Waters Xselect high strength silica (HSS) T3 column (1.0 x 100 mm ID, 3.5 µm) 
A Phenomenex KrudKatcher Ultra 0.5 micron in-line filter was used or the final assessment 
of these columns in preparation for complex samples. This was chosen in place of a guard 
cartridge of the same stationary phases due to the unavailability of this product at this column 
ID. 
 
2.3.1.2: Liquid Chromatography Solvents 
Various compositions of mobile phases were investigated during method development, 
including changing the organic modifier and additives. Optimum conditions (good 
chromatographic peak shape and reproducible chromatography) were observed using the 
following solutions: 
 
Mobile Phase A: 0.1% formic acid in water - The mobile phase was prepared by measuring 
500 mL of HPLC grade water into a 1 L Wheaton bottle. 500 µL was removed using a pipette 
and 500 µL of formic acid was added. The solution was mixed thoroughly before use. 
 
Mobile Phase B: 100% acetonitrile. 
 
Injector Wash: 0.1% formic acid in a mixture of 75% water: 25% acetonitrile - 150 mL of 
HPLC grade water and 50 mL of HPLC grade acetonitrile were mixed together into a 250 mL 
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Duran bottle. 200 µL of the solution was removed replaced with the same volume of formic 
acid. The solution was mixed thoroughly before use. 
 
These were the final conditions used for characterising the LC-MS method and investigating 
the quantitative performance as no carryover of the compounds was observed and remained 
the same for both chromatographic columns and both mass spectrometric systems. 
 
2.3.1.3: Injector Conditions 
The autosampler was maintained at 4°C during operation to prevent solvent evaporation. 
Each sample (5 µL) was injected onto the column via a full loop injection (20 µL) to ensure 
an accurate and reproducible injection volume. The injection needle was washed with 1 mL 
of wash solution to prevent carryover of target analytes and the syringe flushed with 4.8 µL 
of wash solution, twice the volume of the syringe, as part of the wash programme to ensure 
optimum performance of the syringe. 
 
2.3.1.4: Flow Conditions 
A mobile phase flow rate of 50 µL/minute was used throughout analysis and used a gradient 
elution by increasing to 100% B at the rate of 3.4 percent/minute. The elution method also 
comprised a post-gradient wash and a re-conditioning step to ensure column conditions were 
reproducible for each injection. 
 
 Gradient elution: Initial 95% A: 5% B, hold for 2 minutes 
 Linear ramp to 100% B in 28 minutes and hold for 10 minutes 
 Linear ramp to initial conditions in 1 minute and hold for 10 minutes 
 Total run time: 51 minutes 
 
2.3.2: Mass Spectrometry Analysis 
Final quantitation of pharmaceuticals was undertaken using a Waters Micromass ZQ4000 
single quadrupole mass spectrometer, equipped with an electrospray ionisation (ESI) source. 
A simultaneous qualitative pharmaceutical screen and quantitative analysis of biocides was 
carried out using a Thermo Finnigan LCQ Classic 3D ion trap mass spectrometer with ESI 
source. The LCQ was operated in positive ionisation mode only. A confirmatory qualitative 
screen was performed on a Thermo Scientific LTQ Orbitrap XL mass spectrometer to obtain 
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accurate mass data to aid identification of any compounds of interest. As with the LCQ, this 
was operated in positive ionisation mode only. 
 
2.3.2.1: Quantitation Method (ZQ4000) 
Prior to LC-MS method development the mass spectrometer was calibrated and tuned for the 
target precursor ion of the pharmaceutical and internal standard. This involved optimising the 
cone voltage to maximise the precursor ion signal observed without inducing in-source 
fragmentation. The source and desolvation settings used were in accordance with the 
manufacturer specifications for a flow rate of 50 µL/minute.  
 
Table 2.3: This table shows the Waters ZQ4000 electrospray (ESI) source operation settings used for this study. 
The cone voltage for each compound was set within the instrument method. 
Setting Positive Mode Negative Mode 
Capillary Voltage (kV) 3.50 2.81 
Cone Voltage (V) 15 (Variable) 15 (Variable) 
RF Lens (V) 0.5 0.5 
Source Temperature (°C) 80 120 
Desolvation Temperature (°C) 120 100 
Desolvation Gas Flow (L/hr) 250 250 
Cone Gas Flow (L/hr) 50 50 
 
The mass spectrometer was operated in full mass scan mode over a mass-to-charge (m/z) 
range of 125-775, and selected ion monitoring (SIM) mode for the relevant precursor masses 
in positive and negative ionisation conditions. Data was acquired using MassLynx software 
in positive ion mode and was captured in continuum for a complete profile of the ions. As 
quantitative LC-MS requires at least 10 data points across the chromatographic peak, the LC-
MS method was segmented into individual SIM scans, according to each compound’s 
retention time. A full mass scan in positive and negative ionisation mode was recorded over 
the entire chromatographic run (51 minutes) to generate a comprehensive chromatographic 
profile for each sample. Data was processed using QuanLynx using a Savitzky-Golay 
smoothing factor of 1 and a peak threshold of 1.5 and 2.0 for height and area, respectively. 
As part of the quantitative analysis, manual integration was required; this was performed by 
using the automatic peak integration function in the chromatogram window within MassLynx 
software. The peak area was then manually divided by the automated peak area of the 
extracted ion chromatogram of the corresponding internal standard to generate the relative 
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response factor (RRF), which was inputted into the regression equation to determine 
concentration (see Eq 2.9). Statistical analysis was carried out using Microsoft Excel. 
 
Table 2.4: A summary of the optimised cone voltages used for the SIM scan for each compound. Each 
compound had a scan time of 0.4 seconds and an inter-scan delay of 0.01 seconds, with the exception of 
ibuprofen (analysed in negative mode), which had an inter-scan delay of 0.1 seconds. 
Compound Cone Voltage (V) 
Acetaminophen 20 
Acetaminophen-(methyl)-d3 25 
Carbamazepine 20 
Citalopram 20 
Diclofenac 10 
Diphenhydramine 10 
Erythromycin 10 
Fluoxetine 15 
Ibuprofen 15 
Loratadine 10 
Pronethalol 5 
Propranolol 25 
Talopram 15 
10,11-Dihydrocarbamazepine 35 
 
2.3.2.2: Pharmaceutical Screen and Biocide Quantitation Method (LCQ) 
Prior to method development the mass spectrometer was calibrated and tuned using a specific 
calibration mixture containing caffeine, MRFA and Ultramark to optimise the capillary 
voltage (3 V), tube lens offset (10 V) and source voltage (4.5 kV). The sheath gas flow of 60 
and capillary temperature of 200°C were set in accordance to the manufacturer’s 
specification for a flow rate of 50 µL/minute. The mass spectrometer was operated in full 
mass scan mode over a m/z range of 100-800, with product ion scans recorded for target 
pharmaceutical masses and selected reaction monitoring (SRM) mode for the biocides, with 
the exception of HDTMA which was recorded as a SIM scan, in positive ionisation 
conditions.  
For quantifying the target biocides a pilot study carried out in-house determined the optimal 
collision energies for each compound, and these parameters were used in this method. Data 
was acquired using Xcalibur software in positive ion mode and was captured in continuum 
for a complete profile of the ions. As quantitative LC-MS requires at least 10 data points 
across the chromatographic peak, the LC-MS method was partitioned into four segments and 
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the scan events divided across the segments to minimize the duty cycle. Each segment of the 
method recorded a full mass scan to generate a comprehensive chromatographic profile for 
each sample. Data processing was carried out using QualBrowser and QuanBrowser with 
statistical analysis performed using Microsoft Excel. 
 
Table 2.5: A summary of the processing and integration settings used to quantitate the biocides using 
QuanBrowser. All data was processed from the SRM/SIM data with peaks integrated providing the signal-to-
noise (S/N) is above 3, using ICIS peak detection algorithm, a Savitzky-Golay smoothing function of 3 with a 
baseline window of 40 and noise factors of 5 and 10 for area and peak, respectively.  
 Segments 
Compound 
Scan 
Type 
Scan Filter 
1 
(0-5 
min) 
2 
(15-20 
min) 
3 
(20-26 
min) 
4 
(26-51 
min) 
All FMS ms [100.00-800.00]     
Acetaminophen FMS ms2 152.00@35.00 [50.00-200.00]     
Acet-d3 FMS ms2 155.00@35.00 [50.00-200.00]     
Pronethalol FMS ms2 230.00@40.00 [60.00-250.00]     
Propranolol FMS ms2 260.00@40.00 [70.00-275.00]     
Diphenhydramine FMS ms2 256.00@30.00 [70.00-275.00]     
Citalopram FMS ms2 325.00@40.00 [85.00-350.00]     
Erythromycin FMS ms2 734.00@40.00 [200.00-750.00]     
Carbamazepine FMS ms2 237.00@40.00 [65.00-250.00]     
10,11 - DHC FMS ms2 239.00@40.00 [65.00-250.00]     
Fluoxetine FMS ms2 310.00@40.00 [85.00-350.00]     
Talopram FMS ms2 296.00@40.00 [80.00-325.00]     
Loratadine FMS ms2 383.00@40.00 [105.00-400.00]     
Diclofenac FMS ms2 296.00@30.00 [80.00-325.00]     
BAC-C12 SRM ms2 304.00@40.00 [211.00-213.00]     
BAC-C14 SRM ms2 332.00@42.00 [239.00-241.00]     
BAC-C16 SRM ms2 360.00@44.00 [267.00-269.00]     
BAC-C18 SRM ms2 388.00@48.00 [295.00-297.00]     
DDMA SRM ms2 326.00@48.00 [185.00-187.00]     
HDTMA SIM ms [283.00-285.00]     
BAC-C14-d7 SRM ms2 339.00@40.00 [239.00-241.00]     
 
2.3.2.3: Qualitative Screen (LTQ Orbitrap) 
Similar to the LCQ, this mass spectrometer was tuned and calibrated prior to analysis using a 
mixture of caffeine, MRFA and Ultramark to optimise the capillary voltage, tube lens offset 
and source voltage, and an optimal sheath gas flow of 25 and capillary temperature of 275°C 
were used for this analysis. The mass spectrometer was operated in positive ionisation mode 
and data was recorded using a full mass scan over a m/z range of 100-1000 for 51 minutes, 
with an additional DDA scan set to fragment the most intense parent ion detected in the pre-
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scan using a fixed collision energy of 40 V to generate accurate mass data. Data was analysed 
using QualBrowser in Xcalibur 3.0. 
 
Table 2.6: The optimum electrospray source settings for the LTQ Orbitrap used for the qualitative screen. 
Setting Positive Mode 
Capillary Voltage (V) 40 
Capillary Temperature (°C) 275 
Tube Lens Offset (V) 130 
Source Voltage (kV) 3.6 
Sheath Gas Flow (arbitrary units) 25 
 
2.4: Solutions 
2.4.1: Standard Stock Solutions 
1 mg/mL standard stock solution: 1 mg of material was weighed into an amber glass 
chromacol vial and 1 mL of HPLC grade water or acetonitrile was added, followed by 
vortexing to ensure material was completely dissolved. Where possible, solutions were 
prepared in water to limit degradation or evaporative effects, with the exception of the 
biocides, ibuprofen, erythromycin, loratadine, carbamazepine and 10,11-
dihydrocarbamazepine which were made up in 100% acetonitrile, due to limited solubility at 
this concentration. 
 
2.4.2: Working Solutions  
These were used as a sub-stock for the calibration graph, and made as an analyte mixture by 
adding an appropriate amount of the stock solutions to a diluent of 50:50 acetonitrile/water. 
All solutions were vortexed before use. 
 
1 µg/mL working solution: 1 µL of each standard stock solution was dispensed into an 
amber glass chromacol vial containing the appropriate amount of 50:50 HPLC grade 
water/HPLC grade acetonitrile solvent mixture. The sample was vortexed before use and an 
additional mixture prepared for the internal standard working solution. 
 
2.4.3: Calibration and Quality Control (QC) Samples 
Calibration graphs were produced for each compound using eleven calibration standards of 
increasing concentration, made using a 1 µg/mL working solution. Each graph was plotted 
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using regression statistics as relative response ratio versus concentration, and the ability to 
quantitate was characterised using the Xselect HSS T3 columns. 
 
Table 2.7: The concentration range and corresponding volume used for each pharmaceutical calibration 
standard and quality control (QC) standards when analysed using the Xselect H33 T3. SB consisted of 50:50 
acetonitrile/water and the S0 contained 100 ng/mL of internal standard mixture only. 
Calibration Standards for Pharmaceutical Analysis using Xselect HSS T3 
Standard S1 S2 S3 S4 S5 S6 S7 S8 S9 
Concentration (ng/mL) 1 5 10 25 50 100 200 300 400 
 
Quality Control (QC) Samples for Pharmaceutical Analysis using Xselect HSS T3 
Standard V. Low Low Mid High 
Concentration (ng/mL) 15 25 100 350 
 
For biocide measurement, an alternative calibration and QC range were used to accommodate 
the difference in compound sensitivity and expected relative abundance. 
 
Table 2.8: The concentration range and corresponding volume used for each biocide calibration standard and 
quality control (QC) standards when analysed using the Xselect H33 T3. SB consisted of 50:50 
acetonitrile/water and the S0 contained 20 ng/mL of internal standard mixture only. 
Calibration Standards for Biocide Analysis using Xselect HSS T3 
Standard S1 S2 S3 S4 S5 S6 S7 S8 
Concentration (ng/mL) 2 6 10 20 30 50 70 80 
 
Quality Control (QC) Samples for Biocide Analysis using Xselect HSS T3 
Standard V. Low Low Mid High 
Concentration (ng/mL) 8 20 60 80 
 
2.4.4: Sample Preparation Working Solutions 
Several working solutions were prepared in 2 mL and 4 mL amber glass chromacol vials. 
Each working solution was prepared from a 1 µg/mL dilution of the stock solutions to a 
concentration of 200 ng/mL for both the pharmaceuticals and associated IS, and 60 ng/mL 
and 20 ng/mL for the biocides and biocides IS, respectively. 
1. Pharmaceuticals working solution (P) – 200 ng/mL: 200 µL of 1 µg/mL in 800 µL 
of 50:50 acetonitrile/water. 
2. Pharmaceutical IS working solution (P-IS) – 200 ng/mL: 200 µL of 1 µg/mL in 
800 µL of 50:50 acetonitrile/water. 
3. Biocides working solution (B) – 60 ng/mL: 60 µL of 1 µg/mL in 940 µL of 50:50 
acetonitrile/water. 
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4. Biocide IS working solution (B-IS) – 20 ng/mL: 20 µL of 1 µg/mL in 980 µL of 
50:50 acetonitrile/water. 
5. QuEChERS spiking solution – Target analytes only: 400 µL of P + 240 µL of B in 
1360 µL of 50:50 acetonitrile/water. 
6. QuEChERS spiking solution – IS only: 400 µL of P-IS + 80 µL of B-IS in 1520 µL 
of 50:50 acetonitrile/water. 
 
The 1:400 dilutions for the extraction of biocides in soil and sludge were made using the 1 
mg/mL stock solutions. 
1. QuEChERS 1:400 Biocides only: 48 µL of 1 mg/mL stock solution for each biocide 
in 712 µL of 50:50 acetonitrile/water. 
2. QuEChERS 1:400 biocide IS only: 16 µL of 1 mg/mL stock solution for each 
biocide in 984 µL of 50:50 acetonitrile/water. 
 
2.5: Sample Preparation Method 
The sample preparation method used in this study was a based upon the QuEChERS protocol. 
The method was assessed using spike before extraction (SBE) quality controls, which are 
spiked with analyte and IS prior to extraction and spike after extraction (SAE) quality 
controls, spiked with analyte and IS after the extraction. These samples were used to 
determine the matrix effects and recovery of each compound, as described by Matuszewski et 
al. [1].  
 
2.5.1: QuEChERS Extraction 
For method development, QuEChERS extractions were performed in triplicate to obtain 
precision data for matrix effect and recovery measurements. Various modifications were 
made (as described in Chapter 5) to the basic QuEChERS workflow as detailed below. 
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Table 2.9: A summary of the optimised QuEChERS sample preparation protocol used throughout this study. 
The modifications made to the method are detailed in Chapter 5. 
Initial samples made up in water before testing with 2.5 g of soil, sludge or 
homogenised biota samples. 
SBE:  
3.5 mL H2O 
+ 500 µL Drug + Internal Standards 
SAE:  
3.5 mL H2O 
+ 500 µL 50:50 ACN/H2O  
 
+ 10ml ACN + QuEChERS Extraction Mixture 
(4 g MgSO4 + 1.5 g NaOAc) 
Shake for 1 minute 
Centrifuge @ 4000 rpm for 5 minutes (21 °C) 
 
Take extract supernatant (upper organic layer) and add to d-SPE tube 
EN Fruit and Vegetable d-SPE 
(900 mg MgSO4 + 150 mg PSA) 
Vortex for 1 minute 
Centrifuge @ 4000 rpm for 5 minutes 
 
Pre-concentration by evaporation under Nitrogen and reconstitution 
 
Reconstitute in 500  µL of  
50:50 ACN/H2O 
Reconstitute in 500  µL of   
Drug + Internal Standards 
 
Vortex for 1 minute 
Transfer to a LC chromacol vial for analysis 
 
2.5.1.1: Spike Before Extraction Quality Controls 
All SBE samples were prepared in 50 mL centrifuge tube.  
1) For aqueous extractions: 250 µL of separate analyte and IS QuEChERS spiking 
solutions was spiked into 3.5 mL of water before the QuEChERS extraction protocol 
was performed.  
2) For control soil extractions: 2.5 g of soil was weighed into a 50 mL centrifuge tube, 
before the addition of 3.5 mL of water. 250 µL of separate analyte and IS QuEChERS 
spiking solutions was then spiked into the sample before the QuEChERS extraction 
protocol was performed.  
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2.5.1.2: Spike After Extraction Quality Controls 
All SAE samples were prepared in 50 mL centrifuge tube.  
1) For aqueous extractions: Before extraction, 500 µL of 50:50 acetonitrile/water was 
spiked into 3.5 mL of water, replicating the composition of the working solutions. 
After extraction, the samples were reconstituted in 250 µL of separate analyte and IS 
QuEChERS spiking solutions and vortexed before analysis.  
2) For control soil extractions: Before extraction, 500 µL of 50:50 acetonitrile/water and 
3.5 mL of water was spiked into 2.5 g of soil, replicating the composition of the 
working solutions. After extraction, the samples were reconstituted in 250 µL of 
separate analyte and IS QuEChERS spiking solutions and vortexed before analysis. 
3) For the effluent, sludge and biota quantitative samples: IS working solutions only 
were used during these extractions, whereby the sample was reconstituted in 250 µL 
spike of IS spiking solution and 250 µL of 50:50 acetonitrile/water. 
 
2.5.2: Environmental Protection Agency (EPA), Method 1694 Extraction 
The current method for the extraction of pharmaceuticals from environmental matrices is the 
United States Environmental Protection Agency (EPA) Method 1694: Pharmaceuticals and 
Personal Care Products in Water, Soil, Sediment, and Biosolids by HPLC/MS/MS [2]. This is 
a two-part extraction procedure comprised of an extensive liquid extraction protocol 
dependant on analyte chemistry, before SPE using HLB cartridges. The SPE section of the 
method was tested using a water sample spiked with drug and IS before extraction to 
determine the matrix effects and recovery of the target pharmaceuticals within this study, for 
comparison with the optimised QuEChERS method. 
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Figure 2.1: The SPE protocol for the EPA Method 1694 detailing the extraction for acidic and basic 
compounds. 
 
2.5.3: Natural Resources Wales (NRW) Extraction 
Due to varied performance of EPA method 1694 adaptations have been made by other 
regulatory agencies, such as Natural Resources Wales, a local environmental monitoring 
agency that have developed a method for the extraction of a selection of pharmaceuticals 
from sludgecake [3]. This method was investigated using a soil sample spiked with both drug 
and IS before extraction to characterise matrix effects and recovery of the target 
pharmaceuticals and to benchmark the extraction of target compounds from sludgecake 
against the optimised QuEChERS protocol.  
 
ACID 
SPE HLB 20cc/1g 
Condition 
BASE 
SPE HLB 20cc/1g 
Condition 
Load 
Wash 10 mL water,  
Dry 5 minutes,  
Elute with 12 mL MeOH 
Group 1: 
(+) ESI 
Elute with 6 mL 1:1 
acetone:MeOH 
Load 
Dry 5 minutes, 
Elute with 6 mL MeOH, 
9 mL 2% FA in MeOH 
N2 blowdown, 
Reconstitute in 3 mL MeOH, 
 Dilute to 4 mL with 0.1% FA buffer, 
Vortex 
N2 blowdown, 
Reconstitute in 3 mL MeOH, 
 Dilute to 4 mL with 0.1% FA buffer, 
Vortex 
Group 2: 
(+) ESI 
Group 3: 
(+) ESI 
Group 4: 
(+) ESI 
SAMPLE 
4 mL of H2O  
+ Drug and Internal Standards 
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Figure 2.2: The NRW method for the extraction of pharmaceuticals from sludgecake adapted for the analysis of 
a spiked soil sample, detailing the extraction for acidic and basic compounds. 
 
2.6: Statistical Analysis 
A number of statistical tests were used to analyse the LC-MS data. These will be described 
and explained below. 
 
2.6.1: Relative Standard Deviation (%RSD) 
Chromatographic repeatability was determined by calculating the relative standard deviation 
(%RSD) of the retention time of each drug and IS. This is a measure of the relative error of 
the method and is the ratio between the mean and the standard deviation of a data set [4]. A 
value of less than 5% indicates that the chromatography is repeatable between multiple 
injections that are performed sequentially.  
 
          Relative Standard Deviation (%RSD)=100 s/x̅   (Eq. 2.1) 
Where: s = standard deviation 
 ?̅? = mean 
 
 
Weigh 50 mg of soil to a centrifuge tube. 
Roll for 30 minutes. 
Add Drug and Internal Standards. 
ACID 
Add 5 mL of 1:1 H2O:ACN 
+ 0.5% HCl 
BASE 
Add 5 mL of ACN and 100µl 
of 5M sodium hydroxide 
solution 
Vortex each sample for 5 seconds. 
Sonicate the samples for 10mins 
Using a mechanical tumbler, tumble them for a further 10mins. 
Centrifuge the samples for 10mins at 3900rpm. 
Decant the extract into a new labelled 10ml centrifuge tube leaving the 
solid in the tube. 
 
Repeat process resulting in 2 combined extracts. 
Into a vial, add 960µl of H2O and 40µl of the appropriate extract. Mix. 
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2.6.2: F-Test 
Reproducibility was also determined using sequential injections of the same standard over 
two days. The variance (s
2
) for each compound for both data sets are statistically analysed 
using a two-tailed F-test to determine whether a significant difference is observed. The F-test 
is calculated with the larger variance as the numerator, and the result compared to a critical 
value. If the result is below the critical value, then there are no significant differences 
between the data sets, and therefore the chromatography shows good reproducibility over a 
given time period. 
 
        F = 
s1
2
s2
2     (Eq. 2.2) 
 
2.6.3: Grubbs’ Test 
A Grubbs’ Test was used to determine whether outliers were present within the calculated 
concentrations for the QC samples. This statistical test compares the deviation of the suspect 
value from the sample mean, which is divided by the standard deviation of the sample [4]. If 
the calculated value of G is greater than the critical value, the suspect value in question is 
rejected as an outlier, and can therefore be left out of the accuracy and precision calculations 
for the QC set. 
 
Grubbs' Test (G) =  
|suspect value - ?̅?|
s
 (Eq. 2.3) 
 
2.6.4: Accuracy and Precision 
Accuracy and precision of the calculated concentration of the QC samples were assessed to 
determine the feasibility of the method for quantitation. Both inter- and intra-day precision 
was determined using three independent calibration data sets to establish the reliability of the 
method to measure concentration over multiple experiments. The acceptance criteria used to 
define good accuracy and precision are <20% at the limit of quantitation and <15% for the 
remaining QCs.  These figures of merit were determined using the following formulas: 
 
Accuracy (%)= [
Measured concentration-theoretical concentration
Theoretical concentration
] x 100 
 
Precision (%)= [
Standard deviation of measured concentration
Mean of measured concentration
] x 100 
(Eq. 2.4) 
(Eq. 2.5) 
Rachel Townsend 
__________________________________________________________________________________________ 
 
__________________________________________________________________________________________ 
 
Page 63 of 177 
2.6.5: Instrument Detection Limit (IDL) and Instrument Quantitation Limit (IQL) 
The instrument detection limit (IDL) to determine the lowest discernible signal was 
calculated using two different methods, statistically and empirically using the following 
formulas: 
 
 IDL = 
3.3 x Standard errory intercept
Slope
 (Eq. 2.6) 
 IDL = 3 x Standard deviation of the concentration of the blank (Eq. 2.7) 
 
The instrument quantitation limit (IQL) was also determined using two different methods; 
empirically using the formula below and then confirmed with lowest QC to have good 
accuracy and precision (<20%). 
 
 IQL = 10 x Standard deviation of the concentration of the blank (Eq. 2.8) 
 
2.6.6: Regression Statistics 
Regression statistics were calculated manually as a weighted regression functions were 
assessed. The relative response factor for the compounds of interest was determined, and 
used to form the calibration equation (y = mx + c). This was derived from the following 
equations, detailed by Almeida et al. [5], where x and y are the RRF and theoretical 
concentrations of each replicate calibration measurement, respectively, and w is the 
weighting factor chosen (i.e. linear = 1 and weighted = 1/x). 
 
Relative Response Factor (RRF) = 
Peak area of analyte
Peak area of internal standard
 (Eq. 2.9) 
 
𝑏 =
∑ 𝑤𝑖.∑ 𝑤𝑖𝑥𝑖𝑦𝑖−∑ 𝑤𝑖𝑥𝑖.∑ 𝑤𝑖𝑦𝑖
∑ 𝑤𝑖.∑ 𝑤𝑖𝑥𝑖
2−(∑ 𝑤𝑖𝑥𝑖)2
  (Eq. 2.10) 
 
𝑎 =
∑ 𝑤𝑖𝑥𝑖
2.∑ 𝑤𝑖𝑦𝑖−∑ 𝑤𝑖𝑥𝑖.∑ 𝑤𝑖𝑥𝑖𝑦𝑖
∑ 𝑤𝑖.∑ 𝑤𝑖𝑥𝑖
2−(∑ 𝑤𝑖𝑥𝑖)2
  (Eq. 2.11) 
 
𝑟 =
∑ 𝑤𝑖.∑ 𝑤𝑖𝑥𝑖𝑦𝑖−∑ 𝑤𝑖𝑥𝑖.∑ 𝑤𝑖𝑦𝑖
√∑ 𝑤𝑖.∑ 𝑤𝑖𝑥𝑖
2−(∑ 𝑤𝑖𝑥𝑖)2.  √∑ 𝑤𝑖.∑ 𝑤𝑖𝑦𝑖
2−(∑ 𝑤𝑖𝑦𝑖)2
  (Eq. 2.12) 
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2.6.7: Heteroscedasticity 
The heteroscedasticity of the data was assessed using the recommendations detailed by 
Almeida et al. [5]. An F-test of the RRF of the S1 and S9 calibration standards determined 
whether the variance was statistically different between the high and low end of the 
calibration line and if the calculated F value exceed F critical (2,2; 0.95 = 19.00) [4], then the 
response was deemed heteroscedastic. The use of different weighting factors was then tested 
by the percentage relative error (%RE) calculated for the replicate measurement of each 
calibration standard and the weighting factor that gives the smallest sum of absolute relative 
errors is considered the most appropriate. 
 
Relative Error (%RE) = 
Calculated value of x - Theoretical value of x
Theoretical value of x
 x 100 (Eq. 2.13) 
 
2.6.8: Extraction Performance 
The performance of the QuEChERS extraction was assessed using the method set out by 
Matuszewski et al. [1] using the following formulas:  
 
 Matrix Effects (%) = 
Peak area of spike after extraction
Peak area of standard
 x 100 (Eq. 2.14) 
  
 Recovery (%) = 
Peak area of spike before extraction
Peak area of spike after extraction
 x 100 (Eq. 2.15) 
 
Once calculated, these percentages were applied to the peak area of the target analytes 
detected within the effluent, sludgecake and biota samples to determine the “true” 
concentration.  
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Chapter 3: Liquid Chromatography-Mass Spectrometry Method 
Development 
 
3.1: MS Detection and Identification of Pharmaceuticals for Quantitation 
The first aspect of LC-MS method development is to ascertain the selectivity of detection, 
whether the compounds can be detected without interference. This often requires separation 
or analysis of “pure” samples to determine the precursor and characteristic fragment ions that 
may be used to qualify the presence of the precursor compound before online LC-MS 
analysis. Standard solutions were therefore analysed by electrospray ionisation-mass 
spectrometry (ESI-MS) by both positive and negative ionisation modes as the suite of 
pharmaceuticals comprised of acidic and basic drugs. Each compound was infused directly 
into the mass spectrometer at a concentration of approximately 10 pmol/µL. The ability to 
obtain fragmentation data by tandem mass spectrometry (MS/MS) is not available on a single 
quadrupole mass spectrometer operating with a soft ionisation source such as ESI, however, 
the instrument chosen for this work does enable some enhancement of selectivity with 
compound fragmentation by in-source fragmentation. This is achieved by adjusting the 
voltage within the ESI source (i.e. cone voltage) which excites the precursor ion, causing it to 
fragment. Increasing the cone voltage sequentially from 5 – 35 V was shown to be sufficient 
to induce fragmentation providing further information to help identify the compound (i.e. a 
“qualifier” or fragment product ion). The signal-to-noise (S/N) was calculated over 10 scans 
using a background signal and the peak intensities of the target compound and any observed 
product ions to determine which cone voltage (CV) gave the best response for the target 
compound.  
 
3.1.1: Acetaminophen  
Acetaminophen has the molecular formula C8H9NO2 and a monoisoptopic mass of 151 Da. 
When infused as a standard solution an ion consistent with the protonated molecule ion 
[M+H]
+
 is observed at m/z 152. Given the elemental composition, the only isotope pattern 
seen is the 
13
C as expected at a 1.1% height of the total number of carbon atoms, i.e. C8 = 
8.8% 
13
C. The fragmentation of acetaminophen in literature reports that the most common 
product ion is m/z 110 [1], and this is observed with increasing cone voltage. This particular 
fragmentation pattern is the result of a molecular rearrangement of two hydrogen atoms [2] 
Rachel Townsend 
__________________________________________________________________________________________ 
 
__________________________________________________________________________________________ 
 
Page 67 of 177 
and a loss of methanal. This mechanism is confirmed when introducing a deuterated methyl 
group to the structure as shown in Figure 3.2.  
 
 
Figure 3.1: The structure of acetaminophen, with the full mass spectrum showing the precursor ion observed at 
m/z 152 and the optimum cone voltage (CV) determined by the direct infusion experiments.  
 
3.1.2: Acetaminophen-(methyl)-d3 
Similar to acetaminophen (section 3.1.1), acetaminophen-(methyl)-d3 has the molecular 
formula C8H6D3NO2, where deuterium replace three hydrogen atoms in the methyl group 
bonded to the carbonyl of the aliphatic section of the structure . This addition results in an 
increase in mass with the protonated molecule [M+H]
+
 being observed at m/z 155. The 
fragmentation pattern for this compound confirms the hydrogen rearrangement observed with 
acetaminophen, where the fragment ion showing evidence of only one of the deuterium atoms 
remaining giving an overall m/z 111, and the loss of a bi-deuterated methanal neutral 
molecule of 44 Da. 
 
 
Figure 3.2: The fragmentation mechanism for acetaminophen-(methyl)-d3. The mechanism for acetaminophen 
would be the same, with the rearrangement of one hydrogen atom from the methyl group to the nitrogen. 
 
3.1.3: Carbamazepine 
The molecular formula for carbamazepine is C15H12N2O, which gives a monoisotopic mass of 
236 Da. The precursor ion observed during direct infusion corresponded to the protonated 
molecule [M+H]
+
 at m/z 237. With increasing CV fragmentation was observed at m/z 194. 
This fragment ion is consistent with the literature and corresponds with the neutral loss of the 
m/z
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%
0
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carbamoyl (CHNO) group [3]. The isotopic peak for 
13
C can be seen within the spectrum, 
which is consistent with the 1.1% height of the total number of carbon atoms (16.5%), shown 
in Appendix 3.1. 
 
3.1.4: Citalopram 
The standard reference material for citalopram is available as a hydrobromide salt 
(C20H21FN2O.HBr), with a monoisotopic mass of 405 Da. The precursor ion observed 
corresponded to the protonated structure of the loss of the hydrobromide salt, m/z 325 [M-
HBr+H]
+
. This is confirmed in the spectrum by the lack of the distinctive isotope pattern for 
bromine with data showing evidence of 
13
C isotope only. The main fragment seen for 
citalopram was m/z 262, this is proposed to involve the loss of the C2H6N “tail”, and the 
rearrangement of the carbon chain to form a five carbon ring which results in the loss of the 
oxygen atom [4]. 
 
 
Figure 3.3: The structure of citalopram, with the full mass spectrum showing the precursor ion observed at m/z 
325 and the optimum cone voltage (CV) determined by the direct infusion experiments.  
 
3.1.5: Diclofenac 
Diclofenac is an acidic analyte of pKa 4.4 and is suited to analysis by negative ionisation 
mode, with the loss of sodium resulting in a negative charge on the adjacent oxygen atom. 
However, literature and previous in-house studies have showed that it is possible to detect 
diclofenac in positive ionisation mode with an acidified solution. This is consistent with a 
substitution of the sodium to a hydrogen atom and the addition of a proton to the nitrogen 
atom to form ammonium, giving the structure an overall positive charge. While the ZQ4000 
mass spectrometer used for this study is capable of running in positive and negative 
ionisation mode, it was found diclofenac has better signal intensity in positive mode and the 
precursor ion conditions were tuned and characterised accordingly in this mode. The standard 
reference material is available as diclofenac sodium salt (C14H10Cl2NNaO2) with a 
monoisotopic mass of 318 Da. A precursor ion consistent with the loss of sodium from the 
m/z
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structure ([M-Na+H]
+
) was observed at m/z 296. Diclofenac has a distinctive isotope pattern 
due to the presence of two chlorine atoms within the structure; as expected ions consistent 
with chlorine isotopes at a ratio of 3:1 for 
35
Cl/
37
Cl, two base units apart [2] were observed at 
m/z 298 and 300. The fragmentation observed were similar to that described in the literature 
[5,6] with product ions at m/z 278 and 250, consistent with the loss of water and the 
carboxylic acid group, respectively. 
 
3.1.6: Diphenhydramine 
As with citalopram and diclofenac, the standard reference material for diphenhydramine is 
available as a hydrochloride salt (C17H21NO.HCl). The observed precursor ion is consistent 
with the loss of the salt [M-HCl+H]
+
, exhibiting an ion at m/z 256, and this did not appear to 
contain a chlorine isotope pattern, confirming this assumption. Following application of the 
CV diphenhydramine appears to generate a single product ion at m/z 167, indicative of a loss 
of 89 Da, corresponding to the carbon chain from the carbonyl bond [7].  
 
 
Figure 3.4: The structure of diphenhydramine, with the full mass spectrum showing the precursor ion observed 
at m/z 256 and the optimum cone voltage (CV) determined by the direct infusion experiments.  
 
3.1.7: Erythromycin 
Erythromycin is a macrolide antibiotic, containing several ring structures resulting in the 
molecular formula of C37H67NO13. The base peak observed during direct infusion at m/z 716 
corresponded to the potential loss of water from this structure and initial characterisation was 
carried out using this ion. However when injected on column, m/z 716 was not observed, 
rather a single peak at m/z 734 was recorded; the protonated molecular ion [M+H]
+
. This is 
likely due to the increased concentration of acid found in the mobile phase, causing 
protonation. Given this, m/z 734 was assessed in terms of selectivity and adopted as the 
precursor species for quantitation. The main product ion observed for erythromycin is at m/z 
SIM: Scan time = 0.05, inter scan time = 0.01
m/z
234 236 238 240 242 244 246 248 250 252 254 256 258 260 262 264 266 268 270 272 274 276 278 280 282 284
%
0
100
DIPHENHYDRAMINE 13PMOL_UL_0_1FA_CV10 1 (0.085) Scan ES+ 
3.45e7256.2
257.2
Molecular formula: C17H21NO.HCl 
Monoisotopic mass: 291.13 Da 
Precursor ion: m/z 256 
Optimum CV: 10 V 
Rachel Townsend 
__________________________________________________________________________________________ 
 
__________________________________________________________________________________________ 
 
Page 70 of 177 
558. This is the same product ion for both m/z 734 and 716, indicative of the sequential loss 
of water (resulting in the m/z 716 ion) and the cladinose sugar ring [8]. 
 
3.1.8: Fluoxetine 
Fluoxetine is supplied as a hydrochloride salt, with the molecular formula C17H18F3NO.HCl 
and monoisotopic weight of 345 Da. The loss of HCl and protonation of the remaining 
structure gives rise to a precursor ion at m/z 310, consistent with [M-HCl+H]
+
. This is clearly 
observed, along with a product ion at m/z 148 when the cone voltage is increased to 15V, 
corresponding to the neutral loss of C7H5F3O [4] as shown in Figure 3.4. Unlike the other 
common halogen atoms (i.e. chlorine and bromine) fluorine is a monoisotopic element and 
therefore does not give an isotope pattern. Therefore, the only isotope expected for fluoxetine 
is 
13
C, which, and is clearly observed at approximately 18.7% height of the base peak. 
 
Figure 3.5: The fragmentation pattern for fluoxetine showing the precursor ion at m/z 310 and the proposed 
fragmentation to produce the observed product ion at m/z 148, resulting from the neutral loss of C7H5F3O. 
 
3.1.9: Ibuprofen 
Ibuprofen is typically analysed in negative mode, due to the lack of basic groups within the 
structure and the acidic pKa of 4.3. Ionisation occurs through the loss of a proton from the 
carboxylic acid group resulting in a negatively charged ion. However, for this study, 
ibuprofen was analysed in both positive and negative mode to see if a signal could be 
observed similar to diclofenac. The analysis showed negative ionisation mode offered the 
best sensitivity with the data obtained consistent with a precursor ion of [M-H]
-
 at m/z 205. 
During direct infusion a product ion was observed at m/z 161, corresponding to a potential 
loss of the carboxylic acid group, supported by the literature [9].  
 
 
CV: 15 V 
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Figure 3.6: The structure of ibuprofen, with the mass spectrum recorded in negative ion mode showing the 
precursor ion observed at m/z 205 and the optimum cone voltage (CV) determined by the direct infusion 
experiments. 
 
3.1.10: Loratadine 
Loratadine is an antihistamine, with a molecular formula of C22H23N2O2Cl and an ion 
consistent with a protonated precursor species was observed at m/z 383. From analyses 
carried out, the protonated molecular ion [M+H]
+
 at m/z 383 appeared very stable, and in-
source fragmentation required a high cone voltage of 50V to generate a product ion at m/z 
337. This neutral loss of 46 Da corresponds to the loss of ethanol (C2H6O) from the bottom of 
the piperidine ring [10]. There is also a distinctive isotope pattern observed for loratadine 
consistent with chlorine atoms; a peak at +1 and +2 m/z units of 24.2% and approximately 
40% of the base peak, indicative of 
13
C and 
37
Cl isotopes, respectively (see Figure 3.7). 
 
 
Figure 3.7: The structure of loratadine, with the full mass spectrum showing the precursor ion observed at m/z 
383, with the isotope patterns for 
13
C and 
37
Cl and the optimum cone voltage (CV) determined by the direct 
infusion experiments.  
 
3.1.11: Pronethalol 
Pronethalol is an analogue of propranolol, withdrawn from the clinical market due to its 
carcinogenicity in mice [11] and is currently sold as a standard in its hydrochloride form. 
Given this, little is known regarding the fragmentation of pronethalol and so fragmentation 
mechanisms can only be proposed and not confirmed with corresponding literature. The 
molecular formula of pronethalol is C15H19NO.HCl, and a precursor ion, observed in positive 
m/z
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ion mode, at m/z 230 consistent with [M-HCl+H]
+
 was recorded. When the cone voltage was 
increased, another ion at m/z 170 was observed with increasing intensity; this neutral loss of 
60 Da is indicative of a loss of C3H8O, resulting from a proposed structural rearrangement of 
the carbon chain forming an unstable morpholine ring and subsequent fragmentation. 
 
 
Figure 3.8: The fragmentation pattern for pronethalol showing the precursor ion at m/z 230 and the proposed  
fragmentation to produce the observed product ion at m/z 170, resulting from the neutral loss of C3H8O. 
 
3.1.12: Propranolol 
The standard reference material, propranolol hydrochloride has a molecular formula of 
C16H21NO2.HCl and is known to be lost during ionisation with electrospray to form the 
protonated precursor of [M-HCl+H]
+
 at m/z 260. This was apparent in the full mass scan and 
evidence of structural fragmentation was observed with increasing cone voltage with the 
product ion typically seen for propranolol in studies using collision induced dissociation [12] 
at m/z 183. This product ion is believed to form due to the neutral loss of propylamine 
(C3H9N) and water [13] from the aliphatic part of the structure. 
 
3.1.13: Talopram 
Talopram was initially discovered in 1971, however it was not commercialised due to a 
number of suicide attempts during clinical trials [14] and has meant that few available studies 
have characterised talopram by mass spectrometry. The standard reference material is 
supplied as a hydrochloride salt, with the molecular formula C20H25NO.HCl and again, 
appears to generate a precursor ion consistent with the loss of salt, [M-HCl+H]
+
 at m/z 296. 
To assess the MS selectivity of talopram and diclofenac (of sample precursor m/z) the cone 
voltage was ramped for compound fragmentation. Unfortunately talopram also appeared to 
show the same or similar fragmentation as diclofenac (loss of water) with an ion observed at 
m/z 278, indicating that chromatographic selectivity and separation would be key in 
distinguishing these compounds.  
 
Rachel Townsend 
__________________________________________________________________________________________ 
 
__________________________________________________________________________________________ 
 
Page 73 of 177 
 
Figure 3.9: The structure of talopram, with the mass spectrum recorded in positive ion mode showing the 
precursor ion observed at m/z 205 and the optimum cone voltage (CV) determined by the direct infusion 
experiments. 
 
3.1.14: 10,11-Dihydrocarbamazapine 
10,11-Dihydrocarbamazapine is a synthetic impurity of carbamazepine, with a molecular 
formula of C15H14N2O. The structural difference between 10,11-DHC and carbamazepine is 
the absence of the carbon-carbon double bond within the seven-membered ring, and an 
additional two hydrogen atoms at this position in 10,11-DHC. The precursor ion observed 
was the protonated molecule consistent with a [M+H]
+
, at m/z 239. With increasing cone 
voltage very little fragmentation was observed with the only product ions identifiable at m/z 
222 and m/z 194 at cone voltage 35V and 50V, respectively. These product ions corresponded 
to the potential loss of the ammonia [NH3] from the amide functional group, and the loss of 
the entire amide group, leaving a positive charge on the nitrogen atom at the bottom of the 
seven membered ring, similar to the product ion observed for carbamazepine. 
 
 
Figure 3.10: The fragmentation pattern for 10,11-dihydrocarbamazepine showing the precursor ion at m/z 239 
and the proposed fragmentation to produce the observed product ion at m/z 222, resulting from the neutral loss 
of NH3 and the product ion at m/z 194, resulting from the neutral loss of CH3NO. 
 
3.2: Development of LC-MS Separation 
The chromatographic separation of the suite of pharmaceutical compounds was characterised 
using both full mass scan data and individual single ion monitoring (SIM) scans to compare 
changes in the sensitivity of the analysis for quantitation. For example, the full mass scan can 
also act as a screen for later analyses using more complex matrices, and is able to capture 
m/z
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isotope and adduct data for each compound, which can be used to help identify the 
compounds alongside chromatographic retention time. However, given the significant 
amounts of data being captured under these conditions a full mass scan doesn’t typically 
provide the most sensitive acquisition approach unlike SIM. The SIM acquisition can focus 
on a particular m/z ensuring greater signal accumulation over the duration of the 
chromatographic peak and greater sensitivity. This may be improved further by segmenting 
the chromatographic method to only record the SIM scan for the specific chromatographic 
peak however, this can result in false negative results by “missing” the peak for data capture 
by a retention time shift often encountered with complex samples. 
As ibuprofen and diclofenac are normally analysed in negative ion mode, a full mass scan in 
both positive and negative mode were recorded. Within the chromatogram the compounds 
were identified by precursor m/z as a mixture and showed good chromatographic resolution, 
with the exception of acetaminophen and acetaminophen-(methyl)-d3; this is unsurprising 
since the latter is a deuterated analogue but is capable of being distinguished due to differing 
precursor m/z. For accurate integration of the peak area and therefore quantitation of 
compounds, sufficient numbers of mass spectra should be recorded within the 
chromatographic peak. This was initially investigated by determining the data points 
generated when the SIM scans were grouped according to ionisation mode, however by 
separating out the SIM scans; having one for each compound improved the selectivity and 
sensitivity, with most notable improvement being observed for diclofenac. Diclofenac was 
analysed in both positive and negative mode to determine which achieved better sensitivity. 
By separating out the SIM scans it was clear that better sensitivity was seen for diclofenac in 
positive mode (m/z 296) with a tenfold increase in signal intensity,
 
therefore the SIM scan for 
diclofenac in negative was removed in further studies.  
After segmenting the method, adjustments were made to the scan time and the inter-scan 
delay for the SIM scans. These two parameters combined relate to the duty cycle of the 
instrument, which is the overall time it takes the mass analyser to ramp the RF to DC voltage 
and emit the ions into the detector. The quadrupole mass analyser has potential for improved 
quantitation with the ability to quickly scan ions, resulting in a short duty cycle, and a greater 
number of mass spectra generated per second. Decreasing the inter-scan delay from the 
default 0.3 seconds to 0.01 seconds resulted in a small increase in the number of data points 
across the chromatographic peak, with the exception of ibuprofen in negative mode. Under 
these conditions the peak for ibuprofen disappeared, therefore an alternative inter-scan delay 
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setting for the ibuprofen SIM scan was investigated, with a decrease to 0.1 seconds proving 
successful. Further gains in scan time were also achieved by reducing the scan time for the 
full mass scan from 0.8 seconds to 0.5 seconds; this resulted in an increased number of data 
points across the peak, however there was still less than 10 per peak. This was still considered 
insufficient for quantitation and therefore the mass scale recorded was reduced. As the 
smallest m/z of interest is 152 and the biggest being m/z 734, a range of 125-775 Da was 
chosen and the scan time was further reduced to 0.4 seconds. As ibuprofen is the only 
compound being analysed in negative mode, and elutes at approximately 23 minutes, the time 
scale for which the negative full mass scan was recorded was reduced to incorporate this data 
and the wash section of the method to check for carryover on column. These changes finally 
resulted in 10-16 relevant SIM spectra to be captured for each compound for quantitation. 
 
3.2.1: Separation and Column Chemistry 
The mobile phases used comprised of 0.1% formic acid in water (A) and 100% acetonitrile 
(B), as these conditions had been used in the literature [15,16] and in-house for the separation 
of pharmaceuticals. The initial LC method used a 31 minute linear ramp, starting at 95% 
A:5% B with appropriate wash and conditioning phases. A number of different column 
chemistries were investigated to evaluate which provided the best retention of the range of 
chemistries (acidic and basic) within the suite. 
  
3.2.1.1: Xbridge C18 Column 
Initial studies were carried out using as standard C18 column (Xbridge 1.0 x 100mm, 3.5µm) 
as this is the traditional separation platform for reversed-phase chromatography. The Xbridge 
column comprises of C18 chains that are bonded to the silica particle using additional 
bonding i.e. an ethylene-bridge hybrid particle. This is designed to increase the robustness of 
the column for more polar solvent conditions, and reduce any secondary interactions not 
captured with endcapping that may adversely affect the retention of polar compounds. 
Unfortunately, acetaminophen showed little retention on this column and eluted during the 
solvent front of the chromatographic run, resulting in an inability to accurately distinguish it 
from other un-retained matrix interferences. Also, ibuprofen did not appear to be retained on 
this column too and was not seen in negative mode using this column type. Therefore to 
increase retention several changes to the mobile phase composition including acidifying this 
acidic analyte by using 0.1% formic acid in mobile phase B, and altering the gradient run to 
99.5%A:0.5%B, to enhance the polarity of the starting conditions to capture acetaminophen 
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were investigated. Unfortunately, neither change had a positive impact on the retention of 
these compounds so alternative mobile phase additives were investigated. For example, 
ammonium formate has been used as a mobile phase buffer for the analysis of polar 
pharmaceuticals [17] with the aim regulating the pH of the chromatographic conditions to a 
range of 8.2–10.2 [18], stabilising the more basic (and polar) target analytes, ensuring 
maximum retention on column. While these conditions resulted in improved retention of 
acetaminophen, the chromatography was not stable with peak retention times shifting for 
successive runs, therefore was not investigated further and alternative column chemistries 
considered. 
 
3.2.1.2: Xselect Charged Surface Hybrid (CSH) Column 
The Xselect CSH column was investigated as an alternative to the Xbridge C18 as the 
permanently charged bead surface of the Xselect is designed to increase the retention of basic 
compounds. As the dimensions of this particular column differed slightly from the Xbridge; a 
2.1 x 150 mm, 3.5µm column, the mobile phase flow rate was altered to accommodate the 
wider bore of this column.  However the data showed that there was no improvement on the 
retention of acetaminophen, with elution occurring within the solvent front therefore this 
column was not investigated further. 
 
3.2.1.3: Xselect High Strength Silica (HSS) T3 Column 
The Xselect HSS T3 column is designed to improve retention of polar compounds as a result 
of higher silanophilicity/hydrophobicity of the 100% silica particles and was evaluated for 
any improvement of the retention of acetaminophen A 1.0 x 100 mm, 3.5µm column 
equipped with a KrudKatcher in-line filter was investigated using the same mobile phase 
composition as used with the Xbridge C18 (0.1% formic acid in water, and 100% 
acetonitrile). While acetaminophen showed improved retention and chromatography with 
these mobile phases, this was also apparent for the remaining pharmaceuticals with improved 
chromatography and peak shape observed, and less background signal from co-elution of 
interferences at retention times observed for target compounds that elute in the middle of the 
gradient (i.e. carbamazepine) as shown in Figure 3.11. The detection of ibuprofen was also 
improved using this column, with a signal consistent with this pharmaceutical observed in 
negative mode at low concentrations.  
Rachel Townsend 
__________________________________________________________________________________________ 
 
__________________________________________________________________________________________ 
 
Page 77 of 177 
 
Figure 3.11: Chromatograms showing carbamazepine at a concentration of 500 ng/mL recorded on both the 
Xbridge and Xselect HSS T3 columns. As can be seen, the resolution and peak shape of the compound is much 
improved using the Xselect HSS T3 column. 
 
3.2.2: Chromatographic Performance 
Once separation of compounds had been achieved with the sufficient number of data points 
for quantitation, the LC-MS method was characterised by determining the presence of any 
carryover of the compounds, assessing the chromatographic repeatability and reproducibility. 
The initial composition of the wash solution was a 50:50% mixture of acetonitrile and water, 
as used in previous in-house work. For the compounds that were un-retained, it was 
challenging to characterise carryover; with difficulties in discerning these analytes from the 
solvent front. Various wash solutions were investigated, including more aqueous mixtures, 
acidification of the solution, alternative solvents (i.e. methanol) as well as various wash 
volumes to mitigate carryover and evaluate if the wash solution influences retention, given its 
use as a flush solvent in the injection programme. A mixture of 25%: 75% acetonitrile and 
water respectively, acidified with 0.1% formic acid and a wash volume of 1mL proved to be 
the optimum injection wash conditions with no detectable carryover following multiple 
injections of a high concentration standard. 
 
3.2.2.1: Comparison of Column Performance 
Chromatographic performance of both the Xbridge C18 and the Xselect HSS T3 columns 
was evaluated by analysing repeat injections of a high concentration standard to characterise 
the column performance, repeatability and reproducibility to determine which column 
technology was most appropriate for the suite of pharmaceuticals. This was achieved by 
comparing the retention factor, selectivity factor, resolution and efficiency for each 
compound on both chromatographic columns, detailed in Tables 3.1 and 3.3.  
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Carbamazepine: Xbridge C18 column 
Carbamazepine: Xselect HSS T3 column 
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3.2.2.1.1: Xbridge C18 Column: Chromatographic Separation Performance 
The retention factor (k – Eq 1.2) for each of the eleven compounds detected using the 
Xbridge C18 column was greater than the ideal (2<k<10), demonstrating good retention 
efficiency. The column efficiency (N – Eq 1.1), relating to the number of theoretical plates is 
high for each compound, indicating the LC method is suitable for analysis. The selectivity 
factor (α – Eq 1.3) and resolution (Rs – Eq 1.4) for seven out of the eleven compounds fall 
below the acceptable value of α>1.1 and Rs>1.5 (equivalent to 99.7% resolved [19]), 
indicating separation and resolution of compounds is poor using this chromatographic 
column. As each compound within this method is detected using an individual SIM scan, 
evaluation of retention time reproducibility should indicate whether the poor separation and 
resolution would be problematic for this analysis, as if the retention time is not reproducible it 
could suggest interference with other compounds. 
 
Table 3.1: Chromatographic performance for separation of pharmaceuticals and internal standards for the 
Xbridge C18 column. Retention times (tR) and figures of merit are given in order of elution. Values α and Rs are 
shown as selectivity and resolution from the successive compound (e.g. pronethalol from propranolol). 
Compound 
Mean 
Retention 
Time (RT) 
Retention 
Factor 
(k) 
Selectivity 
Factor (α) 
Efficiency 
(N) 
Resolution 
(Rs) 
Pronethalol 13.32 8.3 1.2 40377.4 8.5 
Propranolol 15.23 9.7 1.1 108086.5 4.5 
Diphenhydramine 16.05 10.2 1.0 120087.7 0.3 
Erythromycin 16.11 10.3 1.0 77765.1 1.1 
Citalopram 16.36 10.5 1.0 106490.9 1.2 
Carbamazepine 16.87 10.8 1.0 11039.8 0.3 
10,11-DHC 17.05 10.9 1.0 13530.7 1.0 
Talopram 17.43 11.2 1.1 131824.9 5.9 
Fluoxetine 18.56 12.0 1.0 152102.4 0.9 
Loratadine 18.72 12.1 1.2 146862.6 21.2 
Diclofenac 22.95 15.1 
 
202563.5 
 
 
3.2.2.1.1.1: XBridge C18Column: Chromatographic Repeatability and Reproducibility  
Chromatographic repeatability is “the closeness of agreement between independent results 
obtained with the same method on identical test material, under the same conditions (same 
operator, same apparatus, same laboratory and after short intervals of time)” [20]. This was 
determined by calculating the relative standard deviation (%RSD) of the peak areas of 
multiple injections of the same sample on two separate days. The %RSD of the adjusted 
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retention times were calculated for each compound on both days and were statistically 
analysed as a measure of reproducibility using a two-tailed F-test. For the 8 compounds and 3 
internal standards analysed using the Xbridge column, data showed little variation in 
retention times per day, with %RSD less than 2%. However, when analysed using an F-test 
significant difference was observed between day one and day two, demonstrated by a 
decrease in variation of retention time for day two to less than 1%, indicating an 
improvement in chromatographic stability (see Table 3.2). In preparation for quantitation, the 
variability in peak area was also characterised to assess the repeatability of the autosampler. 
The results showed there was between 5-16% variation between the multiple injections, with 
pronethalol and erythromycin showing the greatest variation at 12.23% and 15.70% 
respectively. This data is shown in full in Appendix 3.2. 
 
Table 3.2: Table shows the summary of reproducibility data obtained using the Xbridge C18 column. The 
relative standard deviation (%RSD) values for each compound are shown for both data sets and the F-test value 
calculated showing that while the variation is significantly different over the two days, the chromatography is 
deemed reproducible. 
 
Adjusted Retention Time 
Critical Value: 
F(9,5) 6.681 
Compound 
%RSD Day 1 
(n=10) 
%RSD Day 2 
(n=6) 
F-Test 
Pronethalol 1.68 0.35 23.23 
Propranolol 0.93 0.24 15.35 
Diphenhydramine 0.82 0.17 24.33 
Citalopram 0.71 0.17 16.61 
Erythromycin 0.79 0.23 11.69 
Carbamazepine 0.77 0.19 16.99 
10,11-DHC 0.46 0.13 11.71 
Fluoxetine 0.47 0.05 80.00 
Talopram 0.60 0.15 16.67 
Loratadine 0.57 0.15 14.34 
Diclofenac 0.32 0.12 7.20 
 
3.2.2.1.2: Xselect HSS T3 Column: Chromatographic Separation Performance 
The retention factor (k – Eq 1.2) for each compound was greater than the ideal (2<k<10), 
demonstrating good retention efficiency, with the exception of acetaminophen and the 
deuterated homolog, acetaminophen-(methyl)-d3, which had a k of 0.4, showing that these 
compounds eluted close to the solvent front. Although these values are above the 
recommended values, the column efficiency (N – Eq 1.1) is high, indicating the LC method is 
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appropriate. The selectivity factor (α – Eq 1.3) and resolution (Rs – Eq 1.4) for the majority 
of the compounds was good, with α>1 and Rs>1.5 (equivalent to 99.7% resolved [19]), 
indicating sufficient separation of compounds. Although select pharmaceuticals show poor 
selectivity and resolution (e.g. acetaminophen-(methyl)-d3, erythromycin and 
carbamazepine), the analysis should be unaffected as each compound is detected using 
individual scan filters (i.e. SIM scans), providing retention time is reproducible.  
 
Table 3.3: Chromatographic performance for separation of pharmaceuticals and internal standards for the 
Xselect HSS T3 column. Retention times (tR) and figures of merit are given in order of elution. Values α and Rs 
are shown as selectivity and resolution from the successive compound (e.g. acetaminophen-(methyl)-d3 from 
acetaminophen). 
Compound 
Mean 
Retention 
Time (tR) 
Retention 
Factor (k) 
Selectivity 
Factor (α) 
Efficiency (N) 
Resolution 
(Rs) 
Acet-d3 1.56 0.4 1.0 1276.0 0.0 
Acetaminophen 1.56 0.4 28.7 1481.2 63.3 
Pronethalol 13.93 11.5 1.1 58941.5 7.7 
Propranolol 15.61 13.0 1.1 89836.1 2.7 
Erythromycin 16.23 14.0 1.0 108328.6 1.0 
Diphenhydramine 16.47 13.7 1.0 92035.6 1.6 
Citalopram 16.80 13.5 1.1 64870.0 4.4 
Talopram 17.69 15.2 1.0 28427.5 1.3 
Carbamazepine 18.11 15.3 1.0 31743.1 0.4 
10,11-DHC 18.26 14.8 1.1 122223.0 1.7 
Fluoxetine 18.76 15.8 1.0 147767.6 2.3 
Loratadine 19.25 16.2 1.3 122672.8 24.6 
Diclofenac 24.67 21.1 1.0 198512.1 1.6 
Ibuprofen 25.01 21.4  222667.1  
 
3.2.2.1.2.1: Xselect HSS T3Column: Chromatographic Repeatability and Reproducibility  
The retention and injection repeatability and reproducibility was assessed for the 
pharmaceuticals retained using this column. The suite of pharmaceuticals now comprised of 
10 compounds, with the inclusion of acetaminophen and ibuprofen, and an additional internal 
standard, acetaminophen-(methyl)-d3. Once the SIM transitions were assessed to ensure a 
sufficient number of data points were still achieved upon addition of three extra SIM scans 
and a full mass scan in negative mode, carryover, chromatographic repeatability and 
reproducibility could be confirmed and characterised, respectively The %RSD for the 
adjusted retention times of all compounds, on both days was repeatable showing a %RSD 
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less than 5%, over multiple injections. The method also showed improved chromatography 
for all compounds with time apart from acetaminophen and acetaminophen-(methyl)-d3, 
which increased from 2% to 5%. Despite increased %RSD for these compounds, the F-test 
showed that there was no significant difference between the variances, therefore the 
chromatography and method was deemed reproducible, and the full data set is shown in 
Appendix 3.3. As with the Xbridge C18 column, injection repeatability was established by 
calculating %RSD of the peak areas of repeat injections of a single high concentration 
standard, at 400 ng/mL, on a single day and compared to determine reproducibility using the 
F-test statistical test. The data shows there is less than 7% variability between the repeat 
injections on day one and less than 5% on day two. This decrease in variation of peak area 
suggested that an overall improvement occurred, and given the ability to detect additional 
compounds, the Xselect HSS T3 column was chosen and characterisation of the method for 
quantitation was carried out. 
 
Table 3.4: Table shows the summary of injection repeatability data obtained using the Xselect HSS T3 column. 
The relative standard deviation (%RSD) values for each compound are shown for both obtained on both days 
and the F-test value calculated showing that the variation shown over two separate days isn’t significant. 
 
Peak Area F(9,5) 6.681 F(5,9) 4.484 
Compound 
%RSD Day 1 
(n=10) 
%RSD Day 2 
(n=6) 
F-Test F-Test 
Acet-d3 6.85 5.03 1.94   
Acetaminophen 1.38 1.16 1.54   
Pronethalol 2.33 1.13 4.39   
Propranolol 1.34 0.77 3.08   
Diphenhydramine 1.80 1.65 1.15   
Citalopram 1.59 1.85   1.29 
Erythromycin 1.34 1.08 1.74   
Carbamazepine 4.52 1.59 9.19   
10,11-DHC 1.86 0.55 11.75   
Fluoxetine 1.45 1.01   2.20 
Talopram 2.15 2.99   1.87 
Loratadine 3.26 1.40 6.25   
Diclofenac 1.38 0.70   4.22 
Ibuprofen 4.87 2.69 2.79   
 
3.3: Quantitation using Xselect HSS T3 Column 
To characterise the ability of an analytical method for performing reliable quantitation the 
construction of a calibration graph comprising of a series of standards prepared over range of 
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concentrations is required. For mass spectrometry methods, internal standards are employed 
to normalise the analyte signal and account for fluctuations of sensitivity caused by matrix 
interference. Therefore, internal standards should be as chemically similar to the target 
analyte requiring quantitation as possible and will require evaluation given structural 
analogues are being used here. A concentration range of 1-400 ng/mL was chosen based upon 
previous data, with screen samples showing this range as fit-for-purpose, and initial 
sensitivity tests performed by injecting serial dilutions of standard solutions during the direct 
infusion stage.  
 
Table 3.5: The table shows the concentration of each calibration standard used for the characterisation of 
quantitation experiments using the Xselect HSS T3 column. 
Standard S1 S2 S3 S4 S5 S6 S7 S8 S9 
Concentration (ng/mL) 1 5 10 25 50 100 200 300 400 
 
This range garnered good linearity for all pharmaceuticals studied, with R
2
 > 0.99, which 
demonstrates a good agreement between the relative response and concentration, supporting 
the use of these internal standards for the suite of pharmaceuticals.  
 
3.3.1: Heteroscedasticity 
Reliability of quantitative results depends upon the quality of the derived calibration graph. 
Regression statistics are typically used to determine the concentration of unknown samples, 
and the data processing should be chosen according to the characteristics of the data and 
measurement process. For example, different detection methods will have inherent errors in 
their measurement and will differ depending on the amount of signal present. This is assessed 
by the percentage relative error (%RE), comparing the calculated concentration obtained 
from the regression equation with the theoretical concentration, and plotting on a graph. This 
process characterises the error and enables a correction to be made (i.e. weighting factor) to 
provide more representative data without “skewing”. The correction or weighting factor is 
chosen according to that which gives the narrowest band of %RE along the concentration axis 
[21]. Data of this type is classed as heteroscedastic, with homoscedastic data being the term 
used to describe equal variances across the analytical data set. For mass spectrometric data 
these conditions are not often met; the deviations observed for the higher concentrations in 
the dynamic range influence, or weight the regression line causing inaccuracy in measuring 
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the lower concentrations and is typically corrected by using a weighted regression function 
such as 1/x or 1/x
2
. 
 
 
Figure 3.12: An example percentage relative error (%RE) versus concentration graph for fluoxetine, showing 
the spread of data for linear regression statistics (□), and weighted 1/x regression data (♦). As shown, the data 
for 1/x shows less variability over the entire concentration range. 
 
The heteroscedasticity of data obtained using the T3 column was assessed, and showed a 
heteroscedastic data set which improved significantly with a smaller, more equal variance for 
all concentrations following application of a weighted regression function of 1/x, clearly 
shown in Figure 3.12. 
 
3.3.2: Instrument Detection Limit (IDL) 
There are many ways to statistically determine the instrument detection limit (IDL) of a 
compound. For method evaluation two different methods were chosen; a statistical 
determination, as described by Miller and Crowther (Eq. 2.6) [22] and an empirical method 
using an internal standard blank, S0 (Eq. 2.7), as described in the NS30 document, A Manual 
on Analytical Quality Control for the Water Industry [23]. When calculated statistically, the 
IDL values for the compounds in the study were between 5-30 ng/mL. This did not correlate 
with the data obtained with chromatographic peaks observed with signal-to-noise (S/N) of 
approximately 3:1 at the lower end of the concentration range (1 ng/mL) for all compounds. 
Using the empirical determination of NS30, values of less the 1 ng/mL were determined, with 
the exception of acetaminophen (5.9 ng/mL). This difference in these calculated values may 
be due to the heteroscedasticity of the data and will require testing. For example, Miller and 
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Miller state that transposing the standard error of regression (Sy/x) required for the statistical 
determination of the IDL, for the standard deviation of the blank (SB) can be used for 
homoscedastic data to make determining the IDL more manageable [24]. However, given the 
noted variation in the calibration data this approximation may not be appropriate and 
determining IDL using a blank sample may be more representative of the IDL and these 
values are far more aligned with the S/N estimates of 3:1, therefore the empirical data was 
considered a more appropriate description of method performance. 
 
3.3.3: Precision and Accuracy 
To assess precision and accuracy, rigorous acceptance criteria that are used within the 
pharmaceutical industry whereby accuracy and precision are determined by quality controls 
(QCs) at key concentrations required for the measured concentration were adopted. It is 
generally accepted that the QC samples should be “within 15% of the actual concentration 
except at the limit of quantitation (LOQ) where it may not exceed 20% accuracy” [25]. The 
precision and accuracy of the method for quantitation was determined using QC samples at 
four different concentrations (15, 25, 100 and 350 ng/mL) which were prepared and analysed 
in triplicate. Using the regression equation generated in the QuanLynx software, the samples 
were analysed to determine the concentration present in each sample. Both inter- and intra- 
day precision was determined using the percentage relative standard deviation (%RSD) of the 
calculated concentration, and was necessary to characterise the ability of the analytical 
method to reliably measure an individual compound. For the QCs chosen for this analysis, the 
intra-day precision was less than 10% for each compound, and inter-day precision values 
determined over three data sets were shown to be less than 11%, indicating that this method 
and these chromatographic conditions are suitable for reliably measuring concentration 
within this given range over multiple injections and over different days (see Table 3.6).  
The accuracy of each replicate was determined by calculating the percentage difference 
between the calculated concentration and the actual spiked concentration. The QCs showed a 
good degree of accuracy at all concentrations for each compound, with the results falling 
below 15%. These results comply with the acceptance criteria used, supporting the indication 
that the method is capable of quantitating low concentrations of pharmaceuticals (15 ng/mL) 
using surrogate internal standards to an appropriate degree of accuracy. 
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Table 3.6: The table shows the intra- and inter-day precision values determined for the chosen analytical 
method. Inter-day precision was determined over three data sets. 
  QCs 
Compound 
Precision 
(%RSD) 
QC1 
(15 ng/mL) 
QC2 
(25 ng/mL) 
QC3 
(100 ng/mL) 
QC4 
(350 ng/mL) 
Acetaminophen 
Intra-Day 9.48 3.54 2.75 4.51 
Inter-Day 4.40 3.85 0.74 2.87 
Propranolol 
Intra-Day 1.75 1.78 1.51 1.19 
Inter-Day 2.80 3.43 3.17 1.63 
Diphenhydramine 
Intra-Day 3.20 1.70 1.18 0.35 
Inter-Day 3.51 4.25 2.58 3.62 
Citalopram 
Intra-Day 2.59 2.84 2.06 0.86 
Inter-Day 6.26 3.87 2.61 2.23 
Erythromycin 
Intra-Day 3.48 6.23 2.88 2.23 
Inter-Day 11.32 11.74 6.36 4.27 
Carbamazepine 
Intra-Day 1.80 2.45 1.61 1.00 
Inter-Day 4.09 4.79 3.52 1.02 
Fluoxetine 
Intra-Day 3.28 4.49 4.50 1.13 
Inter-Day 9.47 8.74 5.51 4.08 
Loratadine 
Intra-Day 2.15 2.56 3.02 2.28 
Inter-Day 8.44 7.83 5.95 3.32 
Diclofenac 
Intra-Day 8.58 10.50 4.42 0.80 
Inter-Day 6.27 10.58 6.70 3.92 
 
3.3.4: Instrument Quantitation Limit (IQL) 
The analytical method was further characterised to establish the instrument quantitation limit 
(IQL). Like the IDL values, the IQL may be determined by two different approaches; by 
assessing the lowest concentration QC giving a good degree of precision and accuracy 
(<20%) and statistically using the standard deviation of the blank (Eq 2.8). Empirically the 
IQL was determined to be 15 ng/mL however, while this provides a more robust approach it 
may not assess what the lowest point may be as per the statistical method. Following the 
statistical approach often used in environmental analysis [26] (Eq.2.8), the resulting values 
suggest this may be significantly lower as expected however, this approach often shows poor 
correlation to what occurs in practice and empirical measurements will be used as a gauge of 
method performance.  
 
3.4: Stability 
The stability of the pharmaceutical stock solutions was investigated to establish how long a 
stock solution can stored under set conditions before the concentration of the compound 
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changes significantly. The stability was assessed by preparing a set of fresh stock solutions, 
from which a series of calibration standards and QCs were made (t0) and compared to 
calibration standards and QCs prepared from 1 month old stock solutions (t28). The 
percentage change of the calculated concentrations for the QCs was determined and the 
statistical results obtained showed that six of the compounds were stable in solution within 
the freezer for 1 month, with a percentage change in concentration of less than 15 %. 
Propranolol, erythromycin and loratadine showed a greater percentage change, with values 
exceeding 25, 17 and 20 %, respectively. A t-test was performed on all of the compounds to 
determine whether the calculated concentrations were significantly different between t0 and 
t28, with results confirming the difference for propranolol and loratadine, but also showing a 
significant difference for citalopram (% change in concentration ≤15%), with a t-value that 
exceeded t-critical (3.75 at 98% confidence). As there are no recommendations set out by the 
FDA guidelines for characterising stability, and a general acceptance criteria similar to that 
used for accuracy and precision (i.e. <15% considered acceptable) was deemed inappropriate 
by the t-test results for citalopram, fresh stock solutions would be prepared before any 
quantitative analysis to ensure accurate results.  
 
3.5: Conclusion 
Liquid chromatography-mass spectrometry is considered the gold standard for analytical 
methods, with reversed-phase C18 methods being the predominant conditions used. The 
analytical method developed in this study was tested for a suite of 10 compounds, with 1 
deuterated internal standard and 3 surrogate internal standards to determine their feasibility 
for quantitation, and evaluated in terms of stability. Data obtained shows that alternative 
column chemistry, the HSS T3 column, is more suited to the wide range of pharmaceuticals 
chosen than a standard C18 column. With these optimised chromatographic conditions, the 
method has a good level of sensitivity, sufficient for the concentrations of pharmaceuticals 
seen in previous in-house studies (1-400 ng/mL). The method also exhibits good precision 
and accuracy for quantitation, with values of less than 10% and 15%, respectively, within the 
necessary measurement range. 
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Chapter 4: Liquid Chromatography-Mass Spectrometry Method 
Development: Biocides 
 
4.1: MS Detection and Identification of Biocides for Quantitation 
Given the significantly higher signal intensity of the proposed biocides in comparison to the 
suspected pharmaceuticals within this initial screen, an alternative ion trap platform was used 
to quantify biocides and undertake a more informative screen. This would not require the 
more challenging sensitivity of pharmaceuticals and therefore further method development 
was undertaken. Analysis of “pure” samples to determine the precursor and characteristic 
fragment ions before online LC-MS analysis is typically performed by infusion of standard 
solutions. Fragmentation data was obtained previously in-house by tandem mass 
spectrometry (MS/MS) using collision induced dissociation (CID), whereby the molecular 
ion is dissociated as a result of interaction with a target neutral species (helium or nitrogen) 
due to the conversion of part of the translational energy of the ion to internal energy within 
the ion during collision [1]. To confirm the precursor ions and ensure the collision energies 
(%CE) for the generation of qualifying product ions were correct for this method, a product 
ion scan was performed for each compound. 
 
4.1.1: Benzalkonium Chlorides (BACs) 
A group of four BAC compounds were studied, BAC-C12, BAC-C14, BAC-C16 and BAC-
C18, with a deuterated BAC-C14 used as the internal standard for the suite. These 
compounds are available as halide salts, typically hydrochloride and are comprised of an 
ammonium group attached to both a benzene head group and an aliphatic carbon chain of 
increasing length by an addition of a methylene group, (CH2)2. The precursor ions observed 
are consistent with the loss of the chloride ion, forming the [M-Cl]
+
 ion. The mass decrease 
observed within the product ion scan for each BAC compound was consistent with a loss of 
92 Da, likely to be the methylbenzene head group (see Figure 4.1), leaving the aliphatic 
amine chain. This is confirmed by the fragmentation observed for the IS, whereby the 
deuterated methylbenzene is lost (99 Da), leaving the same product ion as seen with BAC-
C14 at m/z 240. 
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Figure 4.1: The proposed fragmentation of the BAC compounds, showing the loss of the methylbenzene ring 
leaving the amine chain. 
 
4.1.2: Didecyldimethylammonium Bromide (DDMA) 
Similarly to the BAC compounds, DDMA is supplied as a hydrogen bromide salt, and is 
comprised of two aliphatic carbon chains either side of a nitrogen atom, with the molecular 
formula C22H48N.HBr and monoisotopic weight of 406 Da. The loss of Br gives rise to a 
precursor ion at m/z 326, consistent with [M-Br]
+
. The product ion observed at m/z 186 (see 
Appendix 4.1 for spectrum), corresponds to the loss of one of the carbon chains (C10H20), 
leaving the positively charged amine chain.  
 
 
Figure 4.2: The proposed fragmentation of DDMA, showing the loss of one of the carbon chains leaving the 
amine chain. 
 
4.1.3: Hexadecyltrimethylammonium Chloride (HDTMA) 
The standard reference material is available as a hydrochloride salt, with a molecular formula 
of C19H42N.HBr and monoisotopic mass of 319 Da. The loss of the Cl gives a precursor ion at 
m/z 284. Unlike the other biocides, HDTMA does not produce any stable product ions, likely 
a result of the structure which is an amine head group bonded to an aliphatic carbon chain 
(C16H33); the structure of the product ions of the BACs and DDMA. 
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4.2: Semi-Quantitative Method Development for Biocides  
To develop this dual method the original LC method detailed in Chapter 3 was expanded to 
include the biocides and a standard mixture containing these and the pharmaceuticals were 
used. The SIM scans used for the pharmaceuticals within the original ZQ4000 method were 
replaced with product ion scans, with the aim of supporting positive identification of 
compounds within complex samples and distinguishing any near co-eluting species of the 
same precursor m/z. Pleasingly, the fragmentation patterns observed with the ion trap were 
the same as those seen by in-source CID on the ZQ4000, with the exception of erythromycin, 
where the product ion seen was at m/z 576, rather than m/z 558, corresponding with the loss 
of the cladinose sugar [2]. This is important to establish to ensure the data can be translated 
between the two platforms. Given the pharmaceuticals eluted within the first 24 minutes of 
the chromatographic gradient and the qualitative purpose of their analysis, the method was 
developed without the need to obtain a relatively high number of data points across the 
chromatographic, however the segmentation of the mass spectrometric method was devised 
to ensure a minimum of 5 data points were recorded for the targeted product ion scans. As in 
the initial screen the biocides were observed to elute at 82-100% acetonitrile (mobile phase 
B) after the pharmaceuticals, between 24 and 31 minutes. Given this chromatographic 
separation, this section of the method was dedicated to the quantitation of the biocides with 
data acquisition by selected reaction monitoring (SRM), with the exception of HDTMA; this 
required a SIM scan due to a lack of suitable fragmentation ions (see Table 4.1). A slightly 
bigger mass range of m/z 100-800 was chosen for this method compared with the ZQ4000 
method. This was achievable, without detriment to the data points across the peak due to the 
omission of the negative ionisation mode scans, and was used to ensure detection of all of the 
target precursor and product ion m/z for qualitative and quantitative analysis. A minimum of 
10 data points across the chromatographic peak was required for the accurate quantitation of 
the QACs, and was achieved by altering the number of microscans for both the full mass scan 
and the SRM/SIM scans. A microscan is one mass analysis (i.e ion injection, storage/scan-out 
of ions) followed by ion detection, and the time required to capture all the microscans in the 
mass scan refers to the duty cycle. By using a low number of averaged microscans, the duty 
cycle is reduced, resulting in an increase in mass scans across the chromatographic peak. 
When the method was tested using 1 microscan for the full mass scan and 1 for the SRM/SIM 
scan, 10 data points were recorded across the chromatographic peak for each QAC. 
 
Rachel Townsend 
__________________________________________________________________________________________ 
 
__________________________________________________________________________________________ 
 
Page 92 of 177 
Table 4.1: Summary of the mass spectrometer method parameters for the quantitative method for biocide 
analysis including the observed retention times, scan type, precursor and product ions and the associated 
collision energy used for each biocide. 
Compound 
Retention 
Time 
(minutes) 
Scan 
Type 
Precursor 
Ion (m/z) 
Product 
Ion (m/z) 
Collision 
Energy 
(%) 
BAC-C12 24.2 SRM 304 212 40 
BAC-C14 26.4 SRM 332 240 42 
BAC-C16 28.7 SRM 360 268 44 
BAC-C18 30.9 SRM 388 296 48 
DDMA 27.6 SRM 326 186 48 
HDTMA 26.3 SIM 284 n/a n/a 
BAC-C14-d7 26.3 SRM 339 240 40 
 
4.3: Chromatographic Performance 
Similar to the ZQ4000 method, this combined method was tested for selectivity and carryover 
by assessing whether there was any observed signal attributable to the compounds at high 
concentrations after multiple injections. This method used the same wash solution as the 
ZQ4000 analysis (i.e. 1 mL of 0.1% formic acid in a mixture of 75%:25% water and 
acetonitrile, respectively), which proved sufficient despite the biocides typically eluting at a 
higher organic gradient, as no carryover was observed. The retention factor (k – Eq 1.2) for 
each of the seven compounds was greater than the ideal (2<k<10), demonstrating good 
retention efficiency. The column efficiency (N – Eq 1.1) calculated was also high for each 
compound, indicating the LC method is suitable for analysis of these compounds. The 
selectivity factor (α – Eq 1.3) and resolution (Rs – Eq 1.4) for the majority of the compounds 
fall below the acceptable value of α>1.1 and two compounds, HDTMA and BAC-C14-d7 fall 
below the acceptable value of Rs>1.5 (equivalent to 99.7% resolved [3]), indicating 
separation and resolution of compounds is poor using this chromatographic column. 
However, as the compounds will be detected using individual SRM/SIM scans, the analysis 
should not be affected by the poor separation and resolution provided there is no matrix 
suppression and the retention time is reproducible. 
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Table 4.2: Chromatographic performance for separation of biocides and internal standard for the Xselect HSS 
T3 column. Retention times (tR) and figures of merit are given in order of elution. Values α and Rs are shown as 
selectivity and resolution from the successive compound (e.g. BAC-C12 from HDTMA). 
Compound 
Mean Retention 
Time (tR) 
Retention 
Factor (k) 
Selectivity 
Factor (α) 
Efficiency 
(N) 
Resolution 
(Rs) 
BAC-C12 24.20 21.2 1.1 249567.0 9.9 
HDTMA 26.31 23.2 1.0 204257.6 0.3 
BAC-C14-d7 26.38 23.2 1.0 191212.2 0.1 
BAC-C14 26.42 23.3 1.0 142017.5 4.9 
DDMA 27.61 24.4 1.0 279045.5 4.8 
BAC-C16 28.71 25.4 1.1 202966.3 8.8 
BAC-C18 30.97 27.5  226947.4  
 
4.3.1: Chromatographic Repeatability and Reproducibility 
As with the quantitative pharmaceutical method described in Chapter 3, the chromatographic 
repeatability and reproducibility was determined for the QAC compounds through multiple 
sample injections (n1=10, n2=7). The data showed repeatable, stable chromatography over 
prolonged use, with %RSDs <0.3% for all compounds on both days of analysis. While 
fluctuations in %RSD were observed between day one and day two, the F-test showed that 
there was no significant difference between the variances, indicating the chromatographic 
method was reproducible and stable between different days of analysis (see Table 4.2).  
Injection repeatability was also determined to understand the error between multiple sample 
injections for these compounds on a single day; the %RSD of the peak areas showed there 
was <12% variability, indicating little fluctuation of the ionised signal under these 
chromatographic conditions.  
 
Table 4.3:  Table shows the summary of reproducibility data for the biocide compounds. The relative standard 
deviation (%RSD) values for each compound are shown for both data sets and the F-test value calculated 
showing that the variation is not significantly different over the two days. 
 
Adjusted Retention Time 
F(9,6) 
5.523 
F(6,9) 
4.320 
m/z 
%CV Day 1 
n=10 
%CV Day 2 
n=7 
F-Test F-Test 
BAC-C12 0.23 0.24   1.13 
BAC-C14 0.13 0.19   1.99 
BAC-C16 0.17 0.23   1.81 
BAC-C18 0.18 0.16 1.23   
DDMA 0.19 0.19   1.00 
HDTMA 0.16 0.17   1.11 
BAC-C14-d7 0.21 0.21 1.01   
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4.4: Quantitation of Biocides 
A calibration experiment was performed to characterise the ability of the analytical method 
for reliable quantitation. A series of standards prepared to a range of different concentrations 
were used to construct a calibration graph for each compound. A concentration range of 2-80 
ng/mL was chosen based upon sensitivity tests performed by injecting serial dilutions of the 
standard solutions. A single internal standard, a deuterated analogue of BAC-C14 (BAC-
C14-d7) was used for calibration at a concentration of 20 ng/mL. 
 
Table 4.4: The table shows the concentration of each calibration standard used for the characterisation of 
quantitation experiments for the biocides. 
 
Following application of regression statistics this range showed sufficient linearity for all 
biocides, with R
2
 > 0.97, with the exception of BAC-C18, which had an R
2
 = 0.96 due to a 
decrease in peak area for one of the replicate injections of the highest calibration standard; 
when omitted, the R
2
 increased to 0.98. These values support the use of the chosen internal 
standard for the suite of biocides. A series of QC samples, at four concentrations within the 
calibration range (i.e. 8, 20, 60 and 80 ng/mL), were used to evaluate the performance of 
method.  
 
4.4.1: Heteroscedasticity  
A test of heteroscedasticity was performed to determine the most appropriate weighting 
function for this type of analytical data. Comparison of percentage relative error calculated 
for both equal and 1/x weighted regression functions showed that while the 1/x weighting 
was more suited BAC-C12 and HDTMA, equal weighted linear regression was more suited 
to the rest of the suite.  
 
 
 
 
 
 
 
Standard S1 S2 S3 S4 S5 S6 S7 S8 
Concentration (ng/mL) 2 6 10 20 30 50 70 80 
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Table 4.5: Summary of the % relative error calculated to determine heteroscedasticity. Equal weighted linear 
and 1/x weighted regression functions were compared, with linear showing less variation for the majority of the 
biocides. 
Biocide 
% Relative Error 
Linear 1/x Weighting 
BAC-C12 -4967.10 387.38 
BAC-C14 -4231.48 -40293.33 
BAC-C16 -3212.08 -5171.27 
BAC-C18 -2951.02 -5144.40 
DDMA -4456.42 5898.27 
HDTMA -4798.25 1554.78 
 
As the heteroscedasticity test was inconclusive, a comparison was made between the 
calibration data obtained using both linear and 1/x weighted regression, taking into 
consideration the linearity, precision and accuracy calculated for each compound. These 
results showed that the linearity was comparable between the two regression functions, 
however, while the overall accuracy for each replicate QC was slightly better with the 1/x 
regression, the precision values showed improvement with the linear weighted regression, 
therefore the linear regression function was chosen for further statistical analysis of the 
calibration data (summary found in Appendix 4.2).  
 
4.4.2: Instrument Detection Limit (IDL) 
As with the pharmaceuticals, the IDL for each biocide was determined empirically using an 
internal standard blank, S0, as described in the NS30 document [4], as it was considered a 
more representative description of the method performance. When calculated statistically, the 
IDL values for the compounds in the study were between 11-20 ng/mL. This did not correlate 
with the data obtained, with chromatographic peaks observed with signal-to-noise (S/N) of 
approximately 3:1 at the lower end of the concentration range for all compounds. Using the 
empirical determination of NS30, values of less the 2 ng/mL were determined. 
 
4.4.3: Precision and Accuracy 
The precision of each biocide was assessed by establishing the %RSD of the calculated 
concentrations for the five replicate QCs at each concentration. As with the pharmaceutical 
quantitative method, the acceptance guideline criteria used to assess precision was set at 15% 
RSD of the actual concentration, except at the lowest concentration where this was less than 
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20% RSD [5]. The precision and accuracy of the method for quantitation was determined 
using five replicate QC samples at four different concentrations (8, 20, 16 and 80 ng/mL), 
with the intra-day percentage precision for each biocide equal to or less than 24%. These 
values are higher than those observed for the pharmaceutical method but this could be due to 
the poorer regression value from the alternative mass analyser employed. The larger 
percentage values (highlighted in blue in Table 4.6) were analysed using the Grubbs’ Test to 
determine whether they could be statistically omitted as outlying results. Two values were 
classed as outliers, the third replicate of QC2 (20 ng/mL) for BAC-C16 and the fifth replicate 
of QC1 (8 ng/mL) for BAC-C18, therefore these replicates were omitted and the 
corresponding accuracy and precision value decreased to 22.18% and 7.23%, respectively. 
The omission of the third replicate of QC2 did negatively affect the accuracy value, 
increasing the mean percentage value from -3.67 to -13.09, but was still within the 
acceptance criteria. Inter-day precision was determined using three, independent data sets and 
percentage values were found to be less than 20% across the four concentrations (see 
Appendix 4.4). Although the mean precision for QC2 for the majority of the compounds was 
greater than 15%, NS30 states that total error of 0.2x (where x denotes the actual 
concentration in the sample) is acceptable [6], and the QCs above and below in terms of 
concentration are within the acceptance criteria used to assess the pharmaceuticals, 
highlighting that values may be quantified in this range.  
The accuracy of each replicate was determined by calculating the percentage difference 
between the calculated concentration and the actual spiked concentration. The QCs showed a 
good degree of accuracy at all concentrations for each compound, with the exception of 
HDTMA at QC1, which exceeds the acceptance criteria due to a high replicate injection, 
however the successive QC results fall below 15%. These results comply with the acceptance 
criteria used, supporting the indication that the method is capable of quantitating biocides 
within the range of 8-80 ng/mL) using a single surrogate internal standard to an appropriate 
degree of accuracy. 
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Table 4.6: Summary of the linear weighted quantitative data including linearity (R
2
), instrument detection limit 
(IDL ± SD), mean percentage accuracy and precision of quality control sample (QC) concentration for each 
biocide. The values in red were subjected to the Grubbs’ test and were found to be outliers. The amended 
accuracy and precision values for QC1 are 22.18 and 14.11, and for QC2 -13.09 and 7.23, respectively. 
Biocide 
Linearity 
(R2) 
IDL 
(ng/mL) 
QCs 
Mean Accuracy (%) Mean Precision (%) 
QC1 QC2 QC3 QC4 QC1 QC2 QC3 QC4 
BAC-C12 0.9843 0.30 ± 0.10 3.74 -7.48 -11.11 -4.63 13.90 16.31 17.62 9.47 
BAC-C14 0.9854 0.27 ± 0.09 8.85 -1.97 1.12 -4.64 9.76 15.96 20.09 13.27 
BAC-C16 0.9694 0.19 ± 0.06 17.99 -12.42 -3.67 -9.86 17.25 22.60 13.71 5.09 
BAC-C18 0.9604 0.76 ± 0.25 29.04 -13.99 -0.48 -6.86 16.58 19.12 15.05 1.43 
DDMA 0.9794 0.99 ± 0.33 18.47 -6.68 -2.50 -8.23 8.12 24.75 10.33 10.76 
HDTMA 0.9729 1.79 ± 0.60 26.67 -5.43 0.50 -4.29 7.30 13.60 10.95 7.23 
 
4.5: Conclusion 
As part of the analytical method development, a second method for the combined qualitative 
and quantitative analysis of pharmaceuticals and biocides, respectively was investigated. A 
suite of six biocides and one deuterated internal standard was tested to determine their 
feasibility for quantitation. The calibration performance of this method was limited, with the 
R
2
 values determined to be >0.97. Typical R
2
 values desirable for quantitation are >0.99, 
therefore this method would not meet the strict criteria of a full method validation. However, 
for the purpose of this “proof-of-concept” study, the method was deemed suitable. While the 
precision and accuracy was varied at 24% and 25% RSD, respectively, exceed the acceptance 
criteria used for the pharmaceutical method, possibly attributable to the alternative mass 
analyser used, the method was deemed fit for purpose based upon the NS30 guidelines for 
environmental analysis [6] and the data obtained using the HSS T3 column shows that the 
method has a good level of sensitivity for the suite of biocides, sufficient for the 
concentrations seen in previous in-house studies (2-80 ng/mL). 
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Chapter 5: Sample Preparation Method Development 
 
Pharmaceuticals are suspected persistent organic pollutants and the detection of these 
compounds within matrices such as wastewater fractions is problematic due to the sample 
complexity and the trace amounts of pharmaceutical to be measured. There are various 
methods adopted by industry to analyse complex environmental matrices that include soil and 
wastewater effluent, such as the United States Environmental Protection Agency (EPA) 
Method 1694: Pharmaceuticals and Personal Care Products in Water, Soil, Sediment, and 
Biosolids by HPLC/MS/MS, published in December 2007 [1]. This is an extensive, multi-
step analysis of persistent organic pollutants within aqueous and solid matrices, involving 
solid-liquid extraction, evaporation and pH adjustment before separation into acidic and basic 
SPE fractions for further clean-up before LC-MS/MS analysis. The multitude of procedures 
required to carry out this method are time consuming and laborious, increasing operational 
costs and making this unsuitable for high-throughput analysis. Also, the differing 
performance of this protocol has led to other regulatory agencies and stakeholders in the 
wastewater sector to develop their own protocols. These can also be lengthy, involving 
solvent-based extraction and dilution, coupled with on-line SPE before analysis by LC-
MS/MS [2], with separate protocols required for the other sample types (i.e. effluent and 
biota). As a result, methods to extract and quantitate these compounds from this type of 
sample matrix are necessary and of use to the Chemical Investigation Programme. Pilot in-
house data generated from a feasibility study using a standardised QuEChERS method (EN 
Method [3]) has shown potential in extracting pharmaceuticals [4] and biocides present from 
locally sourced, treated sludgecake. This feasibility study was limited in scope, without 
characterisation and optimisation of the protocol in understanding the efficacy and breadth of 
the extraction. Given the many advantages of the QuEChERS method this approach was 
investigated further with the aim of resolving some of the issues associated with the 
recognised (current) sample preparation methods. 
 
5.1: QuEChERS Extraction Methods 
This is a two-step sample preparation method, initially developed for the extraction of 
pesticides in fruit and vegetables. As the QuEChERS method has been designed to be a 
rough-and-ready approach to sample clean-up, it may be easily modified for high-throughput 
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analyses, targeting the removal of specific classes of matrix interference to enable the 
detection of a broad range of sample constituents.  
 
5.1.1: Standardised Methods 
As discussed in Chapter 1, there are three standardised methods developed by Michelangelo 
Anastassiades and Steven Lehotay; the original, unbuffered method [5], the European 
Standards (EN) method (citrate buffers) [3] and the AOAC International method (acetate 
buffers) [6]. All three methods were initially investigated to determine the effect of buffers on 
the broad range of chemistries being studied in this project and if a product could be 
purchased “as is” without the need for further development. This initial testing was primarily 
concerned with the repeatable recovery of the pharmaceuticals given they represented the full 
range of polar organic pollutants (acid and base). The extractions would be evaluated under 
“ideal” conditions, using water, to enable the best chance of detecting any changes of 
recovery and whether the extraction itself contributed to any matrix interferences. 
 
 
Figure 5.1: Schematic of the QuEChERS extraction procedure, including all components used in the 
standardised methods. 
 
5.1.1.1: Unbuffered QuEChERS Extractions 
The unbuffered experiment was conducted using extraction kits weighed following the 
specifications detailed in the original QuEChERS method [5], i.e. 4 g of magnesium sulphate 
Add 10mL ACN 
+ extraction kit 
Add supernatant to 
dSPE kit Analyse 
Extraction kit: 
drying agent 
(MgSO4) + ion 
pair (NaCl or 
NaOAC) 
+ any buffers 
dSPE kit: 
drying agent 
(MgSO4) + 
dSPE sorbents 
(PSA, C18, 
GCB) 
Vortex + 
centrifuge 
Shake + 
centrifuge 
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and 1 g of sodium chloride and also an unbuffered AOAC method, i.e. 6 g of magnesium 
sulphate only. Using the same volumes as previous in-house studies, an initial spike volume 
of 500 µL was evaporated to dryness before the addition of 4 mL of water, to ensure the 
amount of acetonitrile in the spike did not alter the chemistry of the water sample matrix, and 
affecting the efficiency of the extraction. The determination of matrix effects and recovery 
for each compound followed the method detailed in Matuszewski et al. [7], comparing the 
peak area of the target compound in a “spike before” and “spike after” extraction sample to 
provide the recovery measurement, and the peak area of the “spike after” extraction 
compared to a standard to determine matrix effects. The results of the original unbuffered 
experiment showed that while the recovery of each target compound was good (typically 30-
75%), for the majority of compounds eluting in the middle of the chromatographic run (14 - 
20 minutes), peak broadening was observed (see Figure 5.2), which exaggerated the recovery 
measurement. The matrix effects measurements calculated were varied; the compounds 
affected by peak broadening showed matrix effects of approximately 250-310% and 
significant signal enhancement, while the remaining compounds were around 97-160%. 
 
 
Figure 5.2: Chromatograms of propranolol to show the effect of NaCl on peak broadening; a) propranolol 
standard b) propranolol after extraction using the standardised EN QuEChERS method. 
 
The results of the unbuffered AOAC experiment showed no alteration to the chromatographic 
peak shape, therefore the negative effect on chromatography observed was deduced to be due 
to the presence of NaCl in the EN extraction kit. The results of this experiment showed the 
matrix effects measurements were good, ranging between 95-140%, indicating slight 
ionisation enhancement for some compounds, however, precision was poor with %RSD of 
20-36% (n=3), indicating that the measurements are not reproducible under these conditions. 
The recovery for the target compounds was also poor, with percentages between 0-40% 
(%RSD ≤20), which could be due to the lack of buffer in the extraction kit. 
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5.1.1.2: Buffered QuEChERS Extractions 
To determine whether the poor recovery of target pharmaceuticals and the change in 
chromatographic peak shape was a due to the lack of buffer, the experiment was repeated 
using commercially available buffered extraction kits. The results showed that the buffers in 
both methods (sodium acetate in AOAC method and sodium citrate in the EN method) had 
little improvement on the results of the unbuffered experiment; the chromatographic peak 
shape still showed peak broadening using the EN method, and the recovery was still poor 
using the AOAC method. Given these results it was assessed that the buffer was not the 
overriding factor in the limited performance and chromatographic aberrations observed. 
  
5.1.2: Modifications 
To investigate if the efficiency and performance of the protocol could be improved, 
specifically the chromatography, matrix effects and recovery measurements, a number of 
modifications to the unbuffered QuEChERS method were tested. Firstly, the initial 
evaporation step was removed to reduce the time taken to carry out the protocol for more 
high-throughput applications. However, to do this a smaller, more concentrated spike volume 
was required to minimise the influence of the “spike solvent”; reducing the 500 µL spike to 
40 µL, to give the same concentration of 100 ng/mL would mean the amount of acetonitrile 
in the spike would be negligible, and was suitable for direct addition into the water sample 
matrix for subsequent modification experiments. 
 
5.1.2.1: Evaluation of Initial Extraction Kit 
From the results of the initial unbuffered experiment, it was shown that extractions involving 
1 g of sodium chloride had a negative effect on the chromatographic peak shape of some of 
the pharmaceuticals. Therefore, the impact of salt was investigated by comparing extractions 
using half the original amount of salt (0.5 g) and no salt, leaving just 4 g of magnesium 
sulphate within the initial extraction tube. Interestingly, the results without salt improved; the 
chromatographic peak shape was observed as a more Gaussian peak shape indicating a good 
degree of retention on column. However, the matrix effects and recovery of the target 
pharmaceuticals observed were poor (%ME ≤66%, indicating ionisation suppression, and 
%REC ≈40%) therefore the method needed further adjustment. In an attempt to improve 
recovery without compromising the chromatography, alternative ion pairs to sodium chloride 
were investigated.   
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There have been a number of studies within the literature that describe modifications to the 
ion pair [8,9] including the addition of disodium-EDTA. This was investigated to help reduce 
potential loss from the initial extraction step. However, this led to resulting extracts that 
required extended time to evaporate to dryness (several hours for 6 mL extract) as part of the 
solvent exchange step for LC-MS analysis. The results of this experiment also showed a 
formation of an immiscible layer after centrifugation, potentially caused by the displacement 
of the sodium ions with magnesium from the MgSO4, forming magnesium-EDTA. To assess 
this theory sodium-EDTA was used in conjunction with sodium sulphate (Na2SO4) as an 
alternative to MgSO4 as described in Chuang et al. [8]. However Na2SO4 appeared to have 
little impact as a drying agent, failing to remove the water from the sample tube after 
centrifugation, and was therefore not investigated further. 
 
5.1.2.1.1: Mix and Match Approach to Extraction 
One of the key aspects of creating a modified QuEChERS method is to ensure that it could be 
a cost effect sample preparation method, easily transferrable to a high-throughput industrial 
laboratory. After identifying other potential ion pairs, such as magnesium chloride or 
magnesium-EDTA, it was decided that complicating the extraction kit would potential make 
the method unattractive to future users, therefore keeping to the chemical ingredients of the 
kit may offer the greatest potential in meeting this aim. From the initial experiments 
involving the AOAC and EN methods, results showed that of the initial extraction kits: 
1) AOAC method (6 g MgSO4 and 1.5 g NaOAc) had poorest recovery. 
2) EN method (4 g MgSO4, 1 g NaCl, 1 g sodium citrate and 0.5 g sodium citrate 
sesquihydrate) had high matrix effects (signal enhancement) and poor 
chromatographic peak shape. 
Using these results, a “mix and match” approach was devised; using the AOAC extraction 
tube with the dSPE kit following the EN method specification (900 mg MgSO4 and 150 mg 
PSA), as this formulation contained less MgSO4 and PSA, reducing the potential loss of 
compounds during the dSPE step by binding to the PSA sorbent. This method showed a 
positive impact on previous methods; chromatographic peak shape improved for those 
compounds previously displaying peak broadening (see Figure 5.3) and challenging analytes, 
previously showing poor sensitivity (ibuprofen) was detected above the background noise. 
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Figure 5.3: Chromatograms of propranolol under different extraction conditions to show the effect of NaCl on 
peak broadening; a) propranolol after extraction using the standardised EN QuEChERS method and b) the “mix 
and match” approach to QuEChERS extraction. 
 
Despite the improvement in chromatographic peak shape, the mix and match method still 
showed significant matrix effects, with the majority of compounds exhibiting approximately 
50-60% ionisation suppression, assumed to be a result of the co-extraction of the QuEChERS 
kits. To minimise matrix effects a number of modifications were investigated including 
attempting to reduce the amount of polar co-extractives carried through within the acetonitrile 
supernatant by altering the amount of MgSO4 in the initial extraction and dSPE kits, and 
adding acetic acid to the extract before dSPE as described in Caldas et al. [9]. 
As diclofenac and ibuprofen were recovered using the AOAC method, but not with the EN 
method, the first approach involved increasing the amount of MgSO4 within the EN dSPE kit 
by 300 mg to reflect the amount of drying agent in the AOAC method. The result showed 
improved repeatability for the matrix effects, with %RSD ≤10% however, there was no 
change in %ME or %REC, with calculated average results of 52% and 44%, respectively. As 
expected diclofenac and ibuprofen continued to be extracted using this method, while the 
%ME remained unchanged at 40 and 42% respectively, the recovery for both compounds did 
increase slightly, with %REC at 4% for diclofenac and 28% for ibuprofen. Despite the 
improvement to the acidic compounds, this extraction performance was less successful for 
the other compounds and therefore was not investigated further. 
The second approach involved the addition of 1.0% acetic acid after the first centrifugation 
step, with the aim of increasing the recovery of the more acidic compounds. The volume 
added was determined by the amount of supernatant obtained from the initial extraction, for 
example, if 7 mL of supernatant was carried through to dSPE, 70 µL of acetic acid was 
added. Similar to the previous approach, the matrix effects showed significant signal 
suppression, with an average of 48%, however, the recovery of the compounds improved, 
particularly for the acidic compounds, diclofenac and ibuprofen, increasing to 20% and 30%, 
respectively. The recovery of the basic compounds also increased slightly, with an average 
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recovery of 53%. These positive results showed that this method had potential to extract all 
pharmaceuticals in the suite. 
The third approach involved the reduction of MgSO4 from the AOAC extraction kit to 4 g (as 
found in the EN kit) to determine whether loss of compound was occurring at this initial step 
due to this drying agent. This resulted in an increase in recovery of the basic compounds, 
with %RECs of between 75-95%. The matrix effects also improved, with an increasing 
percentage to an average of 53% (%RSD <10). As the second approach, with the addition of 
acetic acid gave the best recovery for the acidic compounds, a combined method of 4 g of 
MgSO4 + 1.5 g NaOAc, with the addition of 1.0% acetic acid was also investigated, with the 
aim of assessing if good recovery of both the basic and acidic compounds could be acheived. 
However, this combination of extraction conditions caused an adverse effect on the 
chromatography, similar to that seen with the EN extraction method, so this method was not 
investigated further. Therefore, given the results of these modification experiments the third 
approach (i.e. 4 g MgSO4 + 1.5 g NaOAc) appeared to provide the best recovery despite 
significant ionisation suppression being observed and was chosen for further study. 
 
5.1.2.2: Investigation of Alternative dSPE Sorbents 
Standardised QuEChERS methods include a variety of dSPE sorbents depending upon the 
composition of the sample matrix. For the initial method development, the dSPE step 
comprised of PSA and MgSO4, however for more complex samples such as soils and sludge, 
dSPE that includes C18 (used for removal of lipids) and GCB (used for removal of 
pigments/planar compounds) are readily available to tailor the extraction. Given these 
materials are capable of hydrophobic bonding it is likely that these may also remove the 
target pharmaceuticals as well as the interference, resulting in a decrease in recovery. To 
assess whether the inclusion of these sorbents had a positive effect on the matrix effects and 
recovery of pharmaceuticals these were investigated with the modified initial extraction it. 
The evaluation indicated that the presence of C18 adversely affected the chromatography of 
acetaminophen; usually a single peak at 1.56-1.60 minutes, however after extraction, an 
additional peak was seen, affecting the selectivity of the SIM transition (see Figure 5.4). A 
further drawback to this extraction was as expected, a decrease in recovery, despite relatively 
constant matrix effects being observed for each compound. This is understandable given most 
of these compounds (apart from acetaminophen and ibuprofen) showed significant retention 
on C18, albeit as an LC column. 
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Figure 5.4: Chromatograms of acetaminophen using multiple dSPE extraction methods to show the effect of 
different sorbents; a) single peak seen using dSPE containing PSA and MgSO4 only and b) split peaks seen 
using dSPE containing PSA, MgSO4 and C18. 
 
However, the dSPE containing PSA, MgSO4 and GCB (pigmented) showed improved matrix 
effects and recovery results (comparable to the PSA only dSPE) over the extraction using 
C18 (see Appendix 5.3). This indicates that the interaction with the target pharmaceuticals is 
less, and equivalent to the PSA sorbent. Although the matrix effects were still low, this 
equivalent recovery is a positive as the inclusion of GCB could be key in extracting some of 
the interferences expected when analysing more complex matrices such as fulvic acids within 
soil/sludge. However for further investigations into improving matrix effects, the dSPE kit 
containing PSA only was chosen to ensure comparability between previous experiments. 
 
5.1.2.3: Optimisation of Custom QuEChERS Extraction 
The modification of the QuEChERS extraction has led to the development of a repeatable 
method with apparent recovery (albeit to differing amounts) of all analytes however, a 
significant amount of ionisation suppression was observed in each experiment. This is 
important to address as the matrix effects can influence the recovery measurement. To 
investigate ways to improve the matrix effects, the modified extraction that provided the 
highest recoveries (i.e. 4 g MgSO4 + 1.5 g NaOAc), was used. As changes to the QuEChERS 
protocol had been investigated, focus shifted to the initial pharmaceutical spike. Previous 
experiments have used small volumes (20 µL) of highly concentrated pharmaceutical and IS 
mixtures (1 µg/mL) spiked into the water sample before extraction. It was considered 
whether this high concentration mixture was contributing to the matrix suppression with the 
pharmaceuticals influencing the signals observed and suppressing each other. Therefore a less 
concentrated spike was investigated, both as a spike of a separate analyte and IS mixture and, 
as the concentration of the pharmaceutical and IS spikes were the same (100 ng/mL), a more 
efficient, single standard mixture, with a total spike volume of 500 µL. Sadly, the latter 
a) b) 
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approach gave an overall poor result; %ME improved versus the 40 µL spike, but ionisation 
enhancement was observed with values of 83-198%, and poor repeatability of 32-132% RSD 
The single spike also resulted in poor peak shape for pronethalol and carbamazepine, 
confirming that the analytes can influence each other’s observed signal and the combination 
of the pharmaceuticals and IS suite in a single mixture is not compatible with the extraction. 
The experiment was therefore repeated using separate mixtures of pharmaceuticals and IS, 
ensuring the same starting concentrations (100 ng/mL), with an initial spike volume of 250 
µL of each, resulting in 500 µL volume overall. This proved critical reducing the matrix 
effects significantly with %ME between 95-125% for all compounds, with the exception of 
acetaminophen-(methyl)-d3 which had an enhanced signal of 164% ME, possibly due to its 
elution near the solvent front. This approach also showed excellent repeatability, with %RSD 
≤20% for all compounds and was selected as the optimised QuEChERS extraction for further 
investigation, and will be referred to henceforth as the modified QuEChERS method. 
 
5.2: QuEChERS Extraction with Solid-Phase Extraction 
As the sample preparation methods adopted by industry all incorporate traditional solid-phase 
extraction (SPE) using cartridges/columns, it was proposed whether a mix of QuEChERS 
extraction and cartridge SPE could provide improved sample clean-up than the modified 
QuEChERS method as analyte extraction would be more targeted. To determine this, a 
variety of different SPE cartridges were investigated for analyte recovery. 
 
5.2.1: Investigation of Commercial SPE Cartridges 
Cartridge SPE is a highly versatile extraction process capable of operating to both selectively 
extract (retain) the target analytes for enhanced selectivity and high recovery or alternatively, 
to specifically extract a certain type of interference to provide a sample extract that is 
complete as possible for screening (i.e. dSPE approach). Given this, the choice of sorbent 
(and elution solvent) is particularly important to meet the objective of the extraction. For the 
pharmaceutical extraction, both approaches were tested using commercial SPE cartridges, 
supplied by Biotage; ISOLUTE® ENV+ and ISOLUTE® SCX-2, with the aim of assessing 
retention and removal of salt to reduce the matrix enhancement observed, respectively. 
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5.2.1.1: ISOLUTE® ENV+ 
ISOLUTE® ENV+ is a hyper crosslinked hydroxylated polystyrene-divinylbenzene 
copolymer, designed to extract polar analytes from water samples. As these cartridges were 
tested in place of the dSPE step in the QuEChERS protocol, an additional evaporation and 
solvent exchange step was needed after the initial extraction step, to have an aqueous loading 
solution to ensure analyte retention on the hydrophobic sorbent. After loading the sample 
onto the cartridge, analytes were eluted using acetonitrile and, as with the QuEChERS 
extractions were evaporated to dryness for solvent exchange into the mobile phases (50:50 
water/acetonitrile). However, it was found that the solvent evaporation took considerably 
longer than expected (approximately 4 hours for 4 mL), possibly due to co-extraction of 
water from the cartridge. Given these time implications, it was thought that this procedure 
would not be suitable for high throughput analyses and was not investigated further.  
 
5.2.1.2: ISOLUTE® SCX-2 
ISOLUTE® SCX-2 is a strong cation exchange sorbent with minimal non-polar character, 
used to extract basic analytes from aqueous samples. These cartridges were also tested with 
the environmental matrix in mind, as a potential method to retain interferences common to 
soil and sludge [10-12] for removal. The QuEChERS extraction supernatant was loaded onto 
the cartridge and the eluent collected for analysis. However, it was found that the interaction 
between the sorbent and the suite of pharmaceuticals was too strong as each one was retained 
on the cartridge, so was not investigated further. 
 
5.2.2: Investigation of Cartridge-dSPE 
Following on from the “mix and match” approach in the development of the QuEChERS 
protocol we also tested the efficacy of cartridges filled with the QuEChERS dSPE material. 
This initially considered a 3 mL cartridge filled with PSA and MgSO4 however, was deemed 
impractical as the sorbent filled the majority of the cartridge, leaving space to add 
approximately 1 mL of supernatant. This meant that it took an overly lengthy period of time 
for the supernatant to permeate the sorbent, further exacerbated by the typical volume of 
supernatant collected from the QuEChERS extraction (7-8 mL). The results showed that the 
pharmaceuticals also showed poor recovery, possibly due poor solvent recovery and other 
cartridge sizes were considered. A 6 mL and a 15 mL cartridge were then investigated and 
both worked well with all pharmaceuticals extracted. When compared with the optimised 
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QuEChERS with dSPE method, the results obtained for the 15 mL cartridge were more 
competitive to those achieved using dSPE. For example, despite an increase in matrix 
enhancement over the entire suite (91-149% ME) the %REC was generally slightly lower the 
target compounds, apart from carbamazepine, 10,11-dihydrocarbamazepine and loratadine, 
which in fact increased by up to 17%. These comparable results show that this method is 
viable for use within a laboratory set-up to undertaken routine, automated SPE. However, for 
the purpose of this study, the dSPE method was chosen for further investigation due to the 
overall better performance of traditional dSPE. 
 
5.3: Performance of Optimised QuEChERS Method in Water  
The modified QuEChERS method (4 g of MgSO4 with 1.5 g NaOAc), with dSPE containing 
MgSO4 and PSA showed minimal, repeatable matrix effects with results approximately 100% 
ME (see Figure 5.5), with %RSD ≤16% for all compounds. These results provide confidence 
that the recovery measurements for each target compound are a true representation of the 
extraction efficiency enabling a more accurate measurement of the amounts qualified in the 
target sample. When recovery was assessed the majority of the pharmaceuticals showed 
excellent repeatability with %RSD <15%, apart from acetaminophen, which showed greater 
variability than the other compounds, with a %REC of 92% and a %CV of 20%. This 
compound eluted very near the solvent front and this could have resulted in the variability of 
the signal.  
 
 
Figure 5.5: A summary of the percentage matrix effects and recovery for the entire suite of pharmaceuticals 
extracted from “ideal” water matrix using the modified QuEChERS extraction method. 
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However, from a closer inspection of the data it appears that the method shows a more 
favourable recovery for basic compounds with typical recoveries between 42-55%, while the 
acidic compounds showing poorer precision and recovery with a %RSD of 124 and 55% and 
a %REC of 1.1 and 12.4% and for diclofenac and ibuprofen respectively (see Figure 5.5). A 
potential cause of the poor recovery of acidic compounds may be the presence of primary 
secondary amine (PSA) within the QuEChERS dSPE kit as this sorbent has a permanent 
positive charge that could retain these compounds during this extraction step. One way to 
mitigate this may be to alter the dSPE material, opting for an anion exchange sorbent, rather 
than PSA, however, this is likely to affect the basic compounds and could result in further 
matrix suppression with complex matrices, such as sludge that have a high fulvic and humic 
acid content. Based on this premise the method was not optimised further on this sample type 
but applied to a more complex soil matrix.  
 
5.4: Performance of Optimised QuEChERS Method in Soil  
The modified QuEChERS extraction method was tested using locally sourced garden soil as a 
control matrix for treated sludgecake. The soil was fortified with pharmaceutical and IS 
mixtures to determine the %ME and %REC in a more complex sample matrix. As expected, 
the %ME for each compound altered slightly versus the “ideal” water samples, with highly 
repeatable results for all compounds (8% RSD) and the majority of compounds ranging from 
90-155% ME, with a median value of 107%. The higher %ME observed were for the 
compounds that eluted in the middle of the chromatographic gradient (propranolol, 
diphenhydramine, citalopram and erythromycin at 139%, 150% 155% 131% ME, 
respectively), and is likely to be a result of co-elution of interferences (in particular, salts and 
heavy metals [10]) within the soil with a significant number of peaks apparent in the full 
mass scan chromatogram.  
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Figure 5.6: A summary of the percentage matrix effects and recovery for the entire suite of pharmaceuticals 
extracted from fortified soil matrix using the modified QuEChERS extraction method. 
 
The IS, talopram exhibited the highest amount of matrix enhancement, with a %ME of 161%. 
As with the solvent sample, recovery of diclofenac and ibuprofen was poor at 2% and 25% 
respectively, further supporting the idea that retention of compound on the dSPE sorbent 
occurred. However, more pleasingly only a slight decrease in analyte recovery (35-75%) and 
precision (%RSD ≤22%) was seen across the remaining suite of pharmaceuticals which, 
given the increase in %ME would potentially indicate that recovery is in fact a little higher 
than these values.  
 
5.4.1. Comparison Study with Industrial Method 
To benchmark the modified QuEChERS method this was compared to the recognised 
methods used within environmental monitoring. Fortified soil samples were taken through 
the modified QuEChERS protocol and the method used by Natural Resources Wales (NRW) 
[2] (initially developed for use on treated sludgecake) and analysed. Although the NRW 
method specifically targets a small selection of the pharmaceuticals within this study 
(propranolol, erythromycin and fluoxetine), identical spiking solutions were used for both 
methods (i.e. 250 µL of 200 ng/mL pharmaceutical and IS mixtures). The sample preparation 
involves repeated solvent washings of 50 mg of starting material (soil), which is collected in 
one vial to give an acidic and a basic supernatant. In both fractions, not one of the compounds 
spiked at the start of the extraction were detected; potentially lost during sample dilution, thus 
demonstrating that the modified QuEChERS method developed is a more successful method 
for the extraction of pharmaceuticals from soil. 
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The EPA Method (1694) for the analysis of water, soil, sediment, and biosolids [1] is a multi-
step analysis involving solid-liquid extraction, evaporation and pH adjustment before 
separation into acidic and basic SPE fractions for further clean-up before LC-MS/MS 
analysis. The latter stage of this method was evaluated using a spiked water sample to test the 
%ME and %REC of the Oasis HLB SPE cartridge for the target compounds. Pleasingly, all 
pharmaceuticals were detected in both the acidic and the basic fractions however, the results 
showed significant ionisation suppression, with the median %ME of 39% (%RSD ≤10). The 
recovery values showed poor reproducibility, with %RSD of 10-129% (median of 46%), 
further demonstrating that the modified QuEChERS method is more successful for the 
extraction of pharmaceuticals and also offers a labour-saving and cost effective approach for 
high throughput analysis versus current protocols. It is estimated that extraction costs can be 
reduced by >60% solely from the extraction cartridges and further still with analyst time 
saved, from hours to approximately 20 minutes per sample.   
 
5.5: Application of Optimised QuEChERS Method: Pharmaceuticals and 
Biocides 
The optimised QuEChERS method was evaluated for the combined extraction of 
pharmaceuticals and biocides, to replicate the extraction conditions anticipated within sludge 
samples. An in-house pilot study showed the presence of biocides in high abundance within 
sludgecake samples, therefore any effect on matrix suppression or enhancement and recovery 
of pharmaceuticals due to the presence of the biocides needed to be established, in addition to 
the effectiveness of this optimised method on the extraction of biocides for quantitation. 
 
5.5.1: Performance of Optimised QuEChERS Method in Water  
The optimised QuEChERS sample preparation method was tested in water to establish 
whether it could be used for the simultaneous extraction of pharmaceuticals and biocides as 
the presence of biocides within sludge samples could be of interest to CIP. Previous tests 
with QuEChERS have shown that the biocides can be carried through the extraction process; 
therefore it needs to be established what, if any, effects were observed by the presence of 
both compound classes (i.e. matrix interference/reduction in recovery) to ensure the accurate 
quantitation of the target analyte in more complex matrices. The QuEChERS method was 
carried out using a spiking mixture of the pharmaceuticals and biocides, as described in 
Section 2.4.4 and analysed using both analytical methods. While the %RSD for each 
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pharmaceutical was calculated to be 15%, indicating good reliability of the data, the results 
indicate that the matrix effect for each pharmaceutical was impacted by the presence of 
biocide within the extract, despite their later elution off the column, with the majority 
exhibiting a slight degree of enhancement (median value increasing from 106% to 109%). 
The exceptions to this are acetaminophen and erythromycin as both showed slight 
suppression compared to the pharmaceutical only extraction at 90% and 109% respectively, 
which could lead to a slight underestimation of concentration within sludgecake if %ME is 
not taken into account. Acetaminophen-(methyl)-d3, pronethalol and loratadine however, 
appeared to be unaffected by the biocides, with matrix effect remaining the same at 164%, 
97% and 102% respectively. The greatest difference observed was for ibuprofen, the only 
compound analysed in negative ion mode; the %ME increased from 105% to 173%.  
 
 
Figure 5.7: A comparison summary of the percentage matrix effects for the entire suite of pharmaceuticals in 
the presence of biocides, extracted from “ideal” water matrix using the modified QuEChERS extraction method. 
 
The suite of biocides showed repeatable matrix effects (%RSD ≤16%, except DDMA where 
%RSD = 25%), with marginal impact of the signal with a median value of 99%. As the 
biocides are permanently charged salts, they are less prone to competitive ionisation through 
protonation (i.e. as with the pharmaceuticals), therefore the minimal matrix effects observed 
is expected. The highest matrix effect observed was for HDTMA at 124%; this may be due to 
co-eluting species as HDTMA elutes off column similar retention time as BAC-C14 and the 
IS BAC-C14-d7, and from close inspection of the data, a large peak was recorded within the 
SIM window for HDTMA at 35 minutes. This peak had a similar m/z, at 282 and as this peak 
is not observed within the QC samples, it is likely that this interference originated from the 
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QuEChERS extraction sorbents. These results provide confidence that the recovery 
measurements for each compound are a true representation of the extraction efficiency.  
 
 
Figure 5.8: A summary of the percentage matrix effects and recovery for the entire suite of biocides extracted 
from “ideal” water matrix using the modified QuEChERS extraction method. 
 
The recovery measurements were also assessed, and while the biocides had good, repeatable 
recovery (%RSD ≤17%, except BAC-C18 where %RSD = 28%) of approximately 50% for 
each compound (i.e. 31% for BAC-C18 at the lowest, and HDTMA at 59% as the highest), 
all of the pharmaceuticals saw a decrease in recovery, with the exception of the acidic 
compounds, diclofenac and ibuprofen. The increase seen for these compounds could be 
explained by the increase presence of free chloride/bromide ions from the biocides competing 
for the free active sites on the dSPE material, resulting in less compound retention. 
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Figure 5.9: A comparison summary of the percentage recovery for the entire suite of pharmaceuticals in the 
presence of biocides, extracted from “ideal” water matrix using the modified QuEChERS extraction method. 
 
5.5.2: Performance of Optimised QuEChERS Method in Soil   
Similar to the pharmaceutical only study detailed in Section5.4, the QuEChERS sample 
preparation method was evaluated for the extraction of pharmaceuticals and biocides using 
locally-sourced garden soil as a control matrix. Testing this sample matrix with the biocides 
is particularly useful to determine the method’s ability in monitoring for these compounds for 
antimicrobial resistance studies. When comparing the matrix effects for the pharmaceutical 
only study and this extraction, a decrease in enhancement was seen (see Appendix 5.5). For 
example, the pharmaceutical only study showed a %ME of 90-155% (median value of 107% 
and %RSD <8%), with the highest %ME observed for propranolol, diphenhydramine, 
citalopram and erythromycin (139%, 150% 155% 131%, respectively), all of which elute 
between 15-17 minutes. However, when the biocides were included within the spiking 
mixture, these measurements decreased to 125%, 133% 136%, 123% respectively. The %ME 
for this extraction was between 91-141%, with a median value calculated to be 112% and 
%RSD ≤10%, with the exception of erythromycin and ibuprofen, with %RSD of 22% and 
26%, respectively.  
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Figure 5.10: A comparison summary of the percentage matrix effects for the entire suite of pharmaceuticals in 
the presence of biocides, extracted from fortified soil matrix using the modified QuEChERS extraction method. 
 
The majority of the pharmaceuticals saw a slight increase in recovery, with a range of 39-
100% (%RSD ≤17%), giving a median of 54% versus the pharmaceutical only extraction. 
The exception to this was the acidic compounds, diclofenac and ibuprofen, where a decrease 
in %REC were observed, as well as high %RSD at 52% and 36% respectively, indicating that 
the extraction of these compounds from soil and more complex matrices may not be 
repeatable, with a significant risk of underestimating concentrations of these target analytes 
within the environment. 
 
5.5.2.1: 1:400 Dilution for Biocides 
From a previous in-house study, it was observed that biocides were detected in high 
abundance within treated sludgecake, therefore a dilution factor was added to ensure the 
extracts could be quantified within the concentration range used using the ion trap platform. 
A 2.5 g sample of soil was fortified with the spiking solution and taken through the 
QuEChERS protocol, reconstituted as standard before being diluted to 1:400 with a 50:50 
acetonitrile/water mixture. The suite of biocides showed a slight increase in matrix effects 
versus the water extraction, with a range of 108-115%, giving a median value of 111%. 
While a high percentage of matrix enhancement was seen for HDTMA in water (124%), this 
enhancement was reduced when extracted from soil (111%) and may be due to the dilution of 
the sample as this is a common method used to reduce matrix effects within samples. For 
example, dilution enables the reduction of a less detectable level of co-eluting species that are 
causing enhancement. 
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Figure 5.11: A summary of the percentage matrix effects and recovery for the entire suite of biocides extracted 
from fortified soil matrix using the modified QuEChERS extraction method. 
 
The recovery measurements observed in the soil experiment were similar to those seen within 
water; the biocides showed repeatable recovery (%RSD ≤20%) with %REC remaining 
around 50% for each compound (i.e. 44% for BAC-C18 at the lowest, and BAC-C14 at 62% 
as the highest). 
 
 
Figure 5.12: A comparison summary of the percentage recovery for the entire suite of pharmaceuticals in the 
presence of biocides, extracted from fortified soil matrix using the modified QuEChERS extraction method. 
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5.6: Conclusion 
Environmental pollution is a growing concern, with current research methods laborious, time-
consuming and often ineffective at sufficiently preparing complex matrices for extraction for 
potential compounds of interest. The aim of this research is to develop an alternative sample 
preparation method that is quick and simple to carry out, while providing sufficient sample 
clean-up for reproducible matrix elimination and recovery of target pharmaceuticals with 
little to no matrix effects.  A modification to the QuEChERS sample preparation method for 
pharmaceutical extraction was investigated, which has successfully been applied to water and 
fortified soil samples, with the aim of future use for monitoring contamination in locally 
sourced treated sludgecake. Results showed that this method can be used to extract 
pharmaceuticals quickly from both water and soil with excellent repeatability and minimal 
matrix effects, providing confidence that the recovery measurements observed are an accurate 
representation of process (extraction) efficiency. While recovery of certain pharmaceuticals is 
lower than expected, this particular QuEChERS method works well for more basic 
compounds found on the CIP II list and could be a cost-effective alternative to the current 
industry recognised methods for monitoring the sites of waste deposition. This method has 
also shown potential for extracting these analytes from samples of high lipophilicity/organic 
content and could offer a more timely protocol for screening wastewater treatment processes 
to inform the CIP programme and future environmental policy. 
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Chapter 6: Method Application: Complex Matrices 
 
Following positive results of the proof-of-concept work extracting pharmaceuticals from 
solid samples (i.e. soil) using the modified QuEChERS sample preparation method, the 
method was applied on other environmental samples; locally-sourced wastewater effluent, 
treated sludgecake and homogenised mussel tissue. These sample types were chosen to meet 
the demand of the amended Environmental Quality Standards Directive (EQSD) [1], where 
Member States should aim to collect data for priority substances specifically sediment and 
biota for a reliable long-term evaluation of the accumulation of these substances [1].  
 
6.1: Quantitative Analysis of Environmental Matrices 
A quantitative study was conducted for both pharmaceuticals and biocides using a dual mass 
spectrometry approach; an ion-trap and a quadrupole platform due to the different 
sensitivities required for the target pharmaceuticals and biocides. The samples were extracted 
simultaneously to ensure consistent conditions and analysed with a calibration line and full 
set of QCs. Blank samples of each of the matrices were extracted using the optimised 
QuEChERS method to determine selectivity by ensuring the SIM/SRM scans for the internal 
standard are free of signal to ensure accurate quantitation can be carried out and screen for 
evidence of other pollutants. Solvent blanks were also run in between each sample type to 
ensure there was no carryover from the extracted matrices. A three-pronged approach to 
identification was adopted to determine the presence of target compounds within these 
samples, using the known retention times, the m/z of precursor and any known product ions 
for each compound. 
 
6.1.1: Treated Sludgecake 
Two samples of sludgecake were collected from a wastewater treatment plant in South Wales 
at different times of year; a summer and a winter sample. These were chosen to preliminarily 
establish if the compounds of interest were detected at amounts influenced by perceived 
usage, i.e. the sample collected in summer contained higher quantities of pharmaceuticals 
such as antihistamines due to increased use, whereas the sample collected in winter contained 
more painkillers and NSAIDS from a greater use of cold and flu medication. The samples 
were analysed following extraction using the optimised preparation method, and searched for 
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the target compounds then compared between sample types for any difference between the 
content and/or quantities of the compounds found.  
The lipophilicity (i.e. logP) of the pharmaceuticals chosen suggest that the majority are likely 
to adsorb to sludge [2], with values of around 3 and above (see Appendix 2.1). Low logP 
values usually indicate that compounds are more likely to be hydrophilic, and therefore be 
present within aqueous samples. However, citalopram, carbamazepine and erythromycin have 
logP values of 2.51, 2.67 and 2.83 respectively, indicating that the distribution of these 
compounds could be less distinct. Based upon the data provided by Berthod et al. [3] these 
lipophilicity constants could suggest a potential distribution between sludge, and the 
corresponding aqueous sample. Similarly for the biocides, the logP values vary ranging from 
1.69 for BAC-C12 to 4.28 for BAC-C18, increasing with the addition of carbon atoms. For 
the aliphatic analogues DDMA and HDTMA, both have a low logP of 2.51 and 2.40 
respectively, however previous in-house data has shown that these biocides do adsorb to 
sludgecake.   
Blank extracted samples were used to determine selectivity of the internal standards to ensure 
accurate quantitation can be carried out. Unfortunately, selectivity could not be achieved for 
acetaminophen-(methyl)-d3 (m/z 155) and talopram (m/z 296) within the winter sample with 
background response observed at the same retention time as the standard, with the former 
possibly attributable to polar interferences near the solvent front, therefore the quantitation of 
acetaminophen, diphenhydramine, citalopram, fluoxetine and diclofenac was not able to be 
accurately assessed using these ISs. Similarly to the winter sample, the summer sample also 
showed limited selectivity for the selection of ISs with a background response for 
acetaminophen-(methyl)-d3 (m/z 155) and pronethalol (m/z 230). Given these observations the 
use of an alternative IS was investigated to ensure some quantitative measurement could be 
achieved. 
 
6.1.1.1: Evaluation of Alternative IS 
The calibration parameters were tested with alternate internal standards available within the 
relevant samples, i.e. using pronethalol for quantifying diphenhydramine, citalopram, 
fluoxetine and diclofenac, and talopram for propranolol, using the ZQ4000. The calibration 
data showed good linearity for each compound, with R
2
 values equal to 0.99. The accuracy 
and precision were also tested using QC samples at multiple concentrations (i.e. 15, 25, 100, 
350 ng/mL) to assess the robustness of the method. Good precision and accuracy for each of 
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the five pharmaceuticals tested, with results <9% and ≤11% RSD respectively, confirming 
the usability of the alternative ISs for quantifying the relevant compounds within the 
sludgecake samples. The IDL values observed using these alternative ISs were equivalent to 
those determined in Chapter 3, with determined values <2 ng/mL. 
 
Table 6.1: Summary of the 1/x weighted quantitative data including linearity (R
2
), instrument detection limit 
(IDL), mean percentage accuracy and precision of quality control sample (QC) concentration for a selection of 
pharmaceuticals using alternate internal standards (IS).  
Compound 
Internal 
Standard 
(IS) 
Linearity 
(R
2
) 
IDL 
(ng/mL) 
QCs 
Mean Accuracy (%) Mean Precision (%) 
QC1 QC2 QC3 QC4 QC1 QC2 QC3 QC4 
Propranolol Talopram 0.9993 0.20 ± 0.1 2.07 4.13 3.38 3.11 2.19 3.15 1.70 1.36 
Diphenhydramine Pronethalol 0.9990 1.26 ± 0.4 0.63 0.90 -2.28 -1.37 1.74 2.39 2.10 1.86 
Citalopram Pronethalol 0.9976 0.34 ± 0.1 11.92 11.90 4.26 -3.96 1.62 1.25 1.07 2.21 
Fluoxetine Pronethalol 0.9984 0.49 ± 0.2 -2.74 -4.63 -5.54 -1.09 0.43 2.86 4.60 3.06 
Diclofenac Pronethalol 0.9981 1.61± 0.5 -3.06 0.50 -1.75 0.68 6.51 8.79 1.85 2.68 
 
6.1.1.2: Winter Sample 
Of the ten pharmaceuticals in the suite, six were observed by both techniques (see Table 6.2). 
To confirm the presence of a precursor ion, the signal to noise ratio of the extracted ion 
chromatogram was calculated to establish if the signal observed was above a ratio of 3:1 (i.e. 
the IDL) [4]. Of the six pharmaceuticals detected; propranolol, diphenhydramine, citalopram, 
carbamazepine, loratadine and diclofenac, two compounds were quantifiable using the 
alternate IS calibration and these results confirm previous studies of pharmaceuticals within 
wastewater sludge, with concentrations of citalopram being reported between 60-300 ng/g 
[5,6,7], with reports of concentrations determined as high as 1000 ng/g, within Europe [5]. 
Fluoxetine was also detected within the ZQ4000 data, however as only precursor ion data 
was observed, identification and determined concentration are tentative without further, 
confirmatory data. Although the concentration of fluoxetine is an estimation, the 
measurement is slightly higher than concentration reported within the literature with a 
previous study reporting approximately 200 ng/g within treated sludge [5].  
 
 
 
 
 
Rachel Townsend 
__________________________________________________________________________________________ 
 
__________________________________________________________________________________________ 
 
Page 124 of 177 
Table 6.2: A summary of the identification factors used for the qualitative screen in the sample of sludgecake 
collected in winter. The retention time observed were the same over both platforms. *Fluoxetine and ibuprofen 
were detected within the ZQ4000 data only. **The main ion seen for diclofenac within the product ion scan on 
the LCQ was the precursor ion at m/z 296, rather than the product ion at m/z 277.  
Compound 
Retention 
Time 
(minutes) 
Signal: 
Noise 
(S/N) 
Present in 
both 
techniques? 
Concentration 
(µg/kg) 
Propranolol 15.8 7  - 
Diphenhydramine 16.6 7  - 
Citalopram 16.9 29  995.3 ± 126.7 
Carbamazepine 18.1 3  - 
Fluoxetine * 18.7 10  319.5 ± 43.6 
Loratadine 19.2 3  - 
Diclofenac ** 24.4 3  - 
Ibuprofen * 23.8 5   
 
Due to the high abundance of the biocides within sludgecake, a 1:400 dilution of the 
sludgecake extract was required before analysis on the LCQ (as described for the 1:400 soil 
extraction experiment in Section 5.2.2.1) with signal saturation also observed with ZQ4000 
analysis as expected with its higher sensitivity (see Appendix 6.1). All six of the biocides 
were confirmed within the sludge sample, having a signal to noise greater than 3. Of these, 
BAC-C12, BAC-C14, BAC-C18, HDTMA and DDMA appeared most abundant with 
concentrations exceeding beyond the recommendation of CIP II in milligram amounts. 
 
Table 6.3: A summary of the identification factors used for the qualitative screen in the 1:400 dilution of the 
winter sample of sludgecake. The retention time observed matched those recorded for the standard sample. All 
of the compounds have a S/N greater than 3 and therefore can be discerned from the background signal.  
Compound 
Retention 
Time 
(minutes) 
Signal: Noise 
(S/N) 
Concentration 
(mg/kg) 
BAC-C12 24.1 46 44.5 ± 0.9 
BAC-C14 26.4 34 18.6 ± 0.1 
BAC-C16 28.7 5 - 
BAC-C18 30.9 178 5.5 ± 0.9 
DDMA 27.5 30 21.3 ± 3.6 
HDTMA 26.2 34 24.6 ± 4.6 
 
These concentrations are determined by legislation outlined in European Directive 
(2013/39/EU), stating the required limit of detection for emerging compounds, (including 
pharmaceuticals) detected in sludge samples should not exceed 0.1 µg/kg. Importantly, these 
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results are consistent with reports that concentrations of QACs between 10-50 mg/L are 
considered microbicidal [8], assuming that 1 L = 1 kg. Therefore, the use of this sludgecake 
as an agricultural fertiliser may be important in considering the impact of this pollutant, 
specifically in leading to an increased selective pressure towards antibiotic resistance. Given 
this potential link, this data suggests that QACs should be viewed as an emerging compound 
of interest, and the remit of CIP to be extended beyond pharmaceuticals. 
 
6.1.1.3: Summer Sample 
Similarly to the winter sample, three of the pharmaceuticals were detected within the summer 
sample and confirmed using the product ion scans of the LCQ data (see Table 6.4). However, 
these compounds were observed at levels that were unable to be quantified, as the S/N 
determined for each compound detected was less than 10. 
Although the precursor ion for diclofenac was observed at the correct retention time within 
the confirmatory screen, there was insufficient product ion signal for confirmation. This is 
not surprising given diclofenac provided the lowest S/N precursor ion of those detected.  
 
Table 6.4: A summary of the identification factors used for the qualitative screen in the sample of sludgecake 
collected in summer. The retention time of the standard was taken from the top calibration standard (400 ng/mL) 
analysed on the same day as the sludge sample.  
Compound 
Retention 
Time 
(minutes) 
Signal: 
Noise 
(S/N) 
Present in 
both 
techniques? 
Concentration 
(µg/kg) 
Propranolol 15.9 3  - 
Carbamazepine 18.1 5  - 
Loratadine 20.5 5  - 
Diclofenac * 24.4 3  - 
Ibuprofen** 23.7 6   
 
While the difference between these samples did not meet the assumption that the contents 
would reflect the season as more antihistamine medications, such as diphenhydramine and 
loratadine, were detected in higher amounts within the winter samples, it does prove that the 
method works for multiple samples collected at different time points throughout the year.  
As with the winter sludgecake, all six of the biocides of interest were detected within the 
summer sludgecake samples with the concentration range of 2.7-70.4 mg/kg.  
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Table 6.5: A summary of the identification factors used for the qualitative screen in the 1:400 dilution of the 
summer sample of sludgecake. The retention time observed matched those recorded for the standard sample. All 
of the compounds have a S/N greater than 3 and therefore can be discerned from the background signal. 
Compound 
Retention 
Time 
(minutes) 
Signal: Noise 
(S/N) 
Concentration 
(mg/kg) 
BAC-C12 24.1 295 70.4 ± 25.9 
BAC-C14 26.4 162 32.1 ± 12.1 
BAC-C16 28.7 30 2.7 ± 0.4 
BAC-C18 31.0 13 2.8 ± 0.5 
DDMA 27.5 183 26.8 ± 6.4 
HDTMA 26.3 109 41.4 ± 14.7 
 
Again, high concentrations of biocides were observed at milligram level within the summer 
sludgecake sample (see Table 6.5), however these were significantly higher than those 
recorded within the winter sample, with a mean percentage change of 47%, except for BAC-
C18 (see Figure 6.1), suggesting the usage of disinfectants change between different seasons 
potentially due to the use of BACs as an algaecide for swimming pools [9]. 
 
 
Figure 6.1: A bar chart showing the percentage change in calculated concentration of the biocides between the 
samples of sludgecake collected during the winter and summer.  
 
6.1.2: Treated Effluent 
To meet the legislation outlined within the Water Framework Directive (2000/60/EC), 
detailing the requirement that all UK watercourses should be monitored and have a good 
status [10], the QuEChERS method was applied to a complimentary sample of treated 
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effluent collected from the same wastewater treatment plant as the sludgecake, to determine 
what CIP compounds could be observed within a liquid wastewater fraction. Again a 
background response was measured at the transition and retention time for acetaminophen-
(methyl)-d3, therefore it was not used for quantitation.  
 
 
Figure 6.2: The total ion chromatograms (TIC) for a) a standard of acetaminophen-(methyl)-d3 compared to b) 
an extracted blank sample of treated effluent showing the background signal recorded at the SIM scan for 
acetaminophen-(methyl)-d3. As there is no selectivity quantitation of acetaminophen will not be possible. 
 
Based on the CIP selection criteria of lipophilic substances (logP > 3) it was anticipated that 
these would not be observed within the effluent sample as they would be more likely to 
adsorb to sludge. Precursor ions indicative of propranolol, citalopram and carbamazepine 
were observed within this sample; these compounds have logP values ≤3, indicating slight 
lipophilicity [11], meaning that while they are observed in sludgecake, they are also likely to 
be seen within the water fraction. However, despite precursor ions being observed within the 
SIM scan on the ZQ4000, the signal intensity of these “peaks” was low (x104) and had a S/N 
<3, therefore any positive detection/identification would be inaccurate.  
The data has shown that biocides adsorb to sludgecake and are detected in high abundance 
however, the behaviour of biocides in other wastewater fractions, such as effluent, is more 
complicated to predict. The logP values indicate that they are hydrophilic and should be 
detected within effluent, potentially due to decrease in concentration of “free” surfactant 
within the liquid due to the formation of micelles once the surfactant concentrations are 
above the critical micelle concentration (CMC) [12]. This behaviour is indicated by the data, 
as the suite of biocides were observed at significantly lower concentrations (see Figure 6.3) 
with BAC-C12 and BAC-C16 quantifiable above the IDL at 1.1 and 1.6 ng/mL respectively. 
These values are slightly lower than those reported in the literature, with values of 
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approximately 0.062 mg/L (i.e. 62 ng/mL) quantified in sewage effluent in Croatia [13], 
however, this could be due to usage, including its possible use as a dewatering agent during 
the wastewater process within this Member State.  
 
 
Figure 6.3: Extracted ion chromatograms showing the biocides detected within effluent a) BAC-C12, b) 
DDMA, c) BAC-C14, d) BAC-C16 and e) BAC-C18 with the signal-to-noise for each peak.  
 
6.1.3: Biota 
A sample of locally sourced mussel tissue was homogenised and extracted using the 
optimised QuEChERS method to determine whether the pharmaceuticals and biocides 
accumulate similarly to sludgecake due to a comparative lipid content [14,15]. A “wet” 
sample was analysed alongside a lyophilised aliquot, in keeping with the sample pre-
treatment of the sludgecake. The total ion chromatogram recorded for both the wet and 
lyophilised aliquots looked similar to sludgecake, with lyophilised biota showing a slightly 
higher background signal, possibly due to the concentration effect of freeze-drying, see 
Figure 6.4. 
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Figure 6.4: The total ion chromatograms (TIC) for a) an extracted blank sample of treated sludgecake b) an 
extracted blank sample of wet homogenised biota and c) an extracted blank sample of lyophilised homogenised 
biota, which show a higher background signal for the sludgecake and biota samples that were lyophilised. 
 
Once again, in both samples, there is limited selectivity at the transition for acetaminophen-
(methyl)-d3, with a background response being recorded at the retention time. As with all the 
matrices examined, there is interference with the solvent front and therefore reliable 
quantitation of acetaminophen was not possible.  
 
6.1.3.1: Wet Biota 
Three pharmaceuticals were detected within this sample; propranolol, diclofenac and 
ibuprofen, with a S/N of 4, 5 and 9, respectively, therefore quantitation of these peaks was 
unachievable. The majority of the SIM scans for the pharmaceuticals did not show a 
discernible signal from the background, however, the extracted ion chromatograms of the full 
mass scan showed a strong signal indicative of fluoxetine (S/N 177), loratadine (S/N 8) and 
another peak for diclofenac (S/N 59) at differing retention times than typically observed. 
These peaks were also observed within the LCQ data, however only the precursor ion was 
seen for fluoxetine and loratadine, while the product ion for diclofenac was observed. 
a) 
b) 
c) 
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Figure 6.5: The extracted ion chromatograms showing the later elution times for a) diclofenac (m/z 296) b) 
loratadine (m/z 383) c) fluoxetine (m/z 310) and the corresponding expanded spectra showing the precursor ions 
for each of the compounds. 
 
In addition to pharmaceuticals, there was significant evidence suggesting the target biocides 
were present, specifically, BAC-C12, BAC-C14, BAC-C18 and DDMA. This is important as 
it provides evidence to suggest that these are either mobilised from farmland through 
agricultural run-off or are present within the “clean” water fraction that is dispensed into the 
water course. These were observed at lower amounts than sludgecake, with determined 
concentrations of BAC-C12, BAC-C18 and DDMA found to be 7.4, 6.7 and 8.1 µg/kg, 
respectively, perhaps suggesting that direct disposal into the water habitat for these animals is 
less likely and other, more indirect routes described above are more likely to be the route of 
exposure here. 
 
6.1.3.2: Lyophilised Biota 
Lyophilised (freeze-dried) biota was analysed to determine whether the removal of water 
from the sample had affected the concentration of the compounds of interest observed. 
Similar to the wet biota sample, three pharmaceuticals were detected by both techniques; 
carbamazepine, loratadine and ibuprofen, and additionally, diclofenac was detected within 
the SIM data only. Extracted ion chromatograms of the full mass scan showed a signal 
indicative of citalopram (S/N 6) and fluoxetine (S/N 16), with additional peaks indicative of 
loratadine (S/N 7) and diclofenac (S/N 14) at differing retention time than typically observed. 
The majority of the literature regarding pollutants in biota are concerning the concentration of 
pharmaceuticals within mussel tissue, and show that carbamazepine is the most commonly 
detected within different species of biota. A UK based study has also shown this within 
a) b) c) 
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Gammarus Pulex from the Thames, London, where a concentration of 6 ng/g of 
carbamazepine was recorded [16], and a study conducted on multiple classes of biota in 
Spain reported a concentration of 1.3 ng/g of carbamazepine. Other pharmaceuticals include 
citalopram, with a reported concentration of 1.9 ng/g within Crassostrea gigas (Pacific 
oyster) [17]. Positively, although the species of biota differs to this study, both 
carbamazepine and citalopram were detected within the biota samples tested, albeit at a 
concentration below the IQL.  
 
 
Figure 6.6: The extracted ion chromatograms showing the later elution times for a) diclofenac (m/z 296) b) 
loratadine (m/z 383) c) fluoxetine (m/z 310) d) citalopram (m/z 325) and the corresponding expanded spectra 
showing the precursor ions for each of the compounds. 
 
Similar to the wet samples, BAC-C12, BAC-C18 and DDMA were also detected at lower 
concentrations, these made the precursor ions difficult to distinguish from the complex matrix 
interferences. Only BAC-C12 had a distinct signal within the SRM, with S/N>10, and a 
measured concentration of 5.5 µg/kg, slightly lower than the concentration seen in the wet 
sample, which could be due to “free” BAC binding to certain lipid classes [18] within the 
biota sample (i.e. phospholipids), potentially as a result of the reduction of liquid during 
lyophilisation, however further analysis would need to be conducted for confirmation.  
 
6.1.3.3: Manual Integration of Later Eluting Peaks 
Both samples of biota showed peaks with precursor ions consistent with fluoxetine, 
loratadine, and diclofenac, and a peak consistent with citalopram was detected within the 
lyophilised sample. These were integrated manually within the extracted ion chromatogram 
for quantitation as they were not captured by the automated processing method. To ensure 
a) b) c) d) 
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consistency each peak of interest was automatically integrated using the chromatogram 
window within MassLynx and then manually divided by the automated peak area of the 
corresponding internal standard to generate the RRF, used to determine concentration. The 
calculated values are much higher than those reported within the literature, and also those in 
the SIM scan. 
 
Table 6.6: A summary of the concentrations of pharmaceuticals detected and quantified using manual 
integration of the extracted ion chromatogram within the two homogenised biota samples tested.  
 Concentration in Biota 
(µg/kg) 
Compound Wet Lyophilised 
Fluoxetine 499.5 77.4 
Diclofenac 4511.1 894.8 
 
As these values were calculated from peaks with a later retention time than expected, further 
data is needed to support the identification of these compounds, so these calculated 
concentrations can only be used as an estimation of quantities of contaminants within this 
matrix. 
 
6.2: Qualitative Screen using Accurate Mass 
To support the quantitative analysis performed on the ion trap and quadrupole platforms, a 
qualitative screen was carried out using an LTQ Orbitrap mass spectrometer using data 
dependant acquisition (DDA). Extracted matrix blanks were analysed to obtain confirm 
selectively. Similarly to the quantitative analysis, a three-pronged approach was used to 
identify compounds of interest; the retention time, precursor (full mass scan) and product ion 
(DDA) data based on known standards targeted within this project. Using the high mass 
resolution capability of this platform, elemental formula were proposed for both precursor 
and fragment ion species, assisting in identification along with any observed isotope patterns.  
 
6.2.1: Treated Sludgecake 
The samples were first searched to determine whether the target compounds were detected, 
corroborating the findings of the quantitative analysis. Of the target pharmaceuticals and 
biocides, five pharmaceuticals and six biocides were identified using the parameters 
described above, with assigned elemental formulas matching with an error of <1ppm. In 
addition to the identification of the target compounds, the data was represented and studied 
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using the base peak chromatogram to help identify the most abundant species recorded. 
Within the two samples of sludgecake (one collected in winter and one collected in summer) 
there were 10 peaks of interest common to both samples at similar retention times, over a 
mass range of m/z 200-700. The compounds with lower m/z (between m/z 200-370) eluted 
towards the end of the chromatographic gradient, between 22-27 minutes, similar to the target 
QACs (see Appendix 6.2). These compounds did not appear to show distinctive isotope 
patterns indicative of halogenated species but a simple carbon isotope. Using the elemental 
formula search these unidentified compounds showed similarities to the QACs, with most 
consisting of carbon, hydrogen and nitrogen only, indicative of ammonium biocides, with the 
exception of m/z 211.0867 and 258.2796; these were predicted to contain an oxygen atom, 
supported by the product ion data with losses consistent with H2O (18 Da). 
 
Table 6.7: A summary of the ions common to the winter and summer sludgecake samples, showing the 
retention time (RT), mass-to-charge (m/z) and possible chemical formulas generated from Xcalibur 3.0 with the 
associated error of <1ppm, providing confidence in the identification.  
RT m/z 
Possible 
Formula 
Error 
(ppm) 
Product 
Ion 
Possible 
Formula 
Error 
(ppm) 
22.24 211.0867 C13H11N2O 0.25 
193.0765 
169.0762 
C13H9N2 
C11H9N2 
0.45 
0.16 
23.93 258.2796 C16H36NO 0.27 214.2531 C14H32N 0.18 
24.56 200.2372 C13H30N -0.09 - - - 
25.80 228.2684 C15H34N -0.09 - - - 
25.80 270.3155 C18H40N 0.42 158.1907 C10H24N -0.26 
33.43 368.4256 C25H54N -0.05 - - - 
 
The four peaks of interest with higher m/z at 520.3323, 608.3846, 652.4119 and 696.4381, 
eluted earlier in the chromatogram, around 14 minutes. Again, these compounds only showed 
an isotope pattern consistent with 
13
C, and product ion data showed a loss of 17 or 18, which 
is typically related to the loss of NH3 or H2O, respectively. A study of PEG 400 and its 
oligomers by Bhaskar et al. [19] using ESI showed similarities in the observed ions. All four 
ions of interest were present within the literature and identified as polyethylene glycol 400 
(PEG 400) oligomers that had formed ammonium adducts. This supports the product ion data 
observed within the sludgecake samples, and as PEG 400 is commonly used as a 
pharmaceutical excipient [20] there is reason to support the presence of these compounds 
within sludge however, further work with standards would need to be carried out to positively 
identify these peaks. 
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6.2.2: Effluent 
The quantitative method for the effluent sample showed there was limited compound 
recovery for the pharmaceuticals, due to the lipophilicity of the analytes, indicating their 
proclivity to adsorb to sludge. However, similarly to the quantitative analysis, ions indicative 
of the full suite of biocides were detected within the qualitative screen, with BAC-C12 
detected in highest abundance. Product ion data was recorded for BAC-C12 only, with 
identification of the other biocides achieved using the precursor m/z. This further supports the 
literature that QACs are present within aqueous samples, albeit at lower amounts due to 
potential micelle form reducing the concentration of “free” surfactant [12]. 
 
 
Figure 6.7: The chromatogram showing the peaks of interest for treated effluent, with the corresponding mass 
spectra of m/z 430.2435, 150.0911 and 440.4091. 
 
In addition to the identification of the target compounds, a series of peaks within the base 
peak chromatogram eluting between 15-30 minutes were investigated. The 3 peaks of interest 
had a similar m/z range of 400-450, with the exception of the base peak at 21 minutes, which 
was m/z 150. Unfortunately the DDA did not manage to record product ion data so potential 
identification is difficult. From previous studies in the literature a peak at m/z 150.0911 in 
wastewater effluent has been observed, attributable to methamphetamine (C10H15N) [21], 
however the determined accurate mass does not reflect this elemental formula, therefore 
further analysis is needed to identify this compound. Similar issues were encountered with 
the remaining peaks of interest at m/z 430.2435 and 440.4091; each had corresponding 
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product ion data and the elemental formulas generated were ≤1ppm, however, definitive 
identification of these peaks is not possible without further analytical data. 
 
Table 6.8: A summary of the ions identified within the effluent sample, showing the retention time (RT), mass-
to-charge (m/z) and possible chemical formulas generated from Xcalibur 3.0 with the associated error of ≤1ppm, 
providing confidence in the identification.  
RT m/z 
Possible 
Formula 
Error 
(ppm) 
Product 
Ion 
Possible 
Formula 
Error 
(ppm) 
15.61 430.2430 
C21H36O8N 
C20H30O3N8 
-0.40 
-0.41 
216.1232 
C10H18O4N 
C8H16O3N4 
0.22 
1.56 
28.31 440.4091 C25H52O2N4 0.52 226.2166 C12H26N4 1.35 
 
6.2.3: Biota 
Surprisingly, the detection of target analytes within the two biota samples was the same, 
indicating that the lyophilisation process had little effect on potential pollutants within the 
samples. Each sample had precursor ion data for 4 pharmaceuticals and 1 biocide; 
propranolol, fluoxetine, loratadine, diclofenac and BAC-C12, however only BAC-C12 could 
be positively identified due to the additional product ion data recorded. The precursor ion, 
m/z 304.2999 and product ion, m/z 212.2375 were observed at a corresponding retention time 
and formulas, C21H38N and C14H30N (<1ppm).  
As with the previous matrices, the base peak chromatograms for both biota samples were 
investigated. Despite the difference in preparation between the two samples (wet and 
lyophilised), there were 7 main peaks of interest common to both samples at similar retention 
times, at m/z 430.2432, 150.0909, 482.3591, 228.2320, 254.2477, 280.2639 and 282.2791 
(see Figure 6.8).  
 
 
Figure 6.8: The chromatograms showing the common peaks of interest between a) wet and b) lyophilised biota. 
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The first two peaks, m/z 430.2432 and 150.0909 are also observed with the treated effluent 
sample at similar retention times of 15 and 21 minutes, respectively. Isotope patterns were 
assessed and each compound showed an isotope consistent with the 
13
C only, ruling out the 
presence of any chlorine or bromine atoms. Product ion data recorded for m/z 430.2432 
corresponds to a loss of 214 Da, leaving a product ion m/z 216.1231, with potential chemical 
formulas correlating to C21H36O8N and C10H18O4N, respectively, consistent with the effluent 
sample. A product ion consistent with a loss of 17 was observed for m/z 150.0909, leaving 
m/z 133.0881; however, the only formulas generated for these ions that are consistent with a 
loss of NH3 are C8H12N3 and C8H9N2 respectively, with an associated error of <12ppm, 
therefore without more complimentary analytical data, positive identification of these peaks 
is not possible. While there was no product ion data recorded for m/z 228.2320, 280.2639 and 
282.2791, the DDA for m/z 482.3591 shows an ion consistent with a loss of H2O (18 Da), 
indicating the presence of at least one oxygen atom and for m/z 254.2477 a product ion 
consistent with a loss of NH3 (17 Da) was observed at m/z 237.2211, however, further 
analysis would be required to achieve a positive identification of these peaks. 
 
Table 6.9: A summary of the ions common to the wet and lyophilised biota samples, showing the retention time 
(RT), mass-to-charge (m/z) and possible chemical formulas generated from Xcalibur 3.0 with the associated 
error. 
RT m/z 
Possible 
Formula 
Error 
(ppm) 
Product 
Ion 
Possible 
Formula 
Error 
(ppm) 
15.58 430.2432 C21H36O8N -0.65 216.1231 C10H18O4N 0.07 
21.73 150.0909 C8H12N3 -11.7 133.0881 C8H9N2 12.20 
27.82 482.3591 C27H44ON7 -1.11 464.3503 C27H42N7 0.62 
30.79 228.2320 
C14H30ON 
C12H28N4 
-0.18 
1.16 
- - - 
31.72 254.2477 C14H30N4 1.23 237.2211 C14H27N3 1.20 
32.81 280.2639 
C18H34ON 
C16H32N4 
0.23 
1.58 
- - - 
35.04 282.2791 
C18H36ON 
C16H34N4 
0.18 
1.31 
- - - 
 
6.3: Conclusion 
Current industrial sample preparation methods for complex matrices such as wastewater 
products and biota are typically time-consuming and labour intensive, unsuitable for high 
throughput screening. The modified QuEChERS method offers an alternative sample 
preparation method which reduces the extraction time from hours to approximately 20 
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minutes per sample. This method was successfully applied to a wastewater effluent, treated 
sludgecake and homogenised mussel tissue, with results showing the method’s ability to 
extract five targeted pharmaceuticals and six biocides within the treated sludgecake samples, 
three biocides within effluent and four pharmaceuticals and four biocides within the mussel 
tissue samples using a dual ion trap and quadrupole platform. The calculated concentrations 
obtained significantly exceeded the suggested IDL values outlined in the CIP objectives, 
suggesting that significant bioaccumulation or replenishment due to insufficient removal 
during the wastewater treatment process may occur; a problem that will only continue to 
worsen without adequate remediation measures. Further implications of the presence of these 
compounds within the environment is the future risk to public health as a result of exposure 
of these compounds to the food chain through uptake from aquatic animals, either through 
contaminated wastewater effluent being released into watercourses or as a result of 
agricultural run-off from application of sludge to land.  
The concentration of biocides reported within these fractions is also a concern; while 
alternative studies in Europe and China have shown the presence of QACs within sludge 
samples at equivalent concentration, biocides in effluent and biota have not been studied 
before. The detection of these QACs supports the need to identify these biocides as 
compounds of potential environmental concern and for monitoring through programmes such 
as CIP to inform UK Water Industry Research and EU policies, such as WFD.  
A qualitative screen was successfully carried out on each of the environmental matrices of 
interest to this study, with results showing a selection of ions with similar predicted elemental 
formulas based upon their accurate mass. These predicted formulas suggest there could be a 
potential series of compounds, similar to the BACs, present within these sample types, 
indicating that they may be future compounds of interest for further work. 
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Chapter 7: Conclusion and Further Work 
 
The Chemical Investigation Programme (CIP), established in 2009, is a UK based initiative 
aiming to identify and understand the prevalence of potential pollutants within wastewater 
samples, and to establish quality standards in wastewater similar to those outlined in the 
environmental quality standards directive (EQSD) (2008/105/EC). The initial CIP study was 
one of a number that directly fed into the amended environmental directive, 2013/39/EU, 
which also encompassed findings from the Water Framework Directive (WFD) and EQSD. 
This highlighted substances, including a selection of pharmaceuticals, of emerging concern to 
environmental contamination that are not yet subject to legislation but specified on a “watch 
list”. Substances on the “watch list” (currently three pharmaceuticals) are considered to be 
hazardous and are therefore subject to a monitoring period, gathering data to determine the 
risk within the environment. In 2015, the second phase of the CIP study (CIP II) was 
launched to investigate these pharmaceuticals and other compounds identified as a potential 
environmental concern. This ongoing study focused on understanding their concentrations in 
environmental samples to inform policy on which technologies and processes provide the 
best contaminant removal at the most economical cost. There are a wide range of pollutants 
within the environment and pharmaceuticals are one such class of pollutant. Typically small 
molecules at relatively low abundance, the detection of these compounds within complex 
matrices, such as soils and wastewater, can be problematic. As 80% of treated sewage sludge 
is used as fertiliser on agricultural land, it is necessary to monitor whether this disposal route 
may have a negative impact on agricultural soil as a result of bioaccumulation of common 
pharmaceuticals. Previous research has also shown certain biocides are also prone to 
bioaccumulation within treated sewage sludge. Biocides and antibiotics share some 
similarities, whereby both classes of compounds control or destroy bacterial growth. The 
presence of these compounds within treated sewage sludge, and subsequently within 
agricultural soils could lead to an environment that is conducive to bacterial resistance.  
Current recognised methods to analyse complex environmental matrices such as soil and 
wastewater effluent are generally multi-step analyses that are time consuming and laborious, 
with extractions taking up to 2 hours per sample, making them unsuitable for high-throughput 
analysis. These methods, when tested in-house (even on “simple” samples) have shown poor 
extraction of pharmaceuticals with poor repeatability. Given the disadvantages of these 
approaches, an alternative method capable of preparing these complex samples with minimal 
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matrix effects that may adversely influence the measured signal, repeatable recovery and 
performance involving less time and resources is required. 
The main aim of this project was to develop and evaluate a single modified QuEChERS 
sample preparation method suitable for detection and quantitation of compounds of interest to 
CIP within a selection of environmental matrices of interest to WFD. Sample types 
investigated were soil, treated effluent, treated sludgecake and homogenised biota (mussel 
tissue). All extracted samples were analysed using LC-MS with an internal standard approach 
to quantitation.  
 
7.1: Quantitative LC-MS Method Fitness for Purpose 
A quantitative method for detecting and measuring a suite of 10 pharmaceuticals and 4 
internal standards was successfully developed using a ZQ4000 single quadrupole mass 
spectrometer. This method was adapted to include 6 quaternary ammonium compounds with 
1 internal standard (QACs) using an LCQ ion trap mass spectrometer. Both methods were 
successfully evaluated using recognised performance criteria for analytical testing. The 
evaluation confirmed the while the pharmaceutical method was suitable for accurate and 
precise quantitation for concentrations between 15-400 ng/mL, the performance of the 
biocide method was limited, and would benefit from additional development to ensure that 
the best possible data for reliable quantitation could be achieved. The method was evaluated 
for QAC concentrations between 8-80 ng/mL, and deemed fit for purpose for this initial 
“proof-of-concept” study, with IDL values determined empirically to be less than 1 ng/mL 
and 2 ng/mL for pharmaceuticals and QACs, respectively.  
 
7.2: Modified QuEChERS Extraction Fitness for Purpose 
A modified QuEChERS sample preparation method was developed in collaboration with 
Biotage GB. The method uses a custom extraction mixture of 4 g magnesium sulphate 
(MgSO4) and 1.5 g sodium acetate and an EN dSPE kit comprised of magnesium sulphate 
and primary secondary amine (PSA). This method was successfully used to extract both 
suites of pharmaceuticals and biocides from water and soil samples. The matrix effects and 
extraction recovery of each compound were characterised within water and soil samples. The 
matrix effects observed with the modified QuEChERS method were greatly improved versus 
the standardised methods, with recorded percentages for each compound around 100%, 
showing only slight matrix enhancement for some compounds. Although recovery was less 
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than the traditional methods reported in the literature, the QuEChERS extraction and 
preparation method significantly reduced the time and reagents required by traditional sample 
preparation methods such as liquid-liquid, and solid-phase extractions. 
 
7.3: Qualitative and Quantitative Analysis within Environmental Matrices 
The modified QuEChERS extraction method was tested on more complex environmental 
samples; treated effluent, treated sludgecake and homogenised biota (mussel tissue). The 
compounds present within each sample were confirmed using their chromatographic retention 
time, precursor m/z and any fragment m/z, with the latter being used to confirm identity with 
accurate mass data. Each of the QAC biocides were successfully detected and quantified 
within the summer and winter sludgecake samples, with 50% and 80% of the pharmaceutical 
suite detected respectively. Two pharmaceuticals were detected at a quantifiable 
concentration within the winter sludgecake sample, citalopram and fluoxetine, the most 
abundant of which, citalopram, was measured at 995.31 μg/kg, which is slightly higher than 
previous studies. The observed concentration of biocide were much higher, with 
concentrations measured in the mg/kg range, the highest being BAC-C12 at 70.37 mg/kg 
(within the summer sample), which is much higher than previous studies, and the 
concentration of DDMA and HDTMA (26.81 and 41.39 mg/kg, respectively) have not been 
seen at this level. For both preparations of homogenised biota (wet and lyophilised) only 2 
pharmaceuticals and 4 QACs were detected, with measured concentrations of biocides much 
lower than within the sludgecake samples. Although some work has been carried out to detect 
biocides in wastewater sludge, their presence and concentration has not been extensively 
studied within biota previously. The quantitation of compounds of interest from the treated 
effluent was more challenging; the sample was more dilute, therefore the pharmaceuticals 
detected were below the IDL, and the BAC compounds detected were below 5 ng/mL. 
A qualitative screen was successfully performed with each of the sample matrices and in 
addition to confirming the identity of the target compounds, a selection of ions detected (m/z 
150.0911, 228.2320 and 430.2435) were common to all three matrices. Identity of these 
compounds could be useful to further understand the extent of 
bioaccumulation/replenishment of compounds other than pharmaceuticals, within multiple 
wastewater fractions.  
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7.4: Impact of the Findings 
The developed QuEChERS method has shown that it is capable of extracting both 
pharmaceuticals and biocides from multiple environmental matrices. This is the first study to 
demonstrate the ability of a QuEChERS sample preparation method in co-extracting 
pharmaceuticals and QACs from a single sample preparation method, in these environmental 
matrices. The WFD and the CIP programme have specified low limits of detection for 
potential pollutants of interest with suggested IDLs at 0.01 µg/L (or 10 pg/mL), challenging 
the quantitative ability for most analytical instrumentation. However, from our initial screen 
it was apparent that perceived concentrations were considerably higher. Both the ZQ4000 and 
the LCQ ion trap are low-resolution mass spectrometers that have shown sufficient sensitivity 
for the selected pharmaceuticals and QAC biocides respectively, with good levels of 
quantitative accuracy and precision. It has detected and quantified 7 pharmaceuticals and 6 
biocides and confirmed the higher than expected concentrations in samples during different 
seasons (suggesting all-year round release), their presence in effluent as well as the solid 
fraction of wastewater, and a transfer to biota, which along with the detection of QACs in 
these sample, could have a potentially greater impact on public health and ecological risk if 
released into the environment. This project has also created a new product line for Biotage 
GB, in the modified QuEChERS extraction mixture, which is not only suitable for treated 
sludgecake, but has also been successfully applied to soil, treated effluent and homogenised 
biota samples. The loss in recovery from the extraction, although significant for some 
compounds, does not outweigh the benefit of reducing preparation time from hours to 20 
minutes per sample, reducing solvent usage from approximately 200 mL to 15 mL, and 
eliminating the need for a complex vacuum or distillation apparatus as seen in current 
regulatory methods (NRW and EPA). The concentrations at which both the pharmaceuticals 
and the biocides were detected in the sludgecake at high μg/kg and mg/kg contributes to the 
CIP II investigation and also the investigation by which biocides are contributing to antibiotic 
resistance.  This, with the quantities at which these QACs were present within effluent and 
biota samples, supports the need for QACs to be recognised within CIP and the WFD as a 
compound of emerging concern.  
 
7.5: Further Work 
Although the LC-MS method and QuEChERS extraction were fit for purpose, both can be 
improved upon to detect and quantify the suite of pharmaceuticals and biocides at even lower 
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concentrations. While the analytical method for the pharmaceutical suite was deemed suitable 
for quantitation, the use of isotopically labelled internal standards and performing a complete 
method validation would further improve the validity of this method for future research and 
publication opportunities. Amendments to the quantitative method for the suite of biocides 
would also be beneficial in improving the reliability of the data; firstly, additional segmenting 
of the method could be investigated to improve the number of data points across the 
chromatographic peak for quantitation and secondly, the calibration range could be 
considered to help improve the linearity by reducing the concentration of the top standard to 
prevent any potential signal saturation. The use of alternative instrumentation could increase 
the ability to quantify at the lower limits of detection with improved precision and accuracy, 
which subsequently could lead to further improvement of the modified QuEChERS method. 
For example, by using more sensitive instrument, such as a triple quadrupole or quadrupole 
time-of-flight mass spectrometer, a dilution factor could be introduced into the QuEChERS 
protocol, further reducing matrix effects and providing a cleaner extract for analysis. 
Alternative instrumentation could also aid in the identification of target compounds, either 
using a high resolution instrument to acquire accurate mass information, or by using a triple 
quadrupole mass spectrometer, which is a more sensitive instrument than the ZQ4000 or 
LCQ used in this study, and can also provide MS/MS data, which would be particularly 
useful for the identification of the suite of pharmaceuticals. The modified QuEChERS 
method, while successfully applied to the environmental matrices investigated, could be 
further developed. Smaller sample volumes, or a miniaturisation of the protocol as a whole 
could be investigated to further reduce the operational costs further and reduce sample 
handling risks associated with more complex samples. The presence of both pharmaceuticals 
and biocides within the local sludgecake is the first step in understanding the effect of these 
compounds in the wider environment. While the method was only used to characterise the 
extraction procedure in soil, a quantitative analysis of agricultural soils could be useful to 
determine whether these compounds of interest are leaching into the soils from the 
sludgecake used a fertiliser. This information may also be used to underpin studies in 
mapping genetic change in soil bacteria and the potential development in antimicrobial 
resistance. The presence of both pharmaceuticals and QACs within the biota samples tested 
also highlights an important aspect in determining the main route of exposure to these 
animals. Initially it was hypothesised that uptake of contaminant may be occurring via the 
filtering of contaminated waters, however, the concentrations of pharmaceutical and QAC 
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within wastewater effluent were found to be low, therefore suggesting an alternative route of 
exposure, such as absorption via the sediment within the biota beds could be the cause, due to 
the lipophilic nature of these compounds. An investigation into the presence of QACs in the 
environment could be useful to determine how they relate to antibiotic resistant bacteria, 
which could be used to inform policy makers about the public and industrial use of 
quaternary ammonium biocides, and how wastewater and sludge are treated for these 
emerging pollutants. 
 
  
Rachel Townsend 
__________________________________________________________________________________________ 
 
__________________________________________________________________________________________ 
 
Page 146 of 177 
Appendix 1.1 
 
A preliminary chromatogram of treated sludgecake obtained in-house and a summary of 
potential compounds detected. Data was analysed using a combination of Mass Frontier (to 
provide small-molecule structural elucidation) and Xcalibur 2.0.7 software. 
 
 
 
Retention 
Time (min) 
Ion of Interest 
(m/z) 
Possible ID Formula 
Error 
(ppm) 
1.71 152.07 Acetaminophen C8H9NO2 -3.65 
14.67 260.164 Propranolol C16H21NO2 -2.865 
15.24 505.324 Dipyridamole C24H40N8O4 -0.907 
15.57 325.171 Citalopram C20H21FN2O -0.794 
15.58 267.185 Cyclizine C18H22N2 -1.479 
16.57 407.196 Carvedilol C24H26N2O4 -1.114 
17.00 455.291 Verapamil C27H38N2O4 0.804 
17.24 515.2431 Telmisartan C33H30N4O2 -0.683 
17.32 278.1897 Amitriptyline C20H23N -0.166 
18.22 383.152 Loratadine C22H23ClN2O2 -1.232 
21.92 304.2993 BAC-C12 C21H38N -0.777 
23.90 332.3303 BAC-C14 C23H42N -0.877 
23.90 284.3305 HDTMA C19H42N -0.737 
25.13 326.377 DDMA C22H48N -0.627 
25.95 360.3617 BAC-C16 C25H46N -0.537 
25.95 312.3621 Octadecyltrimethylammonium C21H46N -0.177 
27.60 388.3932 BAC-C18 C27H50N -0.761 
29.29 368.425 Trioctylmethylammonium cation C25H54N -0.487 
29.69 368.425 Trioctylmethylammonium cation C25H54N -0.487 
30.89 315.231 Delta-1-THC - also Delta-9-THC C21H30O2 -3.25 
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Appendix 2.1 
 
A summary of pharmaceutical data used in this study organised in order of logP. All pKa and logP data obtained using ACDLabs. 
 
Pharmaceuticals Ion Formula Structure Chemistry logP 
Acetaminophen [M+H]
+
 = 152 C8H9NO2 
 
Basic 0.34 
Acetaminophen-(methyl)-d3 [M+H]
+
 = 155 C8H6D3NO2 
 
Basic 0.34 
Benzyldimethyldodecylammonium 
Chloride (BAC-C12) 
[M-Cl]
+
 = 304 C21H38N 
 
Basic 1.69 
Hexadecyltrimethylammonium 
Chloride (HDTMA) 
[M-Cl]
+
 = 284 C19H42N 
 
Basic 2.40 
Citalopram Hydrobromide [M-HBr+H]
+
 = 325 C20H21FN2O 
 
Basic 2.51 
Didecyldimethylammonium Bromide 
(DDMA) 
[M-Br]
+
 = 326 C22H48N 
 
Basic 2.51 
Benzyldimethyltetradecylammonium 
Chloride (BAC-C14) 
[M-Cl]
+
 = 332 C23H42N 
 
Basic 2.55 
d7-Benzyldimethyltetradecylammonium 
Chloride (BAC-C14-d7) 
[M-Cl]
+
 = 339 C23H35D7N 
 
Basic 2.55 
Rachel Townsend 
___________________________________________________________________________________________________________________________________________ 
 
___________________________________________________________________________________________________________________________________________ 
 
Page 148 of 177  
10,11-Dihydrocarbamazepine [M+H]
+
 = 239 C15H14N2O 
 
Basic 2.6 
Carbamazepine [M+H]
+
 = 237 C15H12N2O 
 
Basic 2.67 
Pronethalol Hydrochloride [M-HCl+H]
+
 = 230 C15H19NO 
 
Basic 2.82 
Erythromycin  [M+H]
+
 = 734 C37H67NO13 
 
Basic 2.83 
Propranolol Hydrochloride [M-HCl+H]
+
 = 260 C16H21NO2 
 
Basic 3.1 
Benzyldimethylhexadecylammonium 
Chloride (BAC-C16) 
[M-Cl]
+
 = 360 C25H46N 
 
Basic 3.42 
Diphenhydramine Hydrochloride [M-HCl+H]
+
 = 256 C17H21NO 
 
Basic 3.66 
Ibuprofen  [M-H]
-
 = 205 C13H18O2 
 
Acidic 3.72 
Diclofenac Sodium 
[M-Na+H]
+
 = 296 
[M-Na]
-
 = 294 
C14H11Cl2NO2 
 
Acidic 4.06 
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Fluoxetine Hydrochloride [M-HCl+H]
+
 = 310 C17H18F3NO 
 
Basic 4.09 
Stearalkonium Chloride (BAC-C18) [M-Cl]
+
 = 388 C27H50N 
 
Basic 4.28 
Talopram Hydrochloride [M-HCl+H]
+
 = 296 C20H25NO 
 
Basic 4.79 
Loratadine [M+H]
+
 = 383 C22H23ClN2O2 
 
Acidic 5.94 
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Appendix 3.1 
 
Mass spectra obtained during direct infusion for each pharmaceutical. Inset: a structure and a 
data table detailing the molecular formula, monoisotopic mass, precursor ion observed and 
the optimum cone voltage (CV) for each compound. All structures were drawn using 
ChemDraw® software, and the data was taken from the ChemSpider database.  
 
Acetaminophen-(methyl)-d3 
 
 
Atenolol 
 
 
 
 
 
 
Carbamazepine 
 
 
 
 
 
 
 
 
 
 
 
m/z
128 130 132 134 136 138 140 142 144 146 148 150 152 154 156 158 160 162 164 166 168 170 172 174 176 178 180 182 184 186 188
%
0
100
ACET_D3_5UG_ML_0_1_FA_CV25 4 (0.341) Cm (1:12) Scan ES+ 
1.35e7154.8
144.7
131.4129.9 146.6
176.9
m/z
230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310
%
0
100
ATENOLOL 15PMOL_UL_0_1FA_CV25 1 (0.085) Scan ES+ 
6.47e7267.3
268.3
Molecular formula: C14H22N2O3 
Monoisotopic mass: 266.16 Da 
Precursor ion: m/z 267 
Optimum CV: 25 V 
m/z
220 222 224 226 228 230 232 234 236 238 240 242 244 246 248 250 252 254 256
%
0
100
CARBAMAZEPINE 8PMOL_UL_0_1FA_CV20 1 (0.170) Scan ES+ 
6.58e6237.2
224.0 229.4227.3
238.2
243.2
239.2
249.2245.4
Molecular formula: C15H12N2O 
Monoisotopic mass: 236.09 Da 
Precursor ion: m/z 237 
Optimum CV: 20 V 
Molecular formula: C8H6D3NO2 
Monoisotopic mass: 154.08 Da 
Precursor ion: m/z 155 
Optimum CV: 25 V 
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Diclofenac 
 
 
 
 
 
 
Erythromycin 
 
 
 
 
 
 
Fluoxetine 
 
 
Loratadine 
 
 
 
 
 
 
 
 
  
m/z
282 284 286 288 290 292 294 296 298 300 302 304 306 308 310 312 314 316 318 320 322 324 326 328 330 332 334 336 338
%
0
100
FLUOXETINE 11PMOL_UL_0_1FA_CV15 1 (0.085) Cm (1:9) Scan ES+ 
3.48e7310.3
311.3
m/z
276 278 280 282 284 286 288 290 292 294 296 298 300 302 304 306 308 310 312
%
0
100
DICLOFENAC 15PMOL_UL_0_1FA_CV10 1 (0.085) Scan ES+ 
7.89e5296.1
279.2
276.2 277.3
278.2 289.2280.3 281.4 286.1284.5
282.2
287.3
292.0291.5
294.9293.1
298.1
297.1
301.3
300.1
299.1 302.3
310.7
308.5306.3
311.3 312.3
Molecular formula: C14H11Cl2NO2Na 
Monoisotopic mass: 316.99 Da 
Precursor ion: m/z 296 
Optimum CV: 10 V 
m/z
701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735
%
0
100
ERYTHROMYCIN 13PMOL_UL_0_1FA_CV10 1 (0.085) Scan ES+ 
6.43e6716.6
702.4
717.6
718.4
Molecular formula: C37H67NO13 
Monoisotopic mass: 733.46 Da 
Precursor ion: m/z 716 & m/z 734 
(online only) 
Optimum CV: 10 V 
Molecular formula: C17H18F3NO.HCl 
Monoisotopic mass: 345.11 Da 
Precursor ion: m/z 310 
Optimum CV: 15 V 
m/z
345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430
%
0
100
LORATADINE 10PMOL_UL_0_1FA_CV10 1 (0.085) Scan ES+ 
1.29e7383.3
385.3
386.3
Molecular formula: C22H23ClN2O2 
Monoisotopic mass: 382.14 Da 
Precursor ion: m/z 383 
Optimum CV: 10 V 
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Pronethalol 
 
 
 
 
 
 
Propranolol 
 
 
10,11-Dihydrocarbamazepine  
 
 
 
 
 
 
  
m/z
232 234 236 238 240 242 244 246 248 250 252 254 256 258 260 262 264 266 268 270 272 274 276 278 280 282 284 286 288 290
%
0
100
PROPRANOLOL 13PMOL_UL_0_1FA_CV25 1 (0.085) Cm (1:11) Scan ES+ 
6.62e7260.2
261.2
m/z
208 210 212 214 216 218 220 222 224 226 228 230 232 234 236 238 240 242 244 246 248 250 252 254
%
0
100
PRONETHALOL 5UG_ML_CV5 1 (0.170) Scan ES+ 
2.08e7230.1
231.1
Molecular formula: C15H19NO.HCl 
Monoisotopic mass: 265.12 Da 
Precursor ion: m/z 230 
Optimum CV: 5 V 
Molecular formula: C16H21NO2.HCl 
Monoisotopic mass: 295.13 Da 
Precursor ion: m/z 260 
Optimum CV: 25 V 
m/z
229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250
%
0
100
10_11_DIHYDROCARBAMAZEPINE 5UG_ML_CV35 1 (0.085) Scan ES+ 
1.15e7239.2
229.3 230.1
245.2
240.2
246.3
Molecular formula: C15H14N2O 
Monoisotopic mass: 238.11 Da 
Precursor ion: m/z 239 
Optimum CV: 35 V 
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Appendix 3.2 
 
A table summarising the injection repeatability data obtained using the Xbridge C18 column. 
 
 
Peak Area 
Critical 
Value 4.484 
m/z 
%CV Day 
1 
%CV Day 
2 
F-Test 
230 
12.23 15.20 1.45 
Pronethalol 
260 
6.69 11.73 4.91 
Propranolol 
256 
6.12 13.33 4.80 
Diphenhydramine 
325 
7.87 22.51 5.64 
Citalopram 
734 
15.70 8.59 4.98 
Erythromycin 
237 
7.15 8.01 2.51 
Carbamazepine 
239 
7.16 11.68 2.31 
10,11-DHC 
310 
6.01 15.36 5.68 
Fluoxetine 
296 
10.81 11.87 4.39 
Talopram 
383 
6.84 8.37 4.27 
Loratadine 
296 
5.34 9.98 3.31 
Diclofenac 
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A table summarising the reproducibility data obtained using the Xselect HSS T3 column. 
 
 
Adjusted Retention 
Time 
F(9,5) 
6.681 
F(5,9) 
4.484 
m/z 
%CV Day 
1 
%CV Day 
2 
F-Test F-Test 
155 
2.84 4.24   2.42 
Acet-d3 
152 
2.84 5.50   4.00 
Acetaminophen 
230 
1.59 0.40 16.66   
Pronethalol 
260 
1.00 0.28 13.26   
Propranolol 
256 
0.86 0.29 9.02   
Diphenhydramine 
325 
0.78 0.36 4.87   
Citalopram 
734 
0.75 0.23 11.18   
Erythromycin 
237 
0.74 0.31 5.85   
Carbamazepine 
239 
0.73 0.23 10.60   
10,11-DHC 
310 
0.56 0.24 5.41   
Fluoxetine 
296 
0.68 0.26 7.10   
Talopram 
383 
0.55 0.18 9.16   
Loratadine 
296 
0.38 0.23 2.86   
Diclofenac 
205 
0.51 0.19 7.60   
Ibuprofen 
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Appendix 3.4 
 
Summary of data obtained to evaluate the heteroscedasticity of the calibration standards using 
the Xselect HSS T3 column. 
 
Compound 
Variance of Relative 
Response Factor F-Calc 
F-Stat (2,2, 
0.95) one 
tailed 
Homoscedastic? 
S1 S9 
Acetaminophen 0.000019 0.009825 517.1228 19 No 
Carbamazepine 3.33E-07 0.004446 13339 19 No 
Citalopram 1.33E-06 0.000224 168.25 19 No 
Diclofenac 4.33E-06 5.033E-05 11.6154 19 No 
Diphenhydramine 2.33E-06 0.003046 1305.571 19 No 
Erythromycin 1.82E-09 2.03E-05 11202.9 19 No 
Fluoxetine 2.33E-06 0.000625 268 19 No 
Ibuprofen 3.33E-07 3.1E-05 93 19 No 
Loratadine 8.24E-08 0.006922 84008.55 19 No 
Propranolol 0.00014 0.14724 1049.219 19 No 
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Calibration graphs for each compound in the suite, generated using MassLynx 4.1 software. These graphs show the 1/x weighted regression 
statistics for the Xselect HSS T3 column. 
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CITALOPRAM 
y = 0.00786403x + 0.00480122 
R
2
 = 0.9966 
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Summary of the 1/x weighted quantitative data including linearity (R
2
), instrument detection 
limit (IDL), instrument quantitation limit (IQL), mean percentage accuracy and precision of 
quality control sample (QC) concentration for each pharmaceutical analysed using the 
Xselect HSS T3 column. 
 
Pharmaceutical 
Linearity 
(R
2
) 
IDL 
(ng/mL) 
IQL 
(ng/mL) 
QCs 
Mean Accuracy (%) Mean Precision (%) 
QC1 QC2 QC3 QC4 QC1 QC2 QC3 QC4 
Acetaminophen 0.9950 5.87 19.58 -12.59 -7.86 -1.51 5.87 9.48 3.54 2.75 4.51 
Propranolol 0.9996 0.78 2.61 1.85 0.49 -1.63 0.38 1.75 1.78 1.51 1.19 
Diphenhydramine 0.9991 0.30 0.99 0.92 4.61 2.72 1.32 3.20 1.70 1.18 0.35 
Citalopram 0.9966 0.22 0.73 12.22 16.00 9.57 -1.39 2.59 2.84 2.06 0.86 
Erythromycin 0.9996 0.55 1.82 0.22 0.24 -1.34 -0.85 3.48 6.23 2.88 2.23 
Carbamazepine 0.9988 0.51 1.69 7.30 7.06 3.94 -1.92 1.80 2.45 1.61 1.00 
Fluoxetine 0.9997 0.14 0.47 -2.40 -1.10 -0.66 1.65 3.28 4.49 4.50 1.13 
Loratadine 0.9979 0.47 1.57 0.31 -2.99 -3.34 -1.44 2.15 2.56 3.02 2.28 
Diclofenac 0.9983 1.04 3.46 -2.93 4.42 3.41 3.45 8.58 10.50 4.42 0.80 
Ibuprofen 0.9811 17.04 64.41 -12.01 -37.95 -0.97 0.60 45.37 12.14 12.15 6.41 
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Appendix 3.7 
 
A summary of stability data, detailing the peak areas for each compound at each concentration and the calculated percentage difference between 
t0 and each data point used to assess compound stability as a mixture over time. 
 
 
   
Mean 
Concentration of 
Drug 
% Diff 
between 
t28 and 
t0 
Peak Area for IS 
% Diff 
between 
t28 and 
t0 
SD Concentration t-test 
98% 
tCRIT3.75 
Compound 
QC 
Conc 
(ng/mL) 
0 28 0 28 0 28 pool 
Acetaminophen 
(IS: 
Acetaminophen-
(methyl)-d3 
Vlow 15 13.63 13.39 -1.80% 41870.08 41713.28 -0.37% 0.59 0.39 0.87 -0.34 
Low 25 23.78 22.32 -6.14% 40486.69 40798.40 0.77% 1.21 1.50 2.01 -0.89 
Mid 100 101.69 97.41 -4.21% 40900.50 40318.96 -1.42% 1.38 1.11 2.10 -2.50 
High 350 373.13 349.15 -6.43% 41133.97 41479.97 0.84% 11.33 1.44 16.05 -1.83 
Propranolol  (IS: 
Pronethalol) 
Vlow 15 11.35 14.63 28.96% 19978.07 17846.54 -10.67% 0.13 0.45 0.36 11.06 
Low 25 19.14 23.64 23.49% 18864.60 18198.21 -3.53% 0.30 0.20 0.44 12.45 
Mid 100 77.87 98.45 26.42% 18983.17 17669.82 -6.92% 0.68 2.90 2.26 11.13 
High 350 271.47 339.08 24.90% 18797.19 17503.08 -6.88% 1.42 4.19 3.58 23.14 
Diphenhydramine 
(IS: Talopram) 
Vlow 15 15.21 14.64 -3.79% 84227.65 83972.36 -0.30% 0.50 0.64 0.84 -0.84 
Low 25 26.52 24.15 -8.92% 77260.56 84348.39 9.17% 0.82 0.79 1.28 -2.26 
Mid 100 107.92 101.23 -6.20% 80884.38 82499.21 2.00% 2.11 1.20 3.10 -2.64 
High 350 368.14 343.26 -6.76% 81117.51 83873.93 3.40% 9.33 7.45 14.21 -2.14 
Citalopram (IS: 
Talopram) 
Vlow 15 18.53 15.92 -14.08% 84227.65 83972.36 -0.30% 0.92 0.72 1.40 -2.28 
Low 25 31.89 26.90 -15.65% 77260.56 84348.39 9.17% 0.36 0.59 0.65 -9.35 
Mid 100 121.77 106.68 -12.39% 80884.38 82499.21 2.00% 0.99 0.40 1.43 -12.95 
High 350 387.99 332.01 -14.43% 81117.51 83873.93 3.40% 9.74 5.10 14.24 -4.81 
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Erythromycin (IS: 
10,11-DHC) 
Vlow 15 14.77 16.12 9.13% 175705.19 133721.23 -23.89% 0.49 2.05 1.61 1.03 
Low 25 23.44 27.57 17.64% 173365.62 130305.01 -24.84% 0.84 2.14 1.92 2.63 
Mid 100 94.04 110.10 17.08% 175577.59 131581.60 -25.06% 3.45 3.15 5.37 3.67 
High 350 326.38 363.47 11.36% 178604.02 134953.90 -24.44% 19.75 26.24 33.53 1.35 
Carbamazepine 
(IS: 10,11-DHC) 
Vlow 15 15.82 15.51 -1.99% 175705.19 133721.23 -23.89% 0.90 0.62 1.35 -0.29 
Low 25 25.76 25.89 0.49% 173365.62 130305.01 -24.84% 1.11 0.26 1.58 0.10 
Mid 100 103.97 103.06 -0.88% 175577.59 131581.60 -25.06% 1.54 2.35 2.74 -0.41 
High 350 343.56 348.96 1.57% 178604.02 134953.90 -24.44% 5.91 2.95 8.61 0.77 
Fluoxetine (IS: 
Talopram) 
Vlow 15 19.30 16.55 -14.28% 84227.65 83972.36 -0.30% 2.51 1.67 3.74 -0.90 
Low 25 28.82 26.50 -8.05% 77260.56 84348.39 9.17% 1.53 3.97 3.54 -0.80 
Mid 100 117.71 102.73 -12.73% 80884.38 82499.21 2.00% 2.86 10.72 8.59 -2.14 
High 350 443.86 392.98 -11.46% 81117.51 83873.93 3.40% 55.82 35.41 82.81 -0.75 
Loratadine (IS: 
10,11-DHC) 
Vlow 15 18.93 14.74 -22.14% 175705.19 133721.23 -23.89% 0.19 0.36 0.37 -13.93 
Low 25 31.30 24.31 -22.31% 173365.62 130305.01 -24.84% 0.61 0.67 0.98 -8.74 
Mid 100 127.58 99.24 -22.21% 175577.59 131581.60 -25.06% 0.62 3.56 2.67 -13.02 
High 350 432.83 346.47 -19.95% 178604.02 134953.90 -24.44% 4.38 6.13 7.57 -13.98 
Diclofenac (IS: 
Talopram) 
Vlow 15 15.66 14.84 -5.22% 84227.65 83972.36 -0.30% 1.68 0.38 2.39 -0.42 
Low 25 28.26 25.20 -10.80% 77260.56 84348.39 9.17% 1.25 1.75 2.15 -1.74 
Mid 100 96.20 98.29 2.18% 80884.38 82499.21 2.00% 2.11 2.33 3.41 0.75 
High 350 323.99 334.93 3.38% 81117.51 83873.93 3.40% 24.63 14.53 36.32 0.37 
Ibuprofen (IS: 
Pronethalol) 
Vlow 15 7.70 16.60 115.67% 19978.07 17846.54 -10.67% 1.93 8.91 6.86 1.59 
Low 25 19.13 21.08 10.17% 18864.60 18198.21 -3.53% 4.92 9.49 9.66 0.25 
Mid 100 97.49 88.61 -9.10% 18983.17 17669.82 -6.92% 9.90 6.40 14.72 -0.74 
High 350 393.38 355.32 -9.67% 18797.19 17503.08 -6.88% 32.15 17.66 47.16 -0.99 
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Mass spectra obtained for each of the biocides studied. Inset: compounds information, 
including name, product ion and optimum collision energy (CE) used to induce 
fragmentation. 
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Appendix 4.2 
 
Data used to compare linear and 1/x weighted regression functions, including the linearity, 
instrument detection limit (IDL), mean accuracies and mean precision values for each 
biocide. 
 
Linear 
Biocide 
Linearity 
(R2) 
IDL 
(ng/mL) 
QCs 
Mean Accuracy (%) Mean Precision (%) 
QC1 QC2 QC3 QC4 QC1 QC2 QC3 QC4 
BAC-C12 0.9843 0.30 ± 0.1 3.74 -7.48 -11.11 -4.63 13.90 16.31 17.62 9.47 
BAC-C14 0.9854 0.27 ± 0.1 8.85 -1.97 1.12 -4.64 9.76 15.96 20.09 13.27 
BAC-C16 0.9694 0.19 ± 0.1 17.99 -12.42 -3.67 -9.86 17.25 22.60 13.71 5.09 
BAC-C18 0.9604 0.76 ± 0.3 29.04 -13.99 -0.48 -6.86 16.58 19.12 15.05 1.43 
DDMA 0.9794 0.99 ± 0.3 18.47 -6.68 -2.50 -8.23 8.12 24.75 10.33 10.76 
HDTMA 0.9729 1.79 ± 0.6 26.67 -5.43 0.50 -4.29 7.30 13.60 10.95 7.23 
 
1/x 
Biocide 
Linearity 
(R2) 
IDL 
(ng/mL) 
QCs 
Mean Accuracy (%) Mean Precision (%) 
QC1 QC2 QC3 QC4 QC1 QC2 QC3 QC4 
BAC-C12 0.9729 0.32 ± 0.1 -12.80 -15.24 -5.56 -1.82 17.40 18.00 18.17 9.68 
BAC-C14 0.9891 0.28 ± 0.1 -1.28 -1.05 -0.59 -2.90 11.12 16.85 20.45 13.46 
BAC-C16 0.9759 0.20 ± 0.1 2.95 -7.20 -10.83 -7.45 20.76 24.64 14.14 5.21 
BAC-C18 0.9669 0.82 ± 0.3 5.04 -6.11 -11.49 -2.61 22.06 21.94 15.83 1.48 
DDMA 0.9806 1.03 ± 0.3 6.54 -5.28 -5.20 -6.25 9.39 26.48 10.58 10.95 
HDTMA 0.9764 1.87 ± 0.6 13.38 -2.56 -3.67 -1.84 8.53 14.66 11.24 7.37 
 
 
  
Rachel Townsend 
__________________________________________________________________________________________ 
 
__________________________________________________________________________________________ 
 
Page 164 of 177 
Appendix 4.3 
 
Calibration graphs for each compound in the suite, generated using QuanBrowser 2.0.1 
software. These graphs show the linear regression statistics for the Xselect HSS T3 column. 
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The table shows the intra- and inter-day precision values determined for each biocide using 
the LCQ analytical method. Inter-day precision was determined over three data sets. 
 
  QCs 
Compound 
Precision 
(%RSD) 
QC1 
(8 ng/mL) 
QC2 
(20 ng/mL) 
QC3 
(60 ng/mL) 
QC4 
(80 ng/mL) 
BAC-C12 
Intra-Day 13.90 16.31 17.62 9.47 
Inter-Day 12.55 17.67 19.10 10.83 
BAC-C14 
Intra-Day 9.76 15.96 20.08 13.27 
Inter-Day 9.26 12.02 17.19 13.60 
BAC-C16 
Intra-Day 17.25 22.60 13.71 5.09 
Inter-Day 11.83 11.38 14.49 8.95 
BAC-C18 
Intra-Day 16.58 19.12 15.05 1.43 
Inter-Day 14.77 15.40 19.21 13.11 
DDMA 
Intra-Day 8.12 24.75 10.33 10.76 
Inter-Day 19.08 17.27 18.34 13.39 
HDTMA 
Intra-Day 7.30 13.60 10.95 7.23 
Inter-Day 11.84 12.24 14.49 9.19 
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Summary of the calculated matrix effects (%ME) and recovery (%REC) and associated 
precision of measurements (%RSD) of each of the pharmaceuticals studied when extracted 
using standardised unbuffered QuEChERS methods. 
 
Compound 
Method 
(unbuffered) 
%ME %RSD %REC %RSD 
Acetaminophen-
(methyl)-d3 
EN Method with PSA dSPE 134.11 7.07 71.53 2.03 
AOAC Method with PSA dSPE 137.67 36.01 37.66 16.25 
Acetaminophen 
EN Method with PSA dSPE 114.24 3.94 53.23 7.21 
AOAC Method with PSA dSPE 119.49 30.06 25.37 11.80 
Pronethalol 
EN Method with PSA dSPE 141.77 3.67 41.62 0.65 
AOAC Method with PSA dSPE 101.05 0.47 12.01 21.77 
Propranolol 
EN Method with PSA dSPE 286.59 2.40 43.05 1.44 
AOAC Method with PSA dSPE 103.16 7.71 11.34 10.51 
Diphenhydramine 
EN Method with PSA dSPE 256.87 5.45 38.21 13.20 
AOAC Method with PSA dSPE 119.42 24.08 10.78 6.05 
Citalopram 
EN Method with PSA dSPE 255.37 1.55 43.91 3.56 
AOAC Method with PSA dSPE 116.09 20.00 12.58 9.89 
Erythromycin 
EN Method with PSA dSPE 308.95 6.42 40.2 1.67 
AOAC Method with PSA dSPE 103.52 9.35 12.91 6.71 
Carbamazepine 
EN Method with PSA dSPE 101.10 0.88 48.25 1.82 
AOAC Method with PSA dSPE 99.72 0.71 24.05 17.05 
10,11-
Dihydrocarbamazepine 
EN Method with PSA dSPE 103.91 1.79 46.54 0.35 
AOAC Method with PSA dSPE 101.50 2.06 23.33 14.56 
Fluoxetine 
EN Method with PSA dSPE 159.18 4.79 43.90 2.42 
AOAC Method with PSA dSPE 122.83 27.15 7.70 13.55 
Talopram 
EN Method with PSA dSPE 210.10 4.17 42.23 0.08 
AOAC Method with PSA dSPE 127.72 32.81 5.15 18.5 
Loratadine 
EN Method with PSA dSPE 100.22 2.41 44.9 4.88 
AOAC Method with PSA dSPE 96.53 1.74 22.43 15.36 
Diclofenac 
EN Method with PSA dSPE 97.74 3.12 10.96 16.95 
AOAC Method with PSA dSPE 96.01 1.34 8.89 5.81 
Ibuprofen 
EN Method with PSA dSPE 109.8 12.84 9.48 33.50 
AOAC Method with PSA dSPE 108.34 24.3 3.26 53.34 
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Summary of the calculated matrix effects (%ME) and recovery (%REC) and associated 
precision of measurements (%RSD) of each of the pharmaceuticals studied when extracted 
using modified QuEChERS methods during method development. 
 
Compound 
Method 
(custom extraction) 
%ME %RSD %REC %RSD 
Acetaminophen-
(methyl)-d3 
Method A 121.62 8.84 84.42 2.42 
Method B 74.94 2.03 81.94 4.49 
Method C 76.78 4.77 90.05 2.61 
Acetaminophen 
Method A 64.86 5.68 62.88 14.20 
Method B 57.45 6.31 79.85 17.75 
Method C 63.36 5.73 88.23 4.54 
Pronethalol 
Method A 35.72 6.25 43.61 4.27 
Method B 39.43 4.91 51.05 20.49 
Method C 43.15 6.77 82.74 18.41 
Propranolol 
Method A 42.30 4.53 40.65 12.37 
Method B 41.65 4.61 52.48 16.17 
Method C 49.66 2.03 91.62 21.50 
Diphenhydramine 
Method A 47.76 0.76 43.04 10.59 
Method B 47.22 11.32 58.26 17.82 
Method C 60.71 5.51 92.37 25.88 
Citalopram 
Method A 46.03 4.86 42.39 12.26 
Method B 45.58 9.03 56.91 18.85 
Method C 58.74 2.23 91.05 25.91 
Erythromycin 
Method A 44.59 10.37 35.73 5.66 
Method B 42.02 4.85 41.71 4.36 
Method C 49.18 6.83 94.00 19.10 
Carbamazepine 
Method A 43.82 4.54 46.75 21.06 
Method B 43.79 2.14 55.17 2.03 
Method C 44.57 4.95 81.33 4.16 
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10,11-
Dihydrocarbamazepine 
Method A 42.92 0.60 47.09 7.18 
Method B 41.5 2.35 56.7 3.14 
Method C 44.23 1.90 81.75 3.06 
Fluoxetine 
Method A 58.91 3.94 41.47 10.46 
Method B 51.66 13.32 52.11 11.23 
Method C 52.78 16.13 76.90 3.42 
Talopram 
Method A 51.86 3.34 41.32 12.14 
Method B 50.45 12.72 56.53 19.84 
Method C 73.05 4.16 75.52 10.19 
Loratadine 
Method A 40.71 5.53 50.71 5.46 
Method B 43.84 3.32 56.20 4.46 
Method C 44.78 1.65 81.01 2.63 
Diclofenac 
Method A 40.74 0.74 3.99 45.15 
Method B 44.02 7.47 19.85 49.55 
Method C 43.51 4.60 6.17 37.78 
Ibuprofen 
Method A 42.46 13.37 28.36 13.71 
Method B 42.49 21.97 30.13 35.49 
Method C 39.47 5.33 2.45 50.48 
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Summary of the calculated matrix effects (%ME) and recovery (%REC) and associated 
precision of measurements (%RSD) of each of the pharmaceuticals studied when extracted 
using alternative QuEChERS dSPE sorbents during method development. 
 
Compound 
Method 
(custom extraction) 
%ME %RSD %REC %RSD 
Acetaminophen-
(methyl)-d3 
EN F&V dSPE 105.17 1.05 115.30 19.85 
EN Waxed dSPE 201.63 28.19 84.41 23.93 
EN Pigmented dSPE 284.09 6.37 102.59 8.07 
Acetaminophen 
EN F&V dSPE 59.73 6.60 90.88 10.11 
EN Waxed dSPE Not able to integrate – split chromatography 
EN Pigmented dSPE 77.09 7.23 74.06 16.63 
Pronethalol 
EN F&V dSPE 40.40 4.94 59.43 17.80 
EN Waxed dSPE 46.36 6.50 20.64 18.24 
EN Pigmented dSPE 43.90 5.35 48.50 5.71 
Propranolol 
EN F&V dSPE 61.53 4.92 69.07 40.28 
EN Waxed dSPE 67.67 8.51 17.02 37.34 
EN Pigmented dSPE 63.37 12.3 42.30 7.83 
Diphenhydramine 
EN F&V dSPE 71.52 6.53 37.71 13.08 
EN Waxed dSPE 78.42 2.20 18.50 23.46 
EN Pigmented dSPE 71.13 17.72 32.09 8.59 
Citalopram 
EN F&V dSPE 89.36 0.46 56.76 13.05 
EN Waxed dSPE 79.17 2.95 33.99 22.64 
EN Pigmented dSPE 90.30 12.89 59.14 8.04 
Erythromycin 
EN F&V dSPE 57.85 3.38 32.19 19.98 
EN Waxed dSPE 62.13 12.48 23.08 39.58 
EN Pigmented dSPE 59.82 17.28 28.44 13.29 
Carbamazepine 
EN F&V dSPE 53.21 8.33 71.68 0.27 
EN Waxed dSPE 42.71 4.68 65.94 10.34 
EN Pigmented dSPE 43.80 5.84 68.43 3.69 
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10,11-
Dihydrocarbamazepine 
EN F&V dSPE 42.03 4.35 67.59 3.81 
EN Waxed dSPE 39.65 4.59 61.71 3.22 
EN Pigmented dSPE 40.33 0.94 68.16 4.44 
Fluoxetine 
EN F&V dSPE 41.07 0.24 44.48 3.40 
EN Waxed dSPE 52.08 5.03 19.44 14.25 
EN Pigmented dSPE 55.74 4.00 44.31 4.17 
Talopram 
EN F&V dSPE 69.35 4.87 51.18 6.37 
EN Waxed dSPE 67.53 8.57 18.86 11.08 
EN Pigmented dSPE 73.91 5.71 51.34 3.32 
Loratadine 
EN F&V dSPE 43.32 2.00 64.54 0.40 
EN Waxed dSPE 42.72 5.39 60.23 4.33 
EN Pigmented dSPE 45.34 4.69 66.88 2.83 
Diclofenac 
EN F&V dSPE 40.36 2.04 0.80 141.42 
EN Waxed dSPE 44.21 4.54 1.28 109.58 
EN Pigmented dSPE 47.63 6.48 1.18 134.15 
Ibuprofen 
EN F&V dSPE 44.82 11.29 43.53 14.37 
EN Waxed dSPE 48.61 11.49 15.79 134.25 
EN Pigmented dSPE 46.59 14.60 27.80 10.32 
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Appendix 5.4 
 
Summary of the calculated matrix effects (%ME) and recovery (%REC) and associated 
precision of measurements (%RSD) of each of the pharmaceuticals studied to compare the 
difference between a QuEChERS extraction using a dSPE step and the equivalent sorbent 
type in a typical SPE cartridge form. 
 
Compound 
Method 
(custom extraction) 
%ME %RSD %REC %RSD 
Acetaminophen-
(methyl)-d3 
PSA dSPE 164.03 4.28 84.46 9.91 
PSA Cartridge-SPE – 6 mL 141.03 5.07 49.80 19.49 
PSA Cartridge-SPE – 15 mL 149.50 4.45 71.51 14.11 
Acetaminophen 
PSA dSPE 96.35 3.43 92.13 20.87 
PSA Cartridge-SPE – 6 mL 99.71 11.67 49.88 26.41 
PSA Cartridge-SPE – 15 mL 94.94 2.74 70.54 3.83 
Pronethalol 
PSA dSPE 97.16 1.10 44.5 9.36 
PSA Cartridge-SPE – 6 mL 89.87 8.98 31.83 33.53 
PSA Cartridge-SPE – 15 mL 85.67 3.54 36.08 28.57 
Propranolol 
PSA dSPE 118.61 10.11 44.04 9.81 
PSA Cartridge-SPE – 6 mL 119.94 6.51 39.65 71.35 
PSA Cartridge-SPE – 15 mL 108.89 0.78 34.06 19.31 
Diphenhydramine 
PSA dSPE 110.2 6.98 47.62 10.30 
PSA Cartridge-SPE – 6 mL 164.11 9.48 42.04 44.84 
PSA Cartridge-SPE – 15 mL 137.60 9.21 52.49 30.68 
Citalopram 
PSA dSPE 109.88 2.12 47.73 11.94 
PSA Cartridge-SPE – 6 mL 150.71 27.80 43.25 69.81 
PSA Cartridge-SPE – 15 mL 114.95 4.51 47.53 25.74 
Erythromycin 
PSA dSPE 112.36 3.95 43.83 12.71 
PSA Cartridge-SPE – 6 mL 127.98 10.01 20.04 56.08 
PSA Cartridge-SPE – 15 mL 109.98 1.30 45.53 16.44 
Carbamazepine 
PSA dSPE 101.19 5.28 55.4 12.7 
PSA Cartridge-SPE – 6 mL 132.46 2.03 69.44 2.18 
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PSA Cartridge-SPE – 15 mL 114.39 2.64 72.47 4.18 
10,11-
Dihydrocarbamazepine 
PSA dSPE 100.45 3.62 53.36 10.57 
PSA Cartridge-SPE – 6 mL 103.16 1.11 59.83 5.75 
PSA Cartridge-SPE – 15 mL 97.57 3.09 62.4 2.88 
Fluoxetine 
EN F&V dSPE 95.26 1.71 46.59 14.27 
EN Waxed dSPE 97.55 2.50 25.27 21.84 
EN Pigmented dSPE 91.70 0.97 38.08 16.96 
Talopram 
PSA dSPE 125.32 13.36 42.76 13.84 
PSA Cartridge-SPE – 6 mL 153.62 1.69 17.28 22.54 
PSA Cartridge-SPE – 15 mL 143.81 5.14 34.98 19.71 
Loratadine 
PSA dSPE 102.65 2.49 53.25 14.29 
PSA Cartridge-SPE – 6 mL 103.16 2.93 55.66 10.89 
PSA Cartridge-SPE – 15 mL 95.12 1.17 61.98 4.74 
Diclofenac 
PSA dSPE 107.19 3.38 1.10 124.92 
PSA Cartridge-SPE – 6 mL 104.03 4.29 0.24 34.64 
PSA Cartridge-SPE – 15 mL 102.24 1.45 0.21 68.33 
Ibuprofen 
PSA dSPE 105.77 16.49 12.36 55.44 
PSA Cartridge-SPE – 6 mL 120.19 8.25 4.01 91.85 
PSA Cartridge-SPE – 15 mL 119.08 3.88 3.51 101.07 
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Appendix 5.5 
 
A summary of the QuEChERS data obtained for the extractions of pharmaceuticals, and pharmaceuticals and biocides showing the mean 
percentage recoveries, matrix effects and relative standard deviation (%RSD) for each extraction. 
 
 
20th June 2017 - Soil - Pharms Only 1st August 2017 - Soil - Pharms + QACs (30ng in 500µL) 
 
Recovery Matrix Effects Recovery Matrix Effects 
Compounds Mean RE St Dev %RSD Mean ME St Dev %RSD Mean RE St Dev %RSD Mean ME St Dev %RSD 
Acet-d3 75.86% 0.04 5.25 150.34% 0.06 4.27 100.12% 0.12 12.21 141.82% 0.03 1.96 
Acetaminophen 68.21% 0.03 4.56 90.43% 0.04 3.88 72.10% 0.12 17.22 110.41% 0.10 8.82 
Pronethalol 40.91% 0.06 14.01 105.51% 0.07 6.53 45.57% 0.05 11.44 97.33% 0.09 8.87 
Propranolol 36.81% 0.07 19.95 138.69% 0.06 4.10 42.14% 0.03 7.10 124.77% 0.12 9.69 
Diphenhydramine 35.59% 0.08 22.61 149.98% 0.10 6.86 39.81% 0.04 10.72 133.31% 0.12 8.82 
Citalopram 44.99% 0.08 17.27 155.14% 0.08 4.91 52.51% 0.04 6.69 136.25% 0.14 10.03 
Erythromycin 37.82% 0.08 20.56 131.26% 0.03 2.62 48.35% 0.05 11.26 122.62% 0.28 22.84 
Carbamazepine 67.95% 0.04 6.02 109.12% 0.04 3.93 68.14% 0.03 4.58 97.73% 0.05 4.97 
10,11-DHC 59.95% 0.03 4.31 95.27% 0.03 2.82 66.66% 0.01 1.53 92.42% 0.01 0.84 
Fluoxetine 41.88% 0.03 8.00 98.50% 0.06 6.26 48.12% 0.04 8.61 91.48% 0.07 7.32 
Talopram 46.49% 0.05 10.04 161.16% 0.07 4.60 56.13% 0.03 6.01 140.18% 0.05 3.35 
Loratadine 57.38% 0.02 2.90 105.35% 0.07 7.04 64.40% 0.03 4.87 99.54% 0.10 9.80 
Diclofenac 2.45% 0.01 28.45 107.98% 0.02 2.08 1.67% 0.01 52.37 110.58% 0.06 5.29 
Ibuprofen 25.62% 0.20 79.36 104.17% 0.06 5.43 23.88% 0.09 36.91 114.10% 0.30 26.24 
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Appendix 6.1 
 
The chromatograms for each of the biocides detected within the sample of sludgecake 
sampled during winter using the ZQ4000 mass spectrometer; a) BAC-C12 b) BAC-C14 c) 
BAC-C16 d) BAC-C18 e) DDMA f) HDTMA. The legend shows the m/z of each compound 
and the signal intensity. 
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The chromatograms for each of the biocides detected within the 1:400 dilution of the sample 
of sludgecake sampled during winter using the LCQ mass spectrometer; a) BAC-C12 b) 
BAC-C14 c) BAC-C16 d) BAC-C18 e) DDMA f) HDTMA. The legend shows the m/z of 
each compound and the signal intensity. 
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Appendix 6.2 
 
The chromatograms for each of environmental matrices investigated using the LTQ Orbtitrap 
mass spectrometer showing the base peaks for; a) treated effluent b) winter sludgecake c) 
summer sludgecake d) wet biota e) lyophilised biota.  
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